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Background  Superparamagnetic particles of iron oxide (SPIO) are part of a novel 
and exciting class of ‘smart’ magnetic resonance imaging (MRI) contrast agents that 
are taken up by inflammatory cells. Ultrasmall SPIO (USPIO; ~30 nm diameter) can 
be used to assess cellular tissue inflammation and SPIO (80-150 nm) have the 
potential to be used to label cells ex vivo for in vivo cell tracking studies.  
  
Objectives  The aims of the thesis were therefore (i) to develop and validate 
quantitative MRI methodology for assessing SPIO uptake within tissues, (ii) to 
demonstrate USPIO accumulation within the aortic wall and its implications in 
patients with abdominal aortic aneurysms (AAA), and (iii) to develop and apply a 
Good Manufacturing Practice (GMP) compliant method of SPIO cell labelling in 
healthy volunteers.  
 
Methods  Patients with asymptomatic AAA >4.0 cm in diameter were recruited. 
Imaging sequences were optimised in eight patients using a 3 tesla MRI scanner. 
Data were analysed using the decay constant for multi echo T2* weighted (T2*W) 
sequences (T2*) or its inverse (R2*) and the repeatability of these measurements was 
established. A further twenty-nine patients underwent MRI scanning before and 24-
36 hours after administration of USPIO. T2 and multi echo T2*W sequences were 
performed and ultrasound-based growth rate data were collected. Operative aortic 
wall tissue samples were obtained from patients undergoing open surgical aneurysm 
repair. 
 
A GMP compliant protocol was developed for labelling cells with SPIO for clinical 
cell tracking studies. The effects of SPIO-labelling on cell viability and function 
were assessed in vitro. A phased-dosing protocol was used to establish the safety of 
intravenous administration of SPIO-labelled cells in healthy volunteers. The 
feasibility of imaging cells at a target site in vivo following local or systemic 
administration was assessed. Tracking of SPIO-labelled cells to a target site was 
investigated by inducing an iatrogenic inflammatory focus in the skin of the anterior 
thigh of healthy volunteers, following which autologous SPIO-labelled cells were 
administered and their accumulation was assessed using MRI scanning and histology 
of skin biopsies. 
 
Results  Robust and semi-quantitative data acquisition and image analysis 
methodology was developed for the assessment of SPIO accumulation in tissues. In 
patients with AAA, histological analysis of aortic wall tissue samples confirmed 
USPIO accumulation in areas of cellular inflammation. USPIO-enhanced MRI 
detected aortic wall inflammation and mural USPIO uptake was associated with a   
3-fold higher aneurysm expansion rate.  
 
Human mononuclear cells were labelled with SPIO under GMP compliant conditions 
without affecting cell viability or function. Both local and intravenous administration 
of SPIO-labelled cells was safe and cells were detectable in vitro and in vivo using a 
clinical MRI scanner. SPIO-labelled cells tracked to a focal iatrogenic inflammatory 
 3 
focus following intravenous administration in humans and were detectable on MRI 
scanning and histological examination of skin biopsies. 
 
Conclusions  SPIO contrast agents have an extensive range of potential clinical 
applications. USPIO uptake in the wall of AAA appears to identify cellular 
inflammation and predict accelerated aneurysm expansion. This is therefore a 
promising investigative tool for stratifying the risk of disease progression in patients 
with AAA, and may also be considered as a biomarker for response to novel 
pharmacological agents. The ability to label cells for non-invasive cell tracking 
studies would facilitate the further development of novel cell-based therapies and 
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F-NAF   
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An aneurysm may be defined as an abnormal, permanent, focal dilatation of a blood 
vessel to more than 1.5 times its normal diameter, differentiating it from vascular 
ectasia which is typically diffuse and widespread. 
 
Abdominal aortic aneurysm (AAA) is the 13
th
 leading cause of death in the United 
Kingdom and other western countries. Around 6,800 deaths each year in the United 
Kingdom and 15,000 deaths annually in the United States are attributed to AAA 
[Ashton et al 2002; General Register Office for Scotland Mortality Statistics 2008; 
Office for National Statistics England and Wales 2008]. The condition is most 
prevalent amongst elderly men. With 5-7.6% of men over the age of 65 years 
affected, AAA accounts for 2-3% of deaths in this age group [Gillum 1995; UK 
National Screening Committee 2010]. 
 
1.2 AETIOLOGY OF ABDOMINAL AORTIC ANEURYSM DISEASE 
 
The aetiology of aneurysm disease is multifactorial with contributions from both 
environmental and genetic influences. Cigarette smoking, hypertension, increasing 
age, male sex and hypercholesterolaemia (elevated serum low-density lipoprotein 
(LDL)) have been correlated positively with the incidence of AAA, whilst for 
reasons that are not fully understood, diabetes mellitus is associated with a reduced 
risk of aneurysm development [Brady et al 2004; Shantikumar et al 2010]. The main 
determinant of rupture is aneurysm diameter but interestingly, whilst continued 
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cigarette smoking and hypertension are also associated with increased risk of 
aneurysm rupture, age is not influential and female rather than male sex increases 
rupture risk [Brown and Powell 1999; Brady et al 2004; Mofidi et al 2007; 
Grootenboer et al 2009]. Chronic obstructive pulmonary disease (COPD) and 
reduced forced expired volume also increase risk of rupture but are difficult to 
disentangle from smoking history as independent risk factors [Brown and Powell 
1999]. 
 
Familial clustering of AAA is well described with an incidence of 19.2% amongst 
first-degree relatives of patients with AAA corresponding to a relative risk of 11.6 
compared to the general population [Johansen and Koepsell 1986]. Data from the 
Swedish twin registry further support the heritability of AAA [Wahlgren et al 2010]. 
Whilst single gene connective tissue disorders including Marfan’s syndrome (defect 
in fibrillin 1 gene) and Ehlers-Danlos syndrome (defect in collagen III synthesis), 
and vasculitides, such as Takyasu’s arteritis and Behçets disease, account for a small 
proportion of these cases, the majority are likely to be polygenetic [Kontusaari et al 
1990; Matsumura et al 1991; Devereux and Roman 1999; Erentug et al 2003]. This 
has led to a number of candidate gene studies. Polymorphisms of putative genes 
involved in processes known to contribute to the pathogenesis of AAA, such as 
inflammation and proteolysis, have been pursued, including matrix 
metalloproteinase (MMP)-2, MMP-9, human leucocyte antigen (HLA) and 
angiotensin-converting enzyme (ACE) [Sandford et al 2007]. More recently whole 
genome expression profiling using microarrays has been used to identify putative 
genes that are differentially expressed in patients with AAA compared to controls, 
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and at sites of AAA rupture compared to elsewhere in the aneurysm [Choke et al 
2009; Giusti et al  2009]. No single causative gene has yet been identified however.  
 
1.3 ANEURYSM DISEASE AND ATHEROSCLEROSIS 
 
Aneurysm disease was traditionally thought to lie within the spectrum of 
atherosclerosis. However, whilst atherosclerosis is a ubiquitous finding in patients 
with AAA and the two processes share a number of common risk factors, there are 
also a number of differences suggesting that aneurysm disease and atherosclerosis 
represent separate pathological entities [Reed et al 1992; Lederle et al 2003]. 
 
Microscopically, atherosclerosis primarily affects the tunica intima and involves loss 
of endothelial function, inflammatory infiltration, deposition of LDL within activated 
macrophages (foam cells) and migration of vascular smooth muscle cells (VSMC) 
from the media into the resulting plaque [Naghavi et al 2003]. In contrast, aneurysm 
disease involves inflammation, loss of VSMC and proteolytic degradation of elastin 
fibres within the tunica media [Choke et al 2005]. Additionally, different stimuli are 
used to induce AAA versus atherosclerosis in animal models, and in human 
populations, whilst atherosclerosis is common, AAA is comparatively rare [Jaffer et 
al 2002]. Atherosclerosis is generally widespread throughout a number of vascular 
beds, including coronary, carotid, cerebral and infrainguinal vessels. Although many 
patients exhibit generalised vascular ectasia, aneurysm formation is typically 
confined to the infrarenal aorta. Within the aorta itself, aneurysm disease affects the 
entire infrarenal segment whilst the atherosclerotic burden is usually concentrated 
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distally around the bifurcation. Finally, whilst population-based primary and 
secondary prevention measures such as best medical therapy and smoking bans have 
reduced the mortality from atherosclerotic disease, AAA-related mortality continues 
to increase [Lederle et al 2003; Meyers et al 2009]. Together these data suggest that 
aneurysm disease is related to but distinct from atherosclerosis. 
 
1.4 PATHOLOGY OF AORTIC ANEURYSMS 
 
Until recently the formation, growth and rupture of aneurysms was attributed to the 
‘wear and tear’ effect of pulsatile blood flow on the aortic wall over a number of 
decades, but is now recognised to be the result of a complex interaction between 
biomechanical factors and biological processes, which include neovascularisation, 
inflammation and proteolysis. 
 
1.4.1   BIOMECHANICAL FACTORS 
The Law of Laplace, which states that wall stress is proportional to the radius of the 
vessel, is no longer thought to be an adequate explanation of aneurysm disease. This 
Law is only valid for thin-walled, uniformly-cylindrical, biologically inert structures. 
It therefore does not take into account the complex geometry, heterogeneity of wall 
thickness, presence of intraluminal thrombus (ILT) or biologically active nature of 
AAA. Finite Element Analysis is evolving as a more accurate tool to predict the wall 
stress in AAA [Raghavan et al 2000]. Finite Element Analysis involves accurate 
delineation of the aneurysm geometry from computed tomography (CT) data with 
subsequent segmentation of the resulting 3-dimensional volume into a number of 
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finite elements. The biomechanical environment of each element can then be 
calculated using iterative mathematical modelling algorithms and combined to give a 
global picture for the whole aneurysm. However, whilst this improved method can 
estimate the radial wall stress more accurately, it fails to address the ability of the 
aneurysm wall to withstand the forces being applied to it, i.e. its tensile strength. 
There is currently no method available that can non-invasively highlight areas of the 
vessel wall that have become weakened and would therefore be more vulnerable to 
rupture.  
 
1.4.2   BIOLOGICAL FACTORS 
Aneurysm tissue is characterised by excessive medial neovascularisation, infiltration 
of inflammatory cells (principally macrophages and lymphocytes) and irreversible 
remodelling of the extracellular matrix (ECM). 
 
Neovascularisation 
In contrast to the thoracic aorta, the tunica media of the abdominal aorta is not 
normally supplied by vasa vasorum and the presence of microvasculature in the 
media of the abdominal aortic wall is a pathological finding [Wolinsky and Glagov 
1969]. Since the aortic wall is nourished directly from the lumen, the presence of 
ILT, renders the inner layer of the media hypoxic [Vorp et al 2001; Choke et al 
2006a]. This stimulus is thought to attract inflammatory cells and induce the 
secretion of angiogenic factors promoting neovascularisation [Vorp et al 2001; 
Choke et al 2006b]. These new vessels not only supply oxygen and nutrients to the 
arterial wall but also amplify the pathological process by promoting further 
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inflammatory infiltration [Thompson et al 1996; Reeps et al 2009b]. Endothelial 
cells within these immature vessels also contribute directly to the destruction of the 
aortic wall through secretion of proteolytic enzymes and cytokine release [Reeps et 
al 2009b]. The presence of neovessels in the aortic wall has been correlated with the 
degree of wasting of the ECM [Reeps et al 2009b]. 
 
1.4.3   INFLAMMATION 
It is widely held that inflammation plays a critical role in the development and 
progression of AAA, and both cellular and humoral mechanisms are involved. 
Inflammatory cells are recruited into the aortic wall by secretion of a variety of 
cytokines and the products of ECM degradation. Inflammatory cells in the media and 
adventitia surround neovessels [Reeps et al 2009b]. The reported composition of the 
inflammatory infiltrate varies in the literature, likely reflecting significant 
heterogeneity amongst patients. Numerically T lymphocytes are the predominant cell 
type and are present along with macrophages and B lymphocytes in the media and 
adventitia [Houard et al 2009; Reeps et al 2009b]. Neutrophils are found in the 
tunica adventitia and in the luminal aspect of the ILT [Eliason et al 2005; Houard et 
al 2009]. Plasma cells and natural killer (NK) cells exist in smaller numbers, and 
more recently a role has been proposed for mast cells in AAA pathophysiology 
[Tsuruda et al 2008; Sun et al 2009]. 
 
Lymphocytes are predominantly T helper (Th) cells with a smaller proportion of 
B cells and plasma cells. T helper cells are not themselves independently cytotoxic or 
phagocytic, but rather modify and orchestrate the actions of cells around them to 
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enhance and co-ordinate the inflammatory response. The humoral inflammatory 
response is induced by Th2 cluster of differentiation (CD)3+ cells, the most 
numerous cell type in AAA, which secrete a range of pro- and anti-inflammatory 
cytokines (interleukin (IL)-4, IL-5, IL-6, IL-8, IL-10, IL-13) that are chemoattractant 
and angiogenic [Schonbeck et al 2002; Santana and Rosenstein 2003]. In addition 
they release the Fas ligand stimulating VSMC apoptosis. This is important because 
VSMC are the major source of ECM generation in the aortic wall. Furthermore, 
secretion of CD40 and interferon gamma (IFN!) induce MMP production by 
monocytes and macrophages. Th1 cells activate and enhance the function of 
macrophages through secretion of IL-2, tumour necrosis factor beta (TNF") and 
IFN! [Santana and Rosenstein 2003]. 
 
Whilst fewer in number than lymphocytes, macrophages accumulate in the aortic 
wall early on during the process of aneurysm development, have a diverse range of 
functions and play a key role in the pathogenesis of AAA. Macrophages secrete pro-
inflammatory cytokines which include IL-1", IL-6, IL-8 and tumour necrosis factor 
alpha (TNF#) which exacerbate tissue injury, stimulate neovascularisation and 
induce the secretion of further cytokines by adjacent leucocytes. Macrophages also 
secrete a number of MMP including MMP-1, -2, -3, -8 and -9, and induce other cells, 
such as VSMC and immature endothelial cells, to secrete further MMP [Wilson et al 
2005; Wilson et al 2006; Reeps et al 2009b]. Through induction of apoptotic 
pathways such as Perforin and Fas, macrophages also lead to loss of VSMC within 
the aortic wall [Geng et al 1997; Henderson et al 1999].  
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The cause of the inflammatory response in AAA remains unclear. Since the 
association was made between aneurysm formation and Treponema pallidum, the 
causative agent for syphilis, other microorganisms have been pursued as part of the 
investigation of the aetiology of inflammation in AAA. Cytomegalovirus infection 
has been associated with inflammatory AAA [Tanaka et al 1994]. Inflammatory 
aneurysms are a specific subtype of AAA characterised by the classical triad of 
thickening of the aortic wall, retroperitoneal fibrosis and adhesions to adjacent 
structures [Walker et al 1972]. Clinically such patients typically present with 
abdominal or back pain, weight loss and ureteric obstruction, along with evidence of 
systemic inflammation (such as elevated erythrocyte sedimentation rate). Rather than 
representing a distinct clinical entity, inflammatory aneurysms are likely to represent 
the extreme end of the spectrum since inflammation is evident to a varying degree in 
all aneurysms.  
 
Chlamydia pneumoniae has also been implicated as a result of the finding of 
Chlamydia pneumoniae deoxyribose nucleic acid (DNA) in the aortic wall and the 
cross-reactivity of circulating antibodies to Chlamydia pneumoniae present in the 
serum of patients with AAA with components of the aortic wall [Juvonen et al 
1997a; Lindholt et al 2003]. The nature of the immune response in AAA is 
consistent with that of an autoimmune disease with a polycolonal T cell response and 
the presence of memory B cells in the aortic wall [Freestone et al 1995]. The 
possibility of an autoimmune aetiology is further supported by the increased 
incidence of other autoimmune diseases in patients with AAA, and the association of 
AAA with specific HLA molecules [Haug et al 2003]. Human leucocyte        
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antigen-DR2, particularly the B1(*)02 and B1(*)04 alleles, are associated with 
inflammatory infiltration of the aortic wall and a doubling of the risk of AAA 
formation [Rasmussen et al 2001; Rasmussen et al 2002]. Molecular mimicry 
between Chlamydia pneumoniae antigens and components of the aortic wall has 
been proposed as a possible link between the infectious and autoimmune 
contributions to the pathophysiology of AAA [Lindholt and Shi 2006]. 
 
Circulating markers of inflammation provide further evidence of the role of 
inflammation in AAA and have attracted interest as potential diagnostic and 
prognostic biomarkers [Golledge et al 2008]. The cytokine profile in AAA is 
characteristically of the Th2 type (IL-4, IL-5, IL-6, IL-8, IL-10, IL-13) rather than the 
Th1 type (IL-2, TNF! and IFN") that dominates in atherosclerotic disease [Libby 
2002; Schonbeck et al 2002]. Interleukin-6, a pro-inflammatory cytokine, is 
produced by a variety of cell types including monocytes, macrophages, 
Th2 lymphocytes, fibroblasts, endothelial cells and VSMC. It is elevated in both 
aortic tissue and serum in patients with AAA [Juvonen et al 1997b; Lindeman et al 
2008]. Interestingly IL-6 levels are highest when blood is sampled just distal to the 
aneurysm suggesting that the aneurysm itself may be the source [Juvonen et al 
1997b; Dawson et al 2006]. An increase in the ratio of IL-6 to the anti-inflammatory 
cytokine IL-10 was observed in patients with AAA [Wallinder et al 2009]. 
Interleukin-1!, IL-2, TNF# and IFN" (female patients only) are also elevated in 
AAA compared to both healthy controls and patients with atherosclerotic disease 
[Juvonen et al 1997b]. Expressed by macrophages, T cells and B cells, and involved 
in leucocyte adhesion and migration, osteopontin is increased in the serum of 
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patients with AAA [Golledge et al 2007b]. Most studies have shown C-reactive 
protein (CRP) to be increased in AAA, particularly in symptomatic patients. 
However, two smaller studies showed no significant difference between patients and 
controls [Powell et al 1987; Hobbs et al 2003; Dawson et al 2007; Golledge et al 
2007a; Sakthivel et al 2007; Tambyraja et al 2007]. 
 
Of these circulating factors, only osteopontin and IFN! have shown a correlation 
with AAA expansion rate, and "1 antitrypsin has been associated with risk of rupture 
[Engstrom et al 2004; Golledge et al 2007b; Juvonen et al 1997b]. Whilst a range of 
cytokines has been related to the presence of AAA, none have sufficient power or 
specificity to predict clinical events accurately, and a biomarker for disease 
progression remains elusive.  
 
In summary, through a number of mechanisms, inflammation plays a key role in the 
pathology of AAA, ultimately compromising the biomechanical properties of the 
aortic wall and rendering it vulnerable to aneurysm formation and rupture.     
 
1.4.4   MACROPHAGES AND OXIDATIVE STRESS 
Oxidative stress causes and amplifies tissue damage, and occurs when there is 
excessive generation of reactive oxygen species or an antioxidant deficit. Activated 
macrophages create a situation of oxidative stress in the aortic wall through 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity producing 
H2O2 and O2 [McCormick et al 2007]. Both neutrophils and macrophages also 
generate HOCl from H2O2 through myeloperoxidase activity. Immature endothelial 
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cells in neovessels exhibit upregulation of inducible nitric oxide synthetase (iNOS). 
Whilst nitric oxide production is considered to be an important part of normal 
endothelial function in health, if produced in excess it can lead to tissue damage 
through a number of mechanisms including reaction with heavy metals and with 
oxygen free radicals leading to nitrosative stress. Activated smooth muscle cells and 
fibroblasts also contribute to oxidative stress. Mechanical forces acting on VSMC, 
oxidised-LDL and cytokines increase NADPH activity, exacerbating tissue oxidative 
stress [Hishikawa et al 1997; Grote et al 2003]. 
 
Free radicals induce tissue damage by reacting with proteins, lipids and DNA. In 
AAA, reactive oxygen species (ROS) lead to disease progression through a number 
of potential mechanisms which include increased secretion of cytokines (including 
IL-8, monocyte chemoattractant protein-1 (MCP-1)) [Lum and Roebuck 2001], 
expression of endothelial leucocyte adhesion molecules [Lum and Roebuck 2001], 
increased MMP and plasminogen activity [Rajagopalan et al 1996; Deng et al 2003; 
Ejiri et al 2003; Satoh et al 2009], increased osteopontin secretion leading to 
enhanced MMP-9 and NADPH activity [Bruemmer et al 2003; Lai et al 2006; 
Golledge et al 2007b], local VSMC apoptosis and systemic vascular hypertension 
[Laursen et al 1997]. 
 
In aneurysm tissue there is evidence of increased ROS production and reduced 
antioxidant availability. Both nitrotyrosine (a marker of amino acid oxidation) and 
nitrites (a marker of nitric oxide activity) are increased in aneurysm tissue [Paik and 
Tilson 1996; Zhang et al 2003]. Furthermore iNOS expression by macrophages and 
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lymphocytes is increased in the diseased aortic wall and superoxide levels in 
aneurysmal aorta are double those in the adjacent atherosclerotic aorta [Miller et al 
2002; Zhang et al 2003]. Levels of antioxidants including zinc, copper, ascorbate, 
glutathione and manganese superoxide dismutase are reduced in the aortic wall in 
AAA [Dubick et al 1987; Dubick et al 1999]. Plasma vitamin E is reduced in 
patients with AAA compared to both healthy controls and patients with 
atherosclerotic disease [Sakalihasan et al 1996; Micheletta et al 2004]. In rodent 
models administration of vitamin E attenuates the size and frequency of AAA, 
although this effect has not yet been replicated in small-scale human studies of 
antioxidant administration [The Alpha-Tocopherol, Beta Carotene Cancer Prevention 
Study Group 1994; Tornwall et al 2001; Gavrila et al 2005].  
 
Together these data support the importance of oxidative stress in AAA 
pathophysiology and emphasise the key role that macrophages play in this process 
[McCormick et al 2007].  
 
1.4.5   PROTEOLYTIC ACTIVITY 
The irreversible remodelling of the aortic wall that results in aneurysm formation, 
expansion and rupture, involves an imbalance between the synthesis and breakdown 
of elastin and collagen: the principal proteins of the ECM. In health, elastin fibres 
constitute the main load-bearing component of the aortic wall at physiological 
pressures. Depletion of elastin fibres in the aortic wall results in dilatation of the 
vessel, transfer of load-bearing to collagen fibres and increased wall stiffness 
[Raghavan et al 1996; Wilson et al 1999; Wilson et al 2001]. Initially, this is 
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accompanied by an increase in the collagen content but later on in the process, focal 
loss of collagen fibres and impairment of tensile strength precede rupture [Raghavan 
et al 1996]. The inflammatory infiltrate has been correlated with depletion of the 
elastin and collagen content of the aortic wall in AAA [Reeps et al 2009b]. 
 
Extracellular matrix is lost through a combination of reduced production and 
increased breakdown. Vascular smooth muscle cell apoptosis and senescence results 
in decreased ECM production. Increased ECM breakdown occurs through 
dysregulation of the ratio between MMP and their endogenous inhibitors, the tissue 
inhibitors of metalloproteinases (TIMP) [Choke et al 2005]. The resulting increase in 
proteolytic activity is central in the pathogenesis of AAA.  
 
The role of fibroblasts in AAA is not well studied. They are a source of proteolytic 
enzymes and secrete chemotactic and pro-angiogenic factors, but as a source of 
collagen may also have a role in repair of the injured aortic wall [Choke et al 2005]. 
Indeed aneurysm disease is associated with increased numbers of fibroblasts in the 
aortic wall [Zou et al 2012]. 
 
Matrix metalloproteinases, a family of zinc-dependent endopeptidases, are 
proteolytic enzymes whose principal substrates are elastin (MMP-2, -7, -9 and -12) 
and collagen (MMP-1, -8 and -13). In particular, MMP-2 and MMP-9 have been 
widely implicated in the pathology of AAA [Freestone et al 1995; Longo et al 2002]. 
Matrix metalloproteinase-2 is elevated in the aneurysmal aorta, particularly in small 
diameter (4-5.5 cm) aneurysms [Freestone et al 1995]. Matrix metalloproteinase-9 is 
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localised to macrophages and is also over-expressed in aneurysm tissue, particularly 
in large AAA >5.5 cm [Thompson et al 1995; Tamarina et al 1997]. Furthermore, in 
ruptured AAA the concentration of MMP-9 is seven times higher at the site of 
rupture than elsewhere in the aneurysm sac [Wilson et al 2006]. It has been 
postulated, therefore, that MMP-2 may initiate aneurysm formation whilst MMP-9 is 
critical for further expansion and subsequent rupture.  
 
1.4.6   THROMBUS 
Intraluminal thrombus is found in the majority of aortic aneurysms with its 
deposition favoured by aortic tortuosity, turbulent flow, endothelial injury and low 
wall shear stress [Hans et al 2005]. Intraluminal thrombus is multi-layered with 
graded changes in composition between its luminal and abluminal surfaces [Adolph 
et al 1997; Matusik et al 2010; Folkesson et al 2011]. The luminal aspect is freshly 
deposited and is typically highly cellular with platelets, erythrocytes and 
polymorphonuclear leucocytes (neutrophils) trapped in a fibrin mesh. The abluminal 
component, in contrast, is virtually acellular consisting of dense, highly-organised 
fibrin through which canaliculi can permit passage of macromolecules [Gasser et al 
2009]. 
 
The role of ILT is not well understood. Indeed it is not yet clear whether the presence 
of ILT favours, protects against or is simply a consequence of AAA expansion. 
Biomechanical models suggest that ILT dissipates the radial stress evenly across the 
aortic wall reducing peak wall stress [Wang et al 2001; Georgakarakos et al 2009; 
Speelman et al 2010]. Mechanical failure of the ILT, allowing blood to track through 
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a fissure into a plane between the thrombus and the aortic wall, may be critical in 
precipitating aneurysm rupture [Polzer et al 2011]. The so-called ‘crescent sign’ 
representing this phenomenon is recognised as a high-risk feature on CT and 
magnetic resonance imaging (MRI) scans [Mehard et al 1994; Roy et al 2008]. 
Thrombus volume has been shown to correlate with aneurysm expansion and 
rupture, although the ratio between ILT volume and total aneurysm volume does not 
appear to be influential so this is of uncertain significance [Stenbaek et al 2000; 
Speelman et al 2010]. 
 
The biological activity of ILT has also been studied in relation to aortic wall 
degradation. Intraluminal thrombus produces MMP, other proteases and plasmin, 
which it was thought might promote aortic wall destruction [Kazi et al 2005]. One 
study observed higher proteolytic activity at the abluminal surface of the thrombus, 
although this may derive from the wall itself rather than from the thrombus [Kazi et 
al 2003; Kazi et al 2005]. A recent study has shown that whilst proteases are 
expressed at both the luminal and abluminal surfaces of the ILT, actual protease 
activity is only found at the luminal surface because proteases at the abluminal 
surface are inactivated by an excess of inhibitors [Folkesson et al 2011]. 
 
An alternative mechanism through which the ILT may influence the aortic wall is by 
creation of a hypoxic environment inducing oxidative stress. The partial pressure of 
oxygen (PO2) is lower in thrombus-covered wall in animal models and in patients 
with AAA [Vorp et al 1996; Bjornheden et al 1999; Vorp et al 2001; Choke et al 
2006a]. Hypoxia alters the behaviour of VSMC and increases MMP-2 production 
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[Erdozain et al 2010]. Thrombus-covered wall has been found to be thinner, with 
evidence of medial neovascularisation, inflammatory infiltration, increased protease 
activity, destruction of elastin fibres and a reduction in tensile strength [Kazi et al 
2003; Choke et al 2006b; Coutard et al 2009]. 
 
1.5 BIOLOGICAL ‘HOTSPOTS’ 
 
These pathological processes do not affect the aorta uniformly but are focal in nature. 
Radial wall stress varies spatially within the aneurysm [Raghavan et al 2000],
 
and 
tensile strength varies in different parts of the aneurysm sac [Vallabhaneni et al 
2004]. Focal neovascularisation is present at the site of rupture [Choke et al 2006b] 
and its presence corresponds to the degree of inflammation [Thompson et al 1996]. 
Matrix metalloproteinases -8 and -9 are increased locally at the site of rupture 
[Wilson et al 2006] and areas of high proteolytic activity correspond to areas of low 
tensile strength [Vallabhaneni et al 2004]. 
 
These biological ‘hotspots’ appear to be weakened areas of the aortic wall and are 
thought to represent sites of potential expansion and rupture. 
 
1.6 CLINICAL ASPECTS OF ANEURYSM DISEASE 
 
1.6.1   RUPTURED AAA AND ANEURYSM SCREENING 
Acute rupture, the most feared complication of AAA, is a catastrophic event 
associated with an overall mortality rate of 65-85%, with many patients succumbing 
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before even reaching hospital [Johansson and Swedenborg 1986; Bradbury et al 
1997; Adam et al 1999; Kniemeyer et al 2000]. Patients with a ruptured aneurysm 
are considered for immediate open surgical or endovascular aneurysm repair 
(EVAR) for which the mortality rate is 35-40% [Bradbury et al 1997; Ashton et al 
2002]. By comparison, elective open surgical or endovascular intervention to prevent 
rupture has an acceptable mortality rate of less than 6% [Brady et al 2000; Ashton et 
al 2002; Prinssen et al 2004; EVAR trial participants 2005; Schermerhorn et al 2008; 
Lederle et al 2009] and is therefore considered in medically fit patients when the 
perceived risk of rupture outweighs the risk of procedural complications. 
 
Most patients with AAA are asymptomatic and, although AAA may be detected as a 
result of physical examination or an imaging investigation performed for another 
reason, the majority of AAA present for the first time with rupture. Aneurysm 
screening has been shown to reduce the risk of aneurysm-related death by 53-73% 
[Ashton et al 2002; Fleming et al 2005; Lindholt et al 2006]. A nationwide screening 
programme is being introduced currently in the United Kingdom [UK National 
Screening Programme 2010]. Men are invited to attend for a single focused 
ultrasound scan of the aorta at the age of 65 [UK National Screening Programme 
2010]. Due to the low prevalence of AAA in women of a similar age (0.8%) 
screening was not found to be cost effective or of sufficient clinical benefit in this 
group [Lederle et al 2001; Ashton et al 2002; UK National Screening Programme 
2010]. Patients are discharged if the aorta is found to be less than 3 cm in diameter. 
If the aorta is aneurysmal with a diameter of 3-5.4 cm the patient will remain under 
yearly (3-4.4 cm) or 3-monthly (4.5-5.4 cm) surveillance. Patients with an aneurysm 
 !" 
greater than 5.5 cm in diameter are referred to a vascular surgeon for consideration 
of surgical or endovascular repair. The results of the MASS trial [2002] show that in 
men aged 65, 4.9% are found to have an AAA of which 71% are small (3-4.4 cm), 
17% are medium-sized (4.5-5.4 cm) and 12% are large measuring at least 5.5 cm in 
diameter [Ashton et al 2002]. The implementation of screening programmes will 
therefore increase considerably the number of patients under long-term surveillance. 
 
1.6.2   CONTEMPORARY ELECTIVE MANAGEMENT OF AAA 
Pharmacological measures 
Patients with small- and medium-sized aneurysms are managed expectantly with 
ultrasound surveillance, lifestyle advice and best medical therapy. Whilst a 
pharmacological agent capable of attenuating or reversing aneurysm expansion is 
highly desirable, the main benefit derived from current agents is through prevention 
of other cardiovascular events, including myocardial infarction and stroke. 
 
More than 90% of patients with AAA have smoked and up to half are current 
smokers [Lederle et al 2003]. Smoking is consistently associated with accelerated 
aneurysm expansion and, whilst there are no trials specifically addressing this 
question, it is likely that smoking cessation would limit AAA growth [The UK Small 
Aneurysm Trial Participants 1998; Lindholt et al 2001]. 
 
There is little association between serum cholesterol and aneurysm expansion, but it 
is plausible that statins might have a beneficial effect on aneurysm expansion 
through their pleiotropic effects which include anti-inflammatory activity and MMP 
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inhibition [Kalyanasundaram et al 2006; Evans et al 2007; Abisi et al 2008; 
Kajimoto et al 2009; Schweitzer et al 2010]. Pre-clinical and small clinical studies 
suggested that statins may limit aneurysm expansion but these encouraging results 
have not been borne out in larger clinical studies [Heart Protection Study 
Collaborative Group 2002; Kalyanasundaram et al 2006; Schouten et al 2006; Heart 
Protection Study Collaborative Group 2007; Forsdahl et al 2009; Karlsson et al 
2009a; Golledge et al 2010; Hurks et al 2010; Sweeting et al 2010; Thompson et al 
2010a]. There are no randomised controlled trials of statins in AAA. The UK heart 
protection study showed no reduction in requirement for aneurysm surgery amongst 
patients taking statins [Heart Protection Study Collaborative Group 2002]. 
 
Following some hopeful results in animal models both beta-adrenoceptor blockers 
(!-blockers) and ACE inhibitors have been assessed in clinical studies [Slaiby et al 
1994]. However, whilst retrospective studies suggested that !-blockers may reduce 
AAA expansion, two randomised clinical trials of propranolol failed to show a 
beneficial effect and were hampered by the poor tolerability of propranolol treatment 
which led to poor compliance [Wilmink et al 2000; Propranolol Aneurysm Trial 
Investigators 2002]. Similarly, although ACE inhibitor use was found to be lower in 
patients admitted with ruptured AAA (n=3,379) compared to patients with non-
ruptured AAA (n=11,947) in a retrospective study, the effects of ACE inhibitors on 
AAA expansion in prospective clinical studies have been variable [The UK Small 
Aneurysm Trial Participants 1998; Hackam et al 2006; Sweeting et al 2010; 
Thompson et al 2010a]. 
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There are no randomised controlled trials of anti-platelet therapy in AAA, primarily 
because the strong evidence for prevention of atherosclerotic clinical events would 
make such a study in AAA patients unethical. In AAA, ILT is biologically active and 
may play an important role in aneurysm disease progression. Rationale for a direct 
aneurysm-related benefit for anti-platelet therapy lies in the limitation of thrombus 
volume and activity. It is also thought that inflammatory mediators released into the 
circulation from the ILT may activate and destabilise atherosclerotic plaque at a 
distant site increasing the risk of other cardiovascular events. 
 
Chlamydia pneumoniae may play a role in the development of AAA and as a result it 
has been proposed that macrolide and tetracycline antibiotics may be effective in 
limiting AAA expansion [Karlsson et al 2000]. In a small clinical study (n=247) 
azithromycin did not reduce AAA growth rate [Karlsson et al 2009b]. Doxycycline, 
probably acting through inhibition of MMP activity rather than through an antibiotic 
mechanism, reduced aneurysm expansion in rodent models of AAA and reduced 
MMP activity in human aortic tissue samples obtained during surgical aneurysm 
repair [Curci et al 1998; Curci et al 2000; Longo et al 2002; Lindeman et al 2009]. 
In a small clinical study AAA growth rate was reduced by doxycycline and there are 
two ongoing randomised controlled trials [Mosorin et al 2001]. 
 
Other novel targets include the cyclooxygenase-2 (COX-2) pathway and the c-Jun N-
terminal kinase (JNK) pathway [King et al 2006]. In mice, inhibition of the JNK 
pathway resulted in aneurysm regression and restoration of normal architecture 
[Yoshimura et al 2005; Kajimoto et al 2009]. Oxidative stress is central to the 
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pathology of AAA and patients with AAA have lower levels of the antioxidant 
vitamin E [Dubick et al 1987; Sakalihasan et al 1996; Dubick et al 1999; Tornwall et 
al 2001; Gavrila et al 2005]. However, amongst patients with AAA (n=181) 
considered as a subgroup of a larger clinical trial of vitamin E supplementation there 
was no apparent clinical benefit [Tornwall et al  2001].  
 
At the present time there is no evidence to support the use of any pharmacological 
agent to suppress aneurysm expansion or reduce the risk of rupture. However, 
recognising the prevalence of atherosclerotic disease in the aneurysm population, 
standard secondary prevention measures should be instituted to reduce the risk of 
myocardial infarction, stroke and other cardiovascular events [Kertai et al 2004a; 
Kertai et al 2004b; Schouten et al 2005]. Development of a drug to slow or even 
reverse aneurysm expansion could revolutionise the management of patients with 
small- and medium-sized aneurysms, but pursuit of such an agent is challenging. 
Rodent models (e.g. abluminal CaCl2 application, elastase infusion, angiotensin 
II/apoliprotein E (ApoE)) produce a dilated aorta but do not replicate the complexity 
of human aneurysm disease, and translation of pre-clinical research findings to the 
clinical setting is uncertain. In clinical studies results are confounded by the 
prevalence of atherosclerotic disease and consequent use of cardiovascular drugs by 
many patients. Assessment of efficacy in clinical studies is challenged by follow-up 
duration and the use of preventative surgery for large aneurysms, which precludes 
the use of rupture as an isolated endpoint.  
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The use of intermediate measures to determine drug efficacy is highly attractive, 
both to titrate treatment in individual patients and in the pharmaceutical industry as 
part of clinical trials. To this end a number of serum biomarkers have been 
investigated, but none have shown sufficient sensitivity and specificity [Golledge et 
al 2008]. Recently, cellular and molecular imaging technologies have allowed 
biological processes to be probed in vivo. Such a method of monitoring disease 
progression and effects of pharmacological intervention would be highly attractive. 
 
Open surgical and endovascular intervention 
Both open surgical repair and EVAR are effective at preventing rupture in patients 
with large aneurysms. Open repair has been the gold standard for the treatment of 
large AAA and remains an acceptable option with proven durability [Hallett et al 
1997; Conrad et al 2007]. The EVAR-1 trial (n=1,082) compared EVAR (n=543) 
with open repair (n=539) in patients with large AAA (! 5.5 cm) considered to be fit 
for either procedure [Brown et al 2004]. Endovascular aneurysm repair was 
associated with a lower procedural mortality than open repair (1.7% versus 4.7%) 
[EVAR Trial Participants 2005]. These data are consistent with the results of other 
randomised controlled trials and registry data [Prinssen et al 2004; Schermerhorn et 
al 2008; Lederle et al 2009]. At 4 years the AAA-related mortality remained lower in 
the EVAR group (3.5% versus 6.3%), however the all-cause mortality was similar 
for both groups (18.4% versus 20.2%) and the complication rate (41% versus 9%) 
and re-intervention rate (20% versus 6%) were higher in the EVAR group [EVAR 
Trial Participants 2005]. By 10 years the early AAA-related event free survival 
advantage in favour of EVAR had been lost (AAA-free survival 93% in both groups) 
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and there was no difference in overall survival (54% in both groups) [Greenhalgh et 
al 2010]. The catch-up in mortality has been attributed to a combination of 
cardiovascular deaths and endograft ruptures in the EVAR group [Greenhalgh et al 
2010; Brown et al 2011]. There was no difference in health-related quality of life 
measures at 4 years and 10 years, and EVAR was more expensive than open repair 
(£13,257 versus £9,946) [EVAR Trial Participants 2005; Greenhalgh et al 2010].  
 
The EVAR-2 trial [Brown et al 2010] showed that in patients considered not fit for 
open surgery, compared to no intervention, EVAR reduced AAA-related mortality at 
4 years (14% versus 19%) but did not improve all-cause mortality (66% versus 
62%). In this group EVAR had a much higher mortality rate than was observed for 
patients in the EVAR arm of the EVAR-1 trial (7.3% versus 1.7%) [EVAR Trial 
Participants 2005]. 
 
1.6.3   AAA SURVEILLANCE 
Once diagnosed, patients with intact, asymptomatic AAA are enrolled in an 
ultrasound-based surveillance programme that involves serial measurements of the 
maximum anteroposterior diameter of the aneurysm [Hirsch et al 2006]. Data from 
two large studies, the United States Aneurysm Detection and Management study 
(USADAM, n=1136) and the United Kingdom Small Aneurysm Trial (UKSAT, 
n=1090), have informed the diameter threshold for consideration of elective 
intervention in surveillance patients [The UK Small Aneurysm Trial Participants 
1998; Lederle et al 2002b]. Both studies compared continued surveillance with 
immediate surgery for AAA with diameter 4-5.5 cm and concluded that there was no 
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survival benefit for immediate surgery in this group of patients. A threshold of 
5.5 cm is therefore considered the appropriate time to intervene [Hirsch et al 2006].  
 
However, whilst the risk of rupture increases with diameter (Lederle et al 2002a; 
Mofidi et al 2007; Thompson et al 2010b], the absolute diameter of the aneurysm is 
not the sole determinant of the risk of rupture [Di Martino et al 2006]. One in 14 
screen-detected aneurysms <5.5 cm in diameter rupture within 3 years of detection, 
and up to one-fifth of ruptured AAA are less than 5.5 cm in diameter [Darling et al 
1977; Nicholls et al 1998; Thompson et al 2010b]. Furthermore, many patients 
present with AAA with diameters considerably greater than 5.5 cm without prior 
symptoms or rupture [Lederle et al 2002a; Powell et al 2008]. Aneurysms commonly 
exhibit a staccato growth pattern and historical growth rates may not correlate with 
future expansion [Kurvers et al 2004]. 
 
It appears that the reliance upon diameter alone to predict rupture is inadequate, 
failing to take into account the biology of the disease and other factors associated 
with increased rupture risk such as gender and co-morbidities. The number of 
patients under long-term surveillance will increase as AAA screening commences 
since up to 90% of patients with screen-detected aneurysms have an aortic diameter 
of less than 5.5 cm. There is therefore an urgent clinical need for a better method of 
predicting aneurysm rupture in order that preventative open surgical and 
endovascular interventions can be targeted appropriately. In addition to measurement 
of aneurysm dimensions, the ability to probe the biological processes affecting the 
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aortic wall is likely to be critical to developing an improved method of assessing 
rupture risk. 
 
1.7 CELLULAR AND MOLECULAR IMAGING 
#
Standard clinical imaging of cardiovascular disease has provided detailed anatomical 
and morphological information focusing on the presence of stenoses and 
calcification. In atherosclerotic disease it has become evident that additional 
information concerning plaque biology would be useful to predict cardiovascular 
events. In the coronary arteries it is recognised that acute clinical events more often 
originate from rupture of plaques that, as a result of outward remodelling, did not 
encroach on the vessel lumen [Libby 1995]. Indeed elective angioplasty of fixed 
stenosing plaques improves symptoms of angina but does not reduce the incidence of 
myocardial infarction or death [Boden et al 2007].  
 
The term ‘vulnerable plaque’ has been coined to describe the atheromatous plaque at 
risk of rupture with distinctive pathological features that include a thin fibrous cap, 
high macrophage density, a large lipid core and a reduction in the number of VSMC  
[Naghavi et al 2003]. Analogous to the concept of the vulnerable plaque, AAA at 
risk of rupture have been described as featuring hotspots of biological activity 
involving neovascularisation, inflammation and proteolytic degradation of the ECM 
of the aortic wall. These hotspots represent weakened areas of the aortic wall and are 
thought to be sites of potential aneurysm expansion and rupture. Consistent with the 
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stacatto growth pattern of AAA, these hotspots are dynamic in nature [Kurvers et al 
2004; Vega de Ceniga et al 2008].  
 
With recent innovations in cellular and molecular imaging, these high-risk 
histological features, along with a number of key biological processes, are viewed as 
possible imaging targets for the detection of vulnerable plaques in vivo. Whilst the 
majority of work in this area has focused on atherosclerotic disease, such techniques 
would be eminently translatable for use in aneurysm disease. 
 
Using cellular or molecular imaging methods to target these hotspots would provide 
real-time information on the metabolic and biological activity within the aortic wall. 
With this insight it may be possible to predict more accurately the risk of aneurysm 
expansion and rupture for an individual patient. Furthermore such a technique would 
facilitate the development and assessment of novel pharmacological interventions to 
limit or reverse aneurysm expansion.  
 
1.8 IMAGING MODALITIES 
 
A range of imaging modalities exists including MRI, single photon emission 
computed tomography (SPECT), positron emission tomography (PET), ultrasound 
scanning (USS), and fluorescence and biolouminescence imaging (Table 1.1). Of 
these, PET has attracted the greatest attention for use in the clinical setting. Positron 
emission tomography provides picomolar chemical sensitivity and when used in 
conjunction with computed tomography (PET-CT), yields 3-dimensional spatial 
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information. However spatial resolution remains inferior to MRI, and PET-CT 
involves a significant dose of ionising radiation. Furthermore PET radiotracers have 
a limited half-life limiting the duration of follow-up to a few hours. Single photon 
emission computed tomography utilises lower energy gamma-emitting radiotracers 
such as indium-111 and technetium-99m. It is also hampered by low spatial 
resolution. Ultrasound scanning avoids ionising radiation and can be used with 
microbubble contrast agents, but is highly operator-dependent and spatial resolution 
is limited.  
 



































Yes Yes No Good 
Ultrasound Moderate 
(mm) 
Low Semi No Yes Good  
 
MRI - Magnetic resonance imaging; PET-CT - Positron emission tomography-computed tomography; 
SPECT - Single photon emission computed tomography.  
 
 
Green fluorescent protein (GFP) and cyan fluorescent protein (CFP) are amongst a 
range of fluorescent and near infrared fluorescent (NIRF) proteins used in 
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fluorescence imaging along with reporter genes such as luciferase which converts 
luciferin to a fluorescent marker. Yielding picomolar sensitivity and information on 
cell viability, fluorescence is excellent in the pre-clinical setting. Unfortunately the 
limited penetration, which even for NIRF agents is restricted to a few centimetres, 
means that it is of limited use in large animals and humans. 
 
Magnetic resonance imaging offers excellent 3-dimensional, sub-millimetre 
resolution and distinct soft tissue contrast. Its avoidance of ionising radiation makes 
it suitable for serial imaging studies. The longevity of some MRI contrast agents 
allows a prolonged follow-up of several days. 
 
1.9 IMAGING TARGETS 
 
Putative imaging targets include a range of pathophysiological processes and 
features. Endothelial damage is a key initiating event in cardiovascular diseases and 
has been assessed using both optical and magnetic resonance imaging [Nahrendorf et 
al 2006]. Neovascularisation is ubiquitous in AAA and is concentrated around sites 
of aneurysm rupture. Gadolinium-enhanced MRI can assess neovascularisation in 
vascular tissue in humans and a novel PET ligand for the pro-angiogenic 
integrin !v"3 has been used in an atherosclerotic mouse model [Kerwin et al 2003; 
Laitinen et al 2009]. Inflammation is central to atherosclerotic and aneurysm disease. 
Phagocytic activity of macrophages has been demonstrated using ultrasmall 
superparamagnetic particles of iron oxide (USPIO) and MRI scanning. USPIO 
accumulate in rupture-prone rather than stable atherosclerotic plaques, and statin 
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therapy reduces both USPIO uptake and inflammation [Kooi et al 2003; Trivedi et al 
2003; Tang et al 2009]. Uptake of USPIO has also been shown in AAA in pre-
clinical models and in small clinical studies [Tang et al 2009; Turner et al 2009; 
Sadat et al 2011]. 
 




F-FDG) is a glucose analogue that is 
taken up by cells but accumulates in a phosphorylated form as it is not a suitable 
substrate for glycolysis and further metabolism. Its accumulation in cells and tissues 
indicates metabolic activity, and in vascular tissue 
18
F-FDG uptake correlates with 
the degree of inflammation [Rudd et al 2007]. In atherosclerotic disease 
18
F-FDG 
uptake predicts acute plaque events, correlates with cardiovascular risk factors and is 
reduced with statin therapy [Rominger et al 2009; Rudd et al 2009; Wasselius et al 
2009]. 
18
F-FDG also accumulates in the wall of AAA but does not correlate clearly 
with AAA diameter or predict aneurysm expansion in small clinical studies [Reeps et 
al 2008; Kotze et al 2009; Reeps et al 2009a; Kotze et al 2011]. 
18
F-FDG uptake was 
higher in patients with acute symptoms and correlated with histological evidence of 
aneurysm instability [Reeps et al 2008]. 
 
Probes have been developed for other pathways including MMP activity, VSMC 
apoptosis and oxidative stress, but are not yet available for clinical use [Fujimoto et 






1.10    CHOICE OF USPIO-ENHANCED MRI TO INVESTIGATE 
ANEURYSM DISEASE 
 
High resolution MRI provides excellent soft tissue contrast and can distinguish 
different components of atherosclerotic plaque including the lipid-rich necrotic core, 
fibrous cap and calcification [Cai et al 2005]. Standard gadolinium-enhanced MRI 
can also identify the fibrous cap and thrombus in AAA [Kramer et al 2004] 
Furthermore, MRI is safe and avoids ionising radiation making it suitable for serial 
imaging studies as would be required for monitoring inflammatory activity in AAA. 
 
Discussed in detail below, USPIO are part of a novel group of MRI contrast agents 
capable of providing additional functional information beyond the anatomical data 
obtained using blood pool agents. USPIO are biodegradable, safe and do not affect 
cell viability or function. These agents have been used to assess inflammation in 
atherosclerotic plaques and several small studies have demonstrated their uptake in 
AAA but have not correlated this with clinical events. A further advantage of these 
agents is their current clinical availability. USPIO-enhanced MRI is a promising 
approach to evaluating dynamic inflammatory processes in AAA. 
 
1.11 SUPERPARAMAGNETIC PARTICLES OF IRON OXIDE  
 
Superparamagnetic particles of iron oxide (SPIO) constitute a novel class of MRI 
contrast agents. Possessing intense superparamagnetism, SPIO are detectable at 
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much lower concentrations than standard gadolinium-based MRI contrast agents 
[Zhang et al 2005]. Beyond the anatomical data provided by blood pool contrast 
agents, these agents can also yield additional biological and functional information. 
Taken up by macrophages both in vitro and in vivo, these nanoparticles accumulate 
at sites of tissue inflammation and have the potential to be used to investigate a range 
of inflammatory disease processes. In the clinical setting, such agents have already 
been used in conjunction with gadolinium for double contrast MRI studies of the 
liver where they are taken up by Kuppfer cells [Bellin et al 1998; Semelka and 
Helmberger 2001]. Furthermore, iron oxide nanoparticles can be used to label cells 
ex vivo and may be suitable for in vivo cell tracking studies that, if successful, would 
be a tremendous asset for advancing the development of cell therapies [Arbab et al 
2004b]. The availability of these agents has therefore opened up a new sphere of 
possibilities for MRI.  
 
These agents divide into two classes based on particle size due to the influence that 
diameter has on their behaviour. SPIO have a diameter in the region of 80-150 nm. 
Examples of SPIO include ferumoxide (Endorem, Guerbet, France) and 
ferucarbotran (Resovist, Bayer-Schering Pharma, Germany). USPIO are less than 
50 nm in diameter and include ferumoxtran-10 (Sinerem, Guerbet, France). It should 
be noted that the quoted hydrodynamic particle size includes the polymeric coating, 
whilst the iron core itself is generally in the region of 4-7 nm regardless of overall 
particle diameter. In addition to size, the behaviour and distribution of different SPIO 




The iron oxide core is manufactured by co-precipitation of magnetite crystals from 
an aqueous solution of ferrous (Fe
2+
) and ferric (Fe
3+
) salts [Laurent et al 2008]. 
Magnetite (Fe3O4) is also termed ferrous-ferric oxide, reflecting the presence of iron 
in two oxidation states within the same molecule. Under aerobic conditions, 
magnetite is gradually oxidised to maghaemite (Fe2O3) and iron nanoparticle 
preparations generally consist of a mixture of the two. Particle size can be modified 
within a reasonably tight range by modifying the conditions of co-precipitation 
including temperature, pH and the ratio of ferric and ferrous salts. 
 
The magnetic core is then coated to stabilise the iron oxide crystal structure and 
prevent agglomeration and sedimentation. The coating may modulate the magnetic 
properties of the particles through a quenching effect. Importantly the surface coating 
is critical in determining the biological behaviour of the particles. A range of 
coatings has been described including dextran (e.g. ferumoxide, ferumoxtran-10), 
carboxydextran (e.g. ferubarbotran), starch, polyethylene glycol, alpha hydroxyacids 
(e.g. citrate-coated VSOP C184) and amino acids. The coating may be neutral, 
anionic or cationic, and ionic coatings appear to increase cellular particle uptake 
[Fleige et al 2002]. Clearly the nature of the coating also determines the suitability of 
the nanoparticle preparation for translational and clinical use. 
 
1.11.1   CELLULAR UPTAKE OF SPIO AND USPIO 
Cellular uptake of SPIO and USPIO occurs through a variety of mechanisms and is 
influenced amongst other things by cell type as well as particle size and coating 
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[Koval et al 1998]. Phagocytosis and receptor-mediated endocytosis are prominent in 
the uptake of larger SPIO particles, whilst pinocytosis appears to be important for 
uptake of USPIO. Scavenger receptors are involved in the internalisation of anionic 
and larger particles by macrophages. Scavenger receptor blockade by 
polysaccharides (e.g. fucoidin) or polynucleotides (e.g. poly-inosinic acid) reduces 
the uptake of both ferumoxides and ferumoxtran-10. Colchicine blocks non-specific 
pinocytosis and thereby inhibits uptake of dextran-coated but not citrate-coated iron 
nanoparticles [Moore et al 1997]. Conversely inhibition of phagocytosis through 
cytochalasin beta blockade of the cytoskeleton inhibited citrate- but not dextran-
coated nanoparticle uptake [Fleige et al 2002]. Within the cell, particles accumulate 
in phagolysosomes [Muller et al 2007]. 
 
Particle internalisation is increased in activated macrophages stimulated by IL-4 and  
#$%! [Rogers and Basu 2005]. There is conflicting evidence regarding the effect of 
statins on iron nanoparticle uptake, with one study showing inhibition of uptake by 
lovastatin and a second study showing no effect of atorvastatin [Rogers and Basu 
2005; Muller et al 2008]. 
 
The avidity of particle uptake determines the circulating half-life of different iron 
nanoparticle contrast agents. SPIO are large enough to be recognised and rapidly 
taken up by Kuppfer cells in the reticuloendothelial system. Significantly higher 
concentrations are observed in the spleen and lymph nodes than in the liver. SPIO 
therefore accumulate in the liver and spleen following intravenous administration 
and have a relatively short plasma half-life in the region of 2-6 hours in humans. 
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Indeed this property is utilised when SPIO are used for the detection of malignant 
lesions in the liver [Bellin et al 1998; Semelka and Helmberger 2001].  
 
In contrast, USPIO escape immediate recognition and persist for longer in the 
circulation [Corot et al 2006]. Ferumoxtran-10, for example, has a circulating half-
life of 16-24 hours in humans and slowly accumulates at sites of inflammation 
allowing its use for vessel wall and lymphatic imaging [Corot 2007].  
 
Whilst following administration SPIO and USPIO accumulate predominantly in the 
lymphoreticular system, accumulations are also observed in macrophages within the 
lung parenchyma and around the airway,but probably not in concentrations high 
enough to affect their overall bioavailability [Tsuchiya et al 2011]. In the absence of 
inflammation, USPIO and SPIO do not accumulate in the kidneys, gastrointestinal 
tract or great vessels [Tsuchiya et al 2011]. 
 
1.11.2   METABOLISM 
A major advantage of using dextran-coated iron nanoparticles is that they are fully 
biodegradable with no long-term toxicity. Cellular iron content reduces from 
72 hours onwards, probably through a combination of the dilution effect of cell 
division and recycling of iron content out of the cell [Sun et al 2005]. The former is 
more prominent in rapidly dividing cells such as stem cells whilst professional 
scavengers such as macrophages return iron to the body’s general iron pool. The use 




C reveals the fate of iron 
nanoparticles in vitro [Corot 2007]. Under acidic conditions within macrophage 
 !" 
lysosomes, USPIO particles are degraded and become soluble within 4 days of 
administration. The dextran coating undergoes renal excretion and 89% has been 
eliminated after 8 weeks. The iron component of the nanoparticles enters the body’s 
iron pool, being incorporated into haemoglobin, myoglobin and other iron-containing 
macromolecular complexes. Iron is excreted very slowly in the faeces: only 20% is 
excreted 3 months after administration. 
 
1.11.3   BIODEGRADABILITY AND BIOCOMPATIBILITY 
On a cellular level in vitro exposure of cells to iron nanoparticles and labelling with 
approximately 10-20 pgFe/cell generally has no adverse effects on cell viability. This 
has been shown in a wide variety of cell types including monocytes, THP-1 cells, 
T lymphocytes, mesenchymal stem cells (MSC), adipose-derived stem cells, neural 
precursor cells, endothelial progenitor cells and embryonic stem cells [Arbab et al 
2004b; Arbab et al 2005; Au et al 2009; Cohen et al 2009; Farrell et al 2009; Hu et 
al 2009; Mai et al 2009; Wang et al 2009]. Normal differentiation of stem cells into 
cardiac myocytes, osteocytes, adipocytes and skeletal myocytes has been 
demonstrated, and there is no impairment of monocyte differentiation into 
macrophages and dendritic cells [Arbab et al 2004b; Arbab et al 2005; Au et al 
2009; Wang et al 2009]. However chondrocyte differentiation of MSC may be 
impaired, although interestingly the behaviour of differentiated chondrocytes 
exposed to SPIO is unaffected [Bulte et al 2004; Farrell et al 2009]. Morphology, 
phenotype, migratory capacity, cytokine secretion and immunomodulatory activity 
are preserved in a range of cell types. Despite the overwhelming majority of studies 
finding no adverse cellular effects, there are a few reports of functional effects of 
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SPIO-labelling [Bulte et al 2004; Schäfer et al 2007; Schäfer et al 2009]. It is worth 
recognising the diversity in cell labelling protocols employed across these studies, 
including differences in the nature of transfection agents, which may explain such 
findings. 
 
There is some evidence that SPIO-labelling promotes MSC proliferation, possibly 
through enhanced peroxidase activity, however the majority of studies have shown 
no effect on cell proliferation. Following cellular ingestion, part of the SPIO load is 
taken up by lysosomes. In this acidic environment, the dextran coating of the 
nanoparticle is degraded and a proportion of the iron oxide liberated may dissociate 
releasing Fe
2+
 that can generate reactive oxygen species through the Fenton reaction. 
Indeed even intact iron nanoparticles have a degree of intrinsic peroxidase-like 
activity through which they deplete cytoplasmic levels of H2O2, tending to promote 
cell proliferation and reduce apoptosis. Cells protect themselves against the potential 
harmful effects of Fe
2+
 by sequestering free iron into ferritin complexes. Increased 
cytoplasmic iron concentration decreases expression of the transferrin receptor 
(CD71) in many cell types but increases it in monocytes and erythrocytes 
[Pawelczyk et al 2006]. Indeed SPIO-labelling is known to upregulate expression of 
the transferrin receptor [Pawelczyk et al 2006; Schäfer et al 2007]. The transferrin 
receptor is associated with regulation of cell proliferation and differentiation. 
However it would appear that monocytes/macrophages, as professional scavengers, 
have an excellent capacity to deal with ingested iron and resist the potentially toxic 
effects [Pawelczyk et al 2006]. It is interesting that in the clinical setting chronic 
exposure of macrophages to iron, as occurs in chronic venous ulceration, polarises 
 !" 
macrophages towards the pro-inflammatory M1 phenotype which may inhibit ulcer 
healing [Sindrilaru et al 2011]. This effect is not seen in ex vivo exposure of cells to 
iron nanoparticles in vitro. Differences in response may be due to the chronicity of 




1.11.4   SAFETY PROFILE 
Intravenous administration of SPIO and USPIO is very well tolerated with few 
clinical side-effects. The incidence of side-effects is reduced if administration is by 
slow intravenous infusion of a dilute suspension of iron oxide nanoparticles. One 
thousand six hundred and sixty-three patients received Sinerem as part of a series of 
37 studies looking at its use for lymph node imaging in patients with cancer 
[Bonnemain 2008]. Of these, seven patients (0.004%) had a serious adverse event 
thought to be related directly to the administration of Sinerem and one patient died 
(0.0006%). Adverse events affected approximately half of patients in these studies of 
which 86% were mild-moderate in their severity and settled if the infusion was 
slowed or stopped. The rate of side-effects was significantly higher if Sinerem was 
administered as a concentrated bolus; if given as a dilute infusion far fewer adverse 
events were encountered. The most common adverse events were back pain (3.3%), 
headache (2.9%), pruritus (2.5%), urticaria (2.4%), nausea (2.3%), flushing (1.9%), 
warm feeling (1.7%) erythema (1.6%), rash (1.4%), chest pain (1.3%) and upper 
abdominal pain (1.2%). In summary administration of dextran-associated iron 
 !" 
nanoparticle preparations is safe with a very low incidence of serious adverse events 
and an acceptable rate of minor or self-limiting side-effects [Bernd et al 2009]. 
 
1.11.5      POTENTIAL USES 
The SPIO preparations ferumoxide (Endorem, Guerbet, France) and ferucarbotran 
(Resovist, Bayer-Schering Pharma, Germany) have been used with gadolinium 
routinely in the clinical setting for double-contrast MRI studies of the liver [Bellin et 
al 1998; Semelka and Helmberger 2001]. The iron nanoparticles are taken up by 
Kuppfer cells and cause a reduction in the signal intensity in normal liver, rendering 
pathological areas such as tumours, which are largely devoid of macrophages, more 
obvious. By increasing the conspicuity of such lesions, metastases as small as          
2-3 mm have been detected.  
 
Other applications for iron nanoparticle-based agents are largely experimental and 
include their use as blood pool contrast agents, for ex vivo labelling of cells for in 
vivo cell tracking studies and in inflammation imaging.  
 
(1) Blood Pool Agent 
As blood pool contrast agents, USPIO have a number of potential advantages over 
standard gadolinium-based agents. USPIO contrast agents have a longer circulating 
half-life and reduced extravasation from the blood pool into the interstitium. This 
renders them suitable for both first-pass and particularly for equilibrium-phase 
perfusion studies, and they have been applied to angiographic imaging of vascular 
tumours [Robert et al 2005; Bremerich et al 2007]. However the requirement for 
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ultrashort echo time (TE) sequences and venous contamination are drawbacks. 
Additionally the use of USPIO negates the risk of nephrogenic systemic fibrosis 
(NSF), a rare and irreversible complication of gadolinium-containing contrast media 
occurring particularly in patients with severe renal dysfunction [Thomsen 2006; 




(2) Inflammation Imaging 
USPIO also have the potential for imaging inflammation and tissue-resident 
macrophages in vivo. USPIO-enhanced MRI increases the sensitivity and specificity 
of detection of lymph node metastases, particularly in non-FDG avid tumours such 
as prostate cancer. Other applications have included imaging macrophage activity in 
transplant allograft rejection, stroke, multiple sclerosis, soft tissue inflammation and 
the pancreas in early type I diabetes [Hauger et al 2000; Kaim et al 2003; Lutz et al 
2004; Dousset et al 2006; Jander et al 2007; Wu et al 2009; Gaglia et al 2010]. 
 
In atherosclerotic plaque, following intravenous administration of USPIO, changes in 
signal intensity on T2 weighted (T2W) imaging have been shown to correlate with 
macrophage density [Morishige et al 2010]. USPIO-enhanced MRI can distinguish 
stable from unstable carotid plaques and treatment with atorvastatin reduced USPIO 
uptake and plaque inflammation [Kooi et al 2003; Trivedi et al 2006; Tang et al 
2008a; Tang et al 2009]. USPIO accumulate in the aortae of hypercholesterolaemic 
rabbits. USPIO also concentrate in human AAA, but the distribution of USPIO 
 !" 
within the aneurysm is unknown and no correlation has been made with aneurysm 
expansion or rupture [Tang et al 2009; Sadat et al 2011]. A correlation has been 
shown between USPIO-MRI and 
18
F-FDG PET-CT in carotid plaque assessment 





(3) Cell Labelling 
Finally, SPIO have been used to label a variety of cell types ex vivo for in vivo cell 
tracking studies.  
 
1.12 IN VIVO CELL TRACKING USING SPIO-LABELLING AND MRI 
 
There is increasing interest in the possibility of using cell-based therapies to treat a 
wide range of diseases. The ability to track cells to a target site following delivery is 
highly desirable for the further development of cell-based treatments. There are a 
number of candidate modalities for this purpose, but SPIO-labelling and tracking of 
cells using MRI has emerged as a leading option. Advantages include excellent 
anatomical detail, high sensitivity and avoidance of ionising radiation, which is 
important when serial imaging studies are required. 
 
1.12.1   CELL LABELLING 
 !! 
When injected directly intravenously, SPIO are rapidly taken up by macrophages in 
the reticuloendothelial system and are therefore unsuitable to be used to image tissue 
inflammation. However, this avidity of uptake by mononuclear cells has been 
exploited for cell labelling. Transfection agents have been used to enhance SPIO 
uptake and include poly-L-lysine (PLL), human immunodeficiency virus 
transactivator of transcription (HIV-Tat) peptide and mechanical measures such as 
electroporation. Arbab and colleagues have described a method of labelling cells 
with SPIO (Endorem) using protamine sulphate to optimise its uptake [Arbab et al 
2004b]. This cationic transfection agent both enhances cell-nanoparticle electrostatic 
interactions, and initiates agglomeration of the iron oxide nanoparticles into 
ferumoxide-protamine complexes promoting recognition and uptake by cells. A 
particular advantage of this method of cell labelling is that it is potentially Good 
Manufacturing Practice (GMP) compliant since both Endorem and protamine 
sulphate are approved for use in humans. As described above, labelling in this way is 
non-toxic to mononuclear cells.  
 
Pre-clinical studies 
The potential of SPIO cell tracking was initially demonstrated in a range of animal 
models. Following direct injection in the target organ, MRI scanning was used to 
track labelled cells to a site of injury, tumour or inflammation in the brain, spinal 
cord, knee joint and heart [Kraitchman et al 2003; Chang et al 2008; Jing et al 2008; 
Cohen et al 2009; Hu et al 2009]. SPIO-labelled cells have been tracked to the 
kidney following renal arterial administration in a rat model of renal ischaemia [Jung 
et al 2009]. SPIO-labelled MSC injected subcutaneously along with breast cancer 
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cells in mice were detected in local tumours and distant pulmonary metastases 
[Loebinger et al 2009].  
 
More recently cells have been tracked following systemic intravenous 
administration. SPIO-labelled MSC transplanted via the tail vein homed to de-
endothelialised common carotid artery in splenectomised rats [Cao et al 2009]. In a 
mouse glioma model, SPIO-labelled cells tracking to the tumour was observed 
following intravenous administration [Anderson et al 2005]. Neural precursor cells 
tracked to the ischaemic rat brain [Song et al 2009]. Tracking of SPIO-labelled 
cardiomyocyte-like cells to the injured canine myocardium was confirmed on 
histology and SPECT scanning, but not using 1.5 tesla (T) MRI [Kraitchman et al 
2005; Kim et al 2009]. It was suggested that MRI did not have the sensitivity to 
detect small numbers of cells.  
 
Clinical studies 
Following intra-nodal injection in patients with locally advanced malignant 
melanoma with nodal spread, SPIO- and 
111
In-labelled autologous dendritic cells 
were tracked to regional lymph nodes using both MRI and scintigraphy [de Vries et 
al 2005]. Magnetic resonance imaging was found to be more sensitive than 
scintigraphy for cell detection, and MRI provided superior anatomical detail. Cells 
were detected in small numbers (1.5 x 10
5
 cells) using MRI. 
 
In a patient with a traumatic brain injury, SPIO-labelled cells were injected around 
the site of the injury using stereotactic surgery. A second patient received unlabelled 
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cells. Labelled but not unlabelled cells migrated and produced a hypointense signal 
around the injured brain [Zhu et al 2006].  
 
Finally SPIO-labelled pancreatic islet cells were administered into the portal vein of 
insulin-dependent diabetic patients [Toso et al 2008]. The labelled cells were 
visualised on MRI scanning as hypointense lesions within the liver, but there was no 
correlation with the number of cells administered. Transplantation was successful in 
achieving independence from insulin in all patients, indicating conservation of cell 
function despite SPIO-labelling. 
 
Successful tracking of SPIO-labelled cells to a target site following intravenous 
administration has not yet been reported. 
 
1.13 MAGNETIC RESONANCE IMAGING OF SPIO 
 
SPIO can be detected with standard, clinically available MRI sequences. Application 
of an excitatory radiofrequency pulse flips the net magnetisation vector (NMV) into 
the transverse plane creating a current in the receiver coil that constitutes the signal. 
The signal is expected to decay exponentially with time and this decay process is 
described by a constant called the T2* value.  
 
Superparamagnetic contrast agents such as SPIO induce local magnetic field 
inhomogeneities leading to a rapid loss of phase-coherence amongst spinning 
magnetic nuclei following application of a radiofrequency pulse. This results in more 
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rapid decay of signal intensity over time corresponding to a shortening of the T2 and 
T2* relaxation times and a sharp reduction in the T2* value. On the resulting images, 
a profound reduction in the signal intensity is evident on T2W and particularly 
T2*W images, and tissues in which SPIO accumulate appear dark on T2W and 
T2*W studies. SPIO also have a T1 shortening effect that is most obvious at low 
concentrations whilst at higher concentrations T2* susceptibility effects predominate 
[Canet et al 1993; Torabi et al 2004]. 
 
Gradient echo sequences have a lower signal-to-noise ratio and inferior spatial 
resolution when compared to standard spin echo sequences, however their exquisite 
sensitivity to iron accumulation is advantageous for SPIO imaging. Using a multi 
echo sequence the signal intensity is sampled serially at increasing echo times 
allowing calculation of the T2* value (S(t)=S(0)exp-(t/T2*)). Changes in signal 
intensity on T2W or T2*W imaging, and changes in T2* value or its inverse R2* 
(T2*=1/R2*), may be used to assess iron accumulation. 
 
1.13.1   CHALLENGES OF QUANTIFICATION OF IRON IN TISSUES 
T2* and R2* values correlate with hepatic and cardiac iron concentration in sickle 
cell and thalassaemia patients with transfusion-related iron overload [Anderson et al 
2001; Wood et al 2005; Storey et al 2007]. A linear, concentration-dependent 
increase in R2 and R2* values has been observed for both free SPIO and SPIO-
labelled cells in in vitro agarose phantoms [Kuhlpeter et al 2007].  
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Interestingly, for free SPIO the R2* values are only slightly longer than the 
corresponding R2 values at a given concentration of iron, but if SPIO are 
compartmentalised within cells the effect on T2* decay is more pronounced and R2* 
values are much longer. Differences have also been noted amongst different cell 
types, presumably related to the way that iron is stored within the cell [Rad et al 
2007]. These differences are observed because, when SPIO particles are clustered 
together, the magnitude of their magnetic properties is similar to that expected from 
the overall size of the cluster rather than the sum of their individual volumes 
[Tanimoto et al 2001]. There may also be an element of magnetic co-operativity 
between particles. Consequently, in accordance with the static dephasing regime 
theory, the susceptibility effect of clustered SPIO is exaggerated and much greater 
than the sum of the effect of individual particles [Tanimoto et al 2001; Bowen et al 
2002]. As a result of this phenomenon, true quantification of SPIO in tissues is 
challenging since interpretation depends upon the context in which the particles are 
imaged. 
 
Spatial resolution is critical to the detection of SPIO. A partial volume effect occurs 
if the size of the signal deficit induced is much smaller than the size of the voxel, 
reducing the sensitivity to detect SPIO. Furthermore, when clustered, SPIO exhibit a 
‘blooming effect’ in which the spatial extent of the magnetic effect of the cluster 
extends substantially beyond the size of the cluster itself. This can make precise 
localisation of SPIO accumulation in tissues challenging, but has the advantage of 
increasing the sensitivity. With sufficient spatial resolution, single cell imaging of 
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cells labelled with micron-sized particles of iron oxide (MPIO) has been reported 
[Heyn et al 2006; Shapiro et al 2006].  
 
1.13.2   APPROACHES TO SPIO DETECTION IN HUMANS 
There are a number of reported methods for assessing SPIO accumulation in tissues. 
Images may be observed for signal deficits which is straight-forward but purely 
qualitative and open to operator bias [Zhu et al 2006]. 
 
Trivedi et al used small, manually-drawn regions of interest (ROI) to sample carotid 
arterial plaque and compared changes in signal intensity normalised to the signal 
intensity of adjacent sternocleidomastoid muscle [Trivedi et al 2006]. This approach 
is susceptible to observer bias and does not sample the whole vessel leading to the 
possibility of missing focal USPIO accumulation. Furthermore, it does not account 
for the T1 effects of USPIO and assumes that the signal intensity in adjacent muscle 
is unchanged by USPIO administration, which may not hold true due to the 
prolonged half-life of USPIO in the blood pool.  
 
In their assessment of carotid plaque, Tang et al adopted a quadrant approach to 
reduce observer bias and allow the entire plaque to be sampled [Tang et al 2009]. 
This did, however, compromise spatial resolution such that focal USPIO 
accumulation may have been masked. This approach also precluded localisation of 
USPIO uptake to different components of the plaque. 
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The advantage of using T2* or R2* values rather than signal intensity to detect 
USPIO accumulation is that, in theory, it is a tissue property which should be 
independent of repetition time (TR), echo time and flip angle as well as the T1 
effects of USPIO which would affect signal intensity values. If the absolute signal 
intensity or T2* value following USPIO administration is used rather than the change 
(pre minus post), other sources of signal deficit such as haemorrhage and 
calcification may confound data interpretation. Even if the latter approach is used, 
signal dropout due to calcification and haemorrhage may mask signal changes 
resulting from USPIO uptake. 
 
A range of positive contrast sequences is being developed to improve tissue detection 
of SPIO agents but at present none of these sequences is commercially available 
[Seppenwoolde et al 2003; Mani et al 2006; Stuber et al 2007; Eibofner et al 2010]. 
 
Some uncertainties still exist around the interpretation of USPIO data. For example 
the exact mechanism by which USPIO enters tissues and cells is unclear. It may be 
that increased capillary permeability allows USPIO to leak out into the interstitium 
where upon it is ingested by tissue resident macrophages. Alternatively 
monocytes/macrophages in the blood stream may ingest the USPIO particles and 
transport them to the site of inflammation. Precisely which aspects of the 
inflammatory process USPIO-enhancement indicates is therefore a subject of debate. 
The specificity of USPIO-enhancement beyond the first 72 hours is also unclear. 
 
 !" 
Regardless of these outstanding questions and challenges, the potential of SPIO and 
USPIO contrast agents to probe biological processes in vivo is without doubt 
exciting. Recognising this, a pragmatic and semi-quantitative approach to data 




Prediction of aneurysm expansion and rupture amongst patients under surveillance 
for AAA is challenging and reliance upon diameter measurements alone appears to 
be inadequate. Hotspots of biological activity are thought to represent weakened 
areas of the aortic wall at risk of expansion and rupture. Evolving cellular and 
molecular imaging techniques open up the possibility of using these hotspots as 
imaging targets to identify unstable aneurysms at risk of rupture. USPIO-enhanced 
MRI scanning can detect cellular inflammation with excellent spatial resolution and 
may be a useful investigative tool for assessing AAA. Accessing the biological 
processes involved in AAA would be useful for developing and monitoring the 
effects of novel pharmacological interventions for aneurysm disease. 
 
Iron oxide nanoparticles can also be used to label cells for in vivo cell tracking 
studies. Capability to do this would be extremely useful for the further development 
and assessment of cell-based therapies for a wide range of diseases. 
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1.15 AIMS AND HYPOTHESES 
 
The aim of this thesis is to investigate the role of magnetic resonance imaging with 
superparamagnetic particles of iron oxide with relevance to the cardiovascular 
system. Specifically, we will develop data acquisition and image analysis 
methodology for the detection of focal iron accumulation in tissues. We will then 
apply these techniques to the detection of inflammation in the aortic wall in patients 
with abdominal aortic aneurysms using USPIO-enhanced MRI, and correlate the 
findings with clinical disease progression. We will also develop a GMP compliant 
method of labelling cells ex vivo with SPIO for clinical cell tracking. We will assess 
the safety of administration of SPIO-labelled cells in humans, and determine the 




The following novel hypotheses will be addressed: 
 
1. Changes in T2* value on clinical MRI scanning can be used to detect focal 
iron accumulation in tissues (Chapter 3). 
2. USPIO-enhanced MRI can be used to detect inflammation in the wall of 
AAA and predict aneurysm expansion (Chapter 4). 
3. Peripheral blood mononuclear cells (PBMC) can be labelled with SPIO ex 
vivo under GMP compliant conditions without affecting cell viability or 
function (Chapter 5). 
4. Local and systemic administration of SPIO-labelled PBMC in humans is safe 
and SPIO-labelled cells can be detected at a target site using clinical magnetic 
resonance imaging (Chapter 6). 
5. SPIO-labelled PBMC can be tracked to an inflammatory focus in humans 

























2.1.1   ETHICAL AND REGULATORY CONSIDERATIONS 
All studies were undertaken with the approval of the Lothian Local Research Ethics 
Committee or Scotland A Research Ethics Committee. The Medicines and 
Healthcare Products Regulatory Agency (MHRA) approved the use of the MRI 
contrast agent Sinerem (Guerbet, France) to investigate patients with AAA as a 
Clinical Trial of an Investigational Medicinal Product (CTIMP). All studies were 
conducted in accordance with the Declaration of Helsinki. Studies were registered on 
the public website www.clinicaltrials.gov (NCT00794092; NCT00972946; 
NCT01169935). 
 
2.1.2   SUBJECT RECRUITMENT 
All participants gave written informed consent before participating in the study. An 
information sheet was provided electronically and participants’ general practitioners 
were informed in writing. 
 
2.1.3   PATIENTS WITH ABDOMINAL AORTIC ANEURYSMS 
Patients with AAA with aortic diameter >4.0 cm on ultrasound scanning were 
identified from the outpatient aneurysm surveillance database at the Royal Infirmary 
of Edinburgh.  
 
Patients who were under the age of 40 years old were excluded from participating in 
the study since we were interested in degenerative aneurysms rather than those 
! "#!
secondary to other conditions such as connective tissue disorders. Patients who were 
pregnant, and those who had active systemic inflammatory or malignant disease, 
renal dysfunction (estimated glomerular filtration rate (eGFR) <25 mL/min), hepatic 
cirrhosis (Child-Pugh score B or C), recent surgical procedure or a contraindication 
to MRI scanning were also excluded from the study.  
 
2.1.4   HEALTHY VOLUNTEERS 
Healthy volunteers (aged >18 years) were recruited by local advertisement through 
the University of Edinburgh.  
 
Volunteers were excluded from participation in the study on the basis of the presence 
of any of the following: renal dysfunction (eGFR <25 mL/min), hepatic dysfunction 
(Child-Pugh score B or C), positive virology screen, pregnancy, breast feeding, 
blood dyscrasia, anaemia (Hb <12 g/dL), iron storage disorder, active malignancy, 
chronic inflammatory condition, history of or risk factors for protamine allergy, 
intercurrent illness, recent surgical procedure and contraindication to MRI scanning. 
 
2.1.5   TUBERCULOSIS CONTACTS 
Participants known to have a positive Mantoux test response, but not suffering from 
active tuberculosis, were identified from the Royal Infirmary of Edinburgh 
Department of Respiratory Medicine database of such patients. All known 
tuberculosis contacts are invited to the respiratory clinic for clinical assessment 
including a Mantoux test, a blood test and a chest radiograph. We included subjects 
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who had had a positive Mantoux test but had no symptoms or radiological features of 
tuberculosis.   
 
Subjects were also excluded from participating in the study if they had renal 
dysfunction (eGFR <25 mL/min), hepatic dysfunction (Child-Pugh score B or C), 
positive virology screen, pregnancy, breast feeding, blood dyscrasia, anaemia 
(Hb <12 g/dL), iron storage disorder, active malignancy, chronic inflammatory 
condition, history of or risk factors for protamine allergy, intercurrent illness, recent 
surgical procedure or a contraindication to MRI scanning. 
 
2.2 EX VIVO LABELLING OF PERIPHERAL BLOOD MONONUCLEAR 
CELLS WITH SPIO 
 
2.2.1   CELL PROCUREMENT  
Venesection  
For in vitro laboratory work, whole venous blood (up to 240 mL) was obtained from 
a vein in the antecubital fossa using a large 17-gauge butterfly needle. Blood was 
collected into 50 mL tubes (Becton Dickinson Biosciences, USA) with 4 mL of the 
anticoagulant citrate per 40 mL of whole blood. Up to ~2 !!10
8
 PBMC can be 
obtained from 250 mL of whole blood. 
 
Where cells were to be processed for autologous reinfusion, blood was collected in 
the Cell Separator Unit of the Royal Infirmary of Edinburgh by connecting a 16-




To achieve higher cell numbers, the process of apheresis, selective collection of 
specific blood components, was used. This process is used routinely in clinical 
practice, with applications including, plasma exchange, peripheral blood stem cell 
donations and red blood cell exchanges. A COBE Spectra apheresis machine 
(Gambro BCT, Lakewood, CO) was used according to the manufacturer’s 
instructions. The manufacturer’s standard validated protocol for donor lymphocyte 
collection (SOP No. 00 513 008: Donor Lymphocyte Collection, COBE Spectra 
Operator’s Manual) was followed. 
 
In brief, whole blood anticoagulated with citrate was drawn continuously from a 
peripheral vein into a rotating centrifuge. Blood components were separated on the 
basis of their density with red blood cells accumulating towards the outside and 
plasma on the inside of the chamber. The PBMC layer, which contains monocytes 
and leucocytes, was harvested between the two. The flow rate was manipulated to 
vary the position of the PBMC layer with relation to the collection port, and these 
adjustments were guided by regular comparison of the colour of the harvested 
product to a validated chart by the operating nurse. This optimised the purity of 
collection, minimising the degree of contamination by other blood components. The 
remaining blood components were continuously returned to the circulation through a 
second point of venous access such that at any point in time not more than 260 mL of 
the circulating volume was extracorporeal. Participants were observed for signs of 
! "#!
hypocalcaemia secondary to citrate toxicity and were treated by oral calcium 
replacement. 
 
A 90-minute collection typically yielded approximately 100-150 mL of apheresis 




2.2.2   CELL PREPARATION AND LABELLING 
Mononuclear cell isolation from whole blood or apheresis product 
Whole blood or apheresis product was diluted 1:1 in phosphate buffered saline (PBS) 
and mononuclear cells were isolated by Ficoll (Histopaque) density gradient 
separation (400 g, 40 min). The mononuclear cell layer was harvested and washed 
twice in PBS.  
 
Arbab protocol for labelling cells with SPIO 
Arbab et al described a method for labelling cells with SPIO using protamine 
sulphate as a transfection agent to enhance its uptake [Arbab et al 2004]. SPIO 
(Endorem, Guerbet, France) was diluted to a concentration of 100 µg/mL in phenol 
red free Roswell Park Memorial Institute (RPMI) medium (Sigma Aldrich). 
Protamine sulphate (ProSulf, CP pharmaceuticals) was added (5 µg/mL) and SPIO-
protamine complexes were allowed to form for 10 minutes. The mononuclear cell 
pellet was re-suspended in the SPIO-protamine suspension with a final cell 
concentration of 4 ! 10
6 
cells/mL and incubated at 37°C for 3 hours in 5% CO2. The 
cell suspension was further diluted to a final SPIO concentration of 50 µg/mL and 
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incubated overnight. At the end of the incubation period, the cells were washed two 
or three times in RPMI until the supernatant was clear.  
 
Edinburgh protocol 
Guided by in vitro assays of cell viability and function, the Arbab protocol was 
adapted for clinical scale labelling of PBMC under GMP compliant conditions 
generating the Edinburgh protocol (Chapter 5). Implementation of the Edinburgh 
protocol in a GMP facility is outlined in full in the standard operating procedure in 
Appendix 1.  
 
In brief, the mononuclear cell pellet was re-suspended in the volume of 0.9% saline 
required to give a cell concentration of 4 ! 10
6 
cells/mL. One hundred µg/mL of 
SPIO (Endorem) and 4 µg/mL of protamine sulphate were added directly into the 
cell suspension. The cells were transferred immediately in 250 mL polypropylene 
tubes (Becton Dickinson Biosciences, USA) to a roller mixer and were incubated at 
room temperature for 2 hours. 
 
For clinical studies, cell preparation and labelling was undertaken in the GMP 
compliant Scottish National Blood Transfusion Service Tissue Services laboratory. 
Consistent with GMP regulations, sterility testing was integrated into each step of the 
protocol. At the end of the incubation period, the cell number was ascertained and 




2.3 IN VITRO EVALUATION OF CELLULAR EFFECTS OF SPIO-
LABELLING 
 
2.3.1 IMMUNOMAGNETIC SEPARATION OF MONOCYTES FROM PERIPHERAL BLOOD 
MONONUCLEAR CELLS 
Using indirect magnetic labelling, monocytes were isolated from PBMC for 
assessment of cellular iron content and migratory capacity. This technique involves 
indirect immunomagnetic labelling of non-monocytes (including T cells, B cells, 
NK cells and basophils) using a cocktail of biotin-conjugated antibodies (CD3, CD7, 
CD16, CD19, CD56, CD123, Glycophorin A) and magnetic anti-biotin Microbeads 
(Monocyte Isolation Kit II, Miltenyi Biotec).  
 
Peripheral blood mononuclear cells were centrifuged (300 g for 10 min), the 
supernatant was aspirated entirely and the cell pellet was resuspended in 30 µL 
per 10
7 
cells of buffer (PBS, 0.5% bovine serum albumin, 2 mM 
ethylenediaminetetraacetic acid (EDTA)). Ten µL of FcR blocking reagent and 
10 µL of biotin-antibody cocktail per 107 cells were added and the mixture was 
incubated for 10 minutes at 4°C. Thirty µL of buffer and 20 µL of anti-biotin 
microbeads per 10
7 
cells were added and the mixture was incubated for 15 minutes at 
4°C. Cells were washed in 2 mL of buffer and centrifuged at 300 g for 10 minutes 
before being re-suspended in 500 µL of buffer. A magnetic-activated cell sorting 
(MACS) column was placed in a magnetic field (1.5T) and primed with 3 mL of 
buffer. Cells were passed through a pre-separation filter (pore size 100 µm) into the 
column and the effluent containing the monocytes was collected. Non-monocytes 
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were retained within the column. Flow cytometry confirmed the monocyte purity to 
be approximately 90%.  
 
2.3.2   QUANTIFICATION OF CELLULAR IRON CONTENT  
Cellular iron content was assessed using the Ferrozine assay. 10
5
 monocytes were 
lysed for 10 minutes in 100 µL of 1% triton. One hundred µL of iron-releasing 
reagent (a freshly mixed solution of equal volumes of 1.4 M HCl and 4.5% KMnO4 
in distilled water) was added and the tubes were incubated at 60°C for 2 hours to 
release protein-bound iron (e.g. haemoglobin, ferritin). The mixture was then cooled 
to room temperature and 30 µL of the iron detection reagent was added (6.5 nM 
Ferrozine, 6.5 mM Neocuprine, 2.5 M ammonium acetate and 1 M ascorbic acid in 
distilled water). After 30 minutes, 280 µL of the resulting solution was transferred to 
a 96-well plate.  
 
In order to determine the actual iron content of the test solutions a standard curve 
was generated using solutions of known concentration of FeCl3 in 10 mM HCl 
(range 0-300 µM). One hundred µL of 50 nM NaOH and 100 µL of the iron 
detection reagent were added to 100 µL of the iron standard solution. After 
30 minutes, 280 µL of the solution was transferred to the 96-well plate. A plate 
reader was used to measure the light absorbance at 490 nm. The iron content was 





2.3.3   CELL VIABILITY 
Cells were allowed to adhere for 1 hour in 24-well tissue culture plates (10
6
 
cells/well; 37°C; 5% CO2) following which the medium was harvested and 
exchanged for fresh Iscove’s modified Dulbecco’s medium (IMDM) supplemented 
with penicillin (100 U/mL), streptomycin (100 U/mL) and 10% autologous serum. 
This prevented continued uptake of SPIO and avoided interference of excess SPIO 
with the assays. 
 
Flow cytometry: annexin V-binding and propidium iodide (PI) staining 
Cells were harvested for analysis at 1, 24 and 72 hours using 0.25% trypsin and 
EDTA. Cell suspensions were incubated for 10 minutes on ice in annexin V-binding 
buffer (Hank’s balanced salt solution (HBSS) containing 5 mM CaCl2) with FITC-
annexin V. Propidium iodide (PI; final concentration 2 µg/mL) was added to the cell 
suspension/annexin V-binding buffer mixture for 1 minute prior to analysis using a 
FACSCalibur flow cytometer (Becton Dickinson Biosciences, USA) equipped with 
CellQuest data analysis software.  
 
Annexin V binds to phosphatidylserine expressed at the surface of cells in the early 
phase of apoptosis, and PI staining indicates permeability of the cell membrane in 
necrotic cells and cells in the late phase of apoptosis. Cells that were negative for 
both annexin V-binding and PI staining were classed as viable. The percentage of 
cells positive for annexin V-binding, PI staining, or both were combined to give an 
overall percentage of cytotoxicity. 
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Lactate dehydrogenase assay 
The potential cytotoxicity of SPIO-labelling was also assessed using a lactate 
dehydrogenase (LDH) assay (Roche, Diagnostics Ltd, UK) according to the 
manufacturer’s instructions. Lactate dehydrogenase is ubiquitous in all cells, is 
released following cell membrane damage and can be used to measure cytoxicity. 
Lactate dehydrogenase catalyses the conversion of lactate to pyruvate and in doing 
so reduces NAD+ to NAD/H
+
. In the assay, in the presence of H
+
, the tetrazolium 
salt (yellow) is converted to formazan (red) and this colour change is detectable 
using spectrophotometry. This test has the sensitivity to detect LDH release from as 
few as 500 cells per well of a 96-well plate. 
 
After 24, 48 or 72 hours supernatants were collected for LDH measurement.  
Remaining cells were lysed and LDH was measured in the cell lysates in order to 
calculate the total LDH activity. The LDH activity in the supernatant as a percentage 
of the total (supernatant plus lysed cells) was calculated to give the percentage 
cytotoxicity.  
 
2.3.4   !"#$%&'&(#%&)$*)'*(+%),&$-*.-/-#0- 
The concentration of the inflammatory cytokines IL-1b, IL-6, IL-8, IL-10, IL-12p70, 
and TNF released from cells post labelling was measured using a cytometric bead 
array kit (Human Inflammatory Cytokine Kit; Becton Dickinson Biosciences, USA) 
according to the manufacturer’s instructions. The limit of detection for this test was 
cytokine-specific: IL-1! 7.2 pg/mL, IL-6 2.5 pg/mL, IL-10 3.3 pg/mL, TNF 
3.7 pg/mL and IL-12p70 1.9 pg/mL. Within the concentration range tested, the 
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cytometric bead array kit has acceptable precision with intra-assay coefficient of 
variation (CV; standard deviation divided by the mean) of 4-9% and inter-assay CV 
of 4-13%.  
 
Labelled and unlabelled cells were plated as described above for 24, 48 and 72 hours. 
Cell supernatants were harvested and stored (-70°C) for batch analysis. Each sample 
(25 !L) was incubated (3 hours; room temperature; protected from light) with the 
mixed Human Inflammation Capture Bead suspension (25 !L) in a round-bottomed 
96-well tissue culture plate. Analysis was performed by FACSArray cytometer 
(Becton Dickinson Biosciences, USA) equipped with FACSArray data analysis 
software. The concentration of each cytokine was calculated from a standard curve 
generated from the Human Inflammation Standards provided.  
 
2.3.5   MIGRATORY CAPACITY 
Labelled and unlabelled MACS-purified monocytes were loaded into the upper 
chamber (2.5 x 10
5
 cells/well) of a modified Boyden chamber (Transwell 
polycarbonate inserts; 5 !m pore size, 24-well plates; Corning Costar, USA). Cells 
were allowed to migrate for 2 hours (37°C with 5% CO2) through the microporous 
membrane into the lower chamber containing 600 µL RPMI with and without the 
chemokine human MCP-1; Recombinant Human CCL2/MCP-1, (R&D Systems; 
50 ng/mL). Cells that had actively migrated through the membrane and adhered to its 
underside were fixed (100% methanol; 10 min) and stained with DiffQuik! 
physiological stain as well as with the Prussian blue stain for iron. Transmigration 
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was quantified by counting the number of cells present in five randomly selected 
high power light microscopy fields (x40).   
 
2.4 HISTOPATHOLOGICAL PROCESSING 
 
2.4.1   CYTOSPIN PREPARATIONS 
Cells (~10
4 
cells) were cyto-centrifuged (300 rpm; 3 min) onto glass microscope 
slides. Resultant slides were fixed in methanol (100%; 1 min) and stained 
appropriately. 
 
2.4.2   TISSUE SAMPLES 
Whole tissue samples were fixed in ample 4% paraformaldehyde for at least 
24 hours, dehydrated in progressively more concentrated alcohol solutions (70-100% 
ethanol), washed with xylene and embedded in paraffin wax. Slices of the tissue 
specimen (typically 5 µm thick) were mounted onto glass slides. In preparation for 
staining, the paraffin wax was removed by washing twice in xylene. Samples were 
then rehydrated in progressively weaker alcohol concentrations (100-70%) and 
rinsed in distilled water before staining. 
 
2.4.3   DIFFQUIK!  PHYSIOLOGICAL STAIN 
Diffquick stain (modified Romanowsky stain) provided cytoplasmic detail. Air-dried 
ethanol-fixed slides were exposed to Diffquick solution 1 (eosinophilic) for 
30 seconds followed by Diffquick solution 2 (basophilic) and allowed to air-dry. 
Monocyte nuclei stained violet and the cytoplasm stained sky blue. 
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2.4.4   PRUSSIAN BLUE STAIN 
Cellular iron uptake was confirmed by Prussian blue staining of tissue or cytospin 
preparations. Slides were stained with a freshly mixed solution of 5% potassium 
ferrocyanide and 5% hydrochloric acid for 15 minutes. Having allowed the slides to 
dry completely they were counter stained with Nuclear Fast Red (Sigma Aldrich, 
UK) prior to observation by light microscopy. Perl’s Prussian blue stain causes iron 
to appear bright/dark blue. 
 
2.5 IN VITRO MRI PHANTOM STUDIES 
 
To mimic vascular tissue, phantoms were generated using 50 mL 0.15% agarose gel 
with 0.11 mM gadolinium EDTA [Walker et al 1989]. In brief, 0.16 g gadolinium 
chloride was dissolved in 10 mL deionised water. 0.32 g EDTA was dissolved in 
10 mL deionised water, combined with the gadolinium chloride and diluted further to 
500 mL. 0.75 g agarose was added and 0.1 M sodium hydroxide was added 
dropwise, titrating the pH to approximately 7.5 to allow full dissolution and achieve 
physiological pH conditions. The resulting agarose/GdCl3/EDTA mixture was heated 
in a water bath at 90ºC for 1 hour before distribution into 50 mL tubes. 
 
Two different preparations of superparamagnetic iron oxide nanoparticles stabilised 
with dextran and citrate were incorporated into these phantoms: ferumoxide 
(Endorem, Guerbet, France; SPIO; mean hydrodynamic particle diameter 80-
150 nm) and ferumoxtran (Sinerem, Guerbet, France; USPIO; mean hydrodynamic 
! "#!
particle diameter 10-30 nm). In addition, using the Edinburgh protocol, human 
mononuclear cells were labelled with Endorem (100 µg/mL) in the presence of 
protamine sulphate (4 µg/mL) in 0.9 % saline for 2 hours at room temperature. Free 
USPIO, free SPIO or SPIO-labelled cells were added to the partially cooled gel in a 
range of concentrations. Phantoms were placed in a water bath and scanned using a 
3T clinical MRI scanner. 
 
2.6 MAGNETIC RESONANCE IMAGING CONTRAST AGENTS 
 
2.6.1   SUPERPARAMAGNETIC PARTICLES OF IRON OXIDE 
Two different SPIO contrast agents were used. SPIO are predominantly strong 
negative T2W and T2*W contrast agents, but also have weak positive T1 
enhancement at low concentrations. Both SPIO preparations consisted of dextran-




Ferumoxide (Endorem, Guerbet, France) consisted of iron oxide particles with a 
mean hydrodynamic particle diameter 80-150 nm. Supplied as an aqueous 
suspension (11.2 mg Fe/mL) it was used for ex vivo labelling of PBMC.  
 
Sinerem 
Ferumoxtran (Sinerem, Guerbet, France) contains USPIO with a mean 
hydrodynamic particle diameter of 10-30 nm. As such, USPIO escape immediate 
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recognition by the reticuloendothelial system and can be used for imaging tissue 
inflammation. Indeed we have used Sinerem for the detection of inflammation in 
AAA. Supplied as a dry powder, it was first reconstituted in 10 mL of 0.9% saline 
and then the weight-adjusted dose of 2.6 mg/kg was diluted further in 100 mL of 
0.9% saline. The resulting USPIO suspension was administered through a filter as a 
slow infusion over 30 minutes through a peripheral 20-gauge intravenous cannula. 
 
Gadolinium 
Gadolinium is a paramagnetic contrast agent that causes positive enhancement on 
T1W images. The gadolinium-based agent Dotarem (0.5 mmol/mL Gd-DOTA; 
Guerbet, France) was supplied as a liquid and administered intravenously using a 
power injector at a dose of 0.2 mL/kg bodyweight. 
 
2.7 MAGNETIC RESONANCE IMAGING 
 
The principles of magnetic resonance imaging are discussed further in Appendix 2.  
 
2.7.1   RELAXATION 
When exposed to the external magnetic field (B0) of the MRI scanner, protons align 
with an orientation parallel (low-energy state) or anti-parallel (high-energy state) to 
B0. A radiofrequency pulse is applied as a result of which a proportion of protons 
gain energy and the NMV is deflected away from the static magnetic field (B0) into 
the transverse plane. Coherent (in phase) transverse magnetisation induces a current 
constituting the signal in the receiver coil. At the end of the radiofrequency pulse, the 
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NMV tends to relax and realign with B0. Recovery of longitudinal magnetisation 
occurs as a proportion of protons in the high-energy state return to the low-energy 
state by emitting some of the energy (photons) that they had gained from the 
radiofrequency pulse (i.e. T1 recovery). The second component of relaxation is loss 
of coherent transverse magnetisation as spinning nuclei transfer energy amongst each 
other leading to loss of phase-coherence (i.e. T2 decay).  
 
T2* decay is the loss of phase-coherence through a combination of T2 decay (due to 
spin-spin interactions) and small local magnetic field inhomogeneities. The T2* 
value is always shorter than the T2 value.  
 
2.7.2   MRI SEQUENCES  
Spin echo sequences 
T1W and T2W turbo spin echo sequences were used to acquire detailed anatomical 
data. Spin echo sequences have a relatively long acquisition time but have a high 
signal-to-noise ratio and give excellent anatomical definition. A 90
o
 radiofrequency 
pulse is applied flipping the NMV into the transverse plane. As a result of T2* 
decay, the precessing protons begin to dephase immediately and phase-coherence is 
lost rapidly. To compensate for T2* decay, a further 180
o
 rephasing radiofrequency 
pulse is applied at a time t (where t=TE/2), which reverses the direction of the NMV. 





Gradient echo sequences 
Gradient echo sequences were used to detect SPIO accumulation. A gradient 
magnetic field is induced at an angle to B0 and interacts with the main magnetic field 
such that the composite field strength varies along the axis of B0. Protons in different 
parts of the magnetic field are therefore exposed to different field strengths and 
precess at different frequencies. Gradual dephasing of coherent transverse 
magnetisation occurs and protons are rephased by application of a second gradient. 
The signal induced in the receiver coil at this point is called the gradient echo. 
 
Compared to images acquired using spin echo sequences, gradient echo sequences 
have a poorer signal-to-noise ratio but are acquired much more quickly. There is no 
compensation for T2* decay and gradient echo sequences are therefore highly 
sensitive to the magnetic field inhomogeneities induced by SPIO.  
 
Multi echo gradient echo sequences  
In a multi echo gradient echo sequence the signal is sampled at multiple echo times 
following a radiofrequency pulse. Compared to acquiring the echoes using separate 
radiofrequency pulses, the use of a multi echo sequence reduces the acquisition time 
and, because the echoes are collected only milliseconds apart, avoids the need to 






2.7.3   DATA ANALYSIS:  
Following a radiofrequency pulse sequence, the signal decays exponentially with 
increasing echo time. Both endogenous iron and SPIO induce local magnetic field 
inhomogeneities. Rapid dephasing of coherent transverse magnetisation occurs and 
the signal intensity decays more rapidly in the presence of SPIO. As a result, tissues 
in which SPIO accumulate appear dark on T2W and particularly T2*W images. 
SPIO also have a T1 shortening effect that is most obvious at low concentrations, 
whilst at higher concentrations T2* susceptibility effects predominate [Canet et al 
1993; Torabi et al 2004]. These T1 effects may confound data interpretation data if 
analysis is based on measurement of signal intensity at a single echo time. 
 
The rate of decay of signal intensity is determined by the decay constant the T2* 
value calculated by the equation S(t)=S(0)exp-(t/T2*), where S(t) is the signal 
intensity at time t, and S(0) is the signal intensity at time 0. The rate of decay of 
signal intensity with echo time is increased in the presence of SPIO with a 
corresponding reduction in T2* value. Changes in T2* value and its inverse the R2* 
value (T2*=1/R2*) have been exploited for the detection of endogenous iron 
accumulation such as occurs in haemochromatosis and transfusion-related iron 
overload in patients with thalassaemia major. Using multi echo sequences, a 
reduction in T2* value or an increase in R2* value is observed in the myocardium 
and the liver in patients with systemic iron overload [Anderson et al 2001; Wood et 
al 2005; Storey et al 2007]. 
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The advantage of using T2* or R2* for analysis is that these measures are 
independent of tissue effects and the T1 effects of SPIO. 
 
Registration 
T2W images have excellent discrimination of the lumen, thrombus, aortic wall and 
surrounding tissues.  
 
T2*W sequences have less distinct soft tissue contrast but are exquisitely sensitive to 
the effects of USPIO accumulation. To allow comparison of serial imaging studies 
and to utilise the strengths of both of these image weightings, the T2W and T2*W 
images were co-registered.  
 
Registration was performed using a semi-automatic 3-dimensional rigid voxel 
registration protocol utilising a normalised mutual information algorithm (Analyze, 
Mayo Clinic). The T2W images acquired on the first study visit were designated as 
the baseline images to which all other images were registered. T2*W images (first 
echo) were registered to the corresponding T2W images acquired on the same day. 
Subsequent T2W images were registered to the baseline T2W images. The use of 
multi echo T2*W sequences obviated the need for registration of individual echoes 
to each other since they were acquired only milliseconds apart. Where echoes were 





T2* and R2* value calculation 
A Gaussian filter was applied to the individual echoes to minimise noise corruption 
of the raw data. Using a multi echo T2*W sequence or by careful registration of 
separately-acquired echoes, the T2* or R2* value was calculated on a single voxel 
basis. For each voxel position, a plot of the natural log of the signal intensity versus 
the corresponding echo time was produced with the negative inverse gradient giving 
the T2* value. The R2* value was calculated using the negative gradient. A straight 
line was fitted to the four data points using a standard least squares method. The 
coefficient of determination (r
2
) and the sum of squared deviations due to error (SSE) 
were used to exclude data that did not have an acceptable straight line fit. The 
thresholds for r
2
 and SSE were determined experimentally by examining a subset of 
the data (Matlab, The Mathworks Inc, USA).  
 
Data presentation 
Data were then presented as T2* or R2* maps where the magnitude of each voxel 
represented the T2* or R2* value. Where appropriate, data were also presented using 
!T2* maps where each voxel represented the change in T2* value following the 
administration of the contrast agent. A colour scale was used to facilitate qualitative 
data interpretation. T2*W sequences are sensitive not only to the presence of iron but 
also to other sources of artefact. Where possible the repeatability of the T2* value 
measurement in the absence of SPIO or USPIO was established and used to define a 
threshold above which any changes in T2* could be attributed with confidence to 
SPIO or USPIO accumulation.  
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Regions of interest were defined on anatomical T1W or T2W images, applied to the 
T2* or R2* maps and used to compare data quantitatively.  
 
2.7.4   STATISTICAL ANALYSIS  
The Bland and Altman method was used to evaluate the repeatability of the T2* 
measurements [Bland and Altman 1986]. Continuous data were compared with a 
two-tailed Student t-test, whilst paired continuous data were compared with a two-
tailed paired Student t-test. Continuous data with multiple timepoints were compared 
using a one-way analysis of variance (ANOVA) with repeated measures and Tukey’s 
or Bonferroni’s post-test comparison. Categorical data were anlaysed using Chi-
squared test with cross-tabulation. Analyses were performed using 
Statistical Package for the Social Sciences (SPSS), Minitab or GraphPad Prism 
(GraphPad Software, USA) where appropriate. In each case statistical significance 
was taken as two-sided P <0.05.!!
 








ASSESSMENT OF TISSUE ACCUMULATION OF 
SUPERPARAMAGNETIC PARTICLES OF IRON OXIDE USING 
MAGNETIC RESONANCE IMAGING 
!
!




Contrast agents containing SPIO have been used for clinical MRI of vascular 
inflammation and in vivo cell tracking. However data acquisition and analysis of the 
resulting data pose a number of challenges. The aims of this study were to use in 
vitro phantoms and a population of patients undergoing USPIO imaging of AAA to 
define data acquisition and image analysis methodology to assess SPIO accumulation 
in tissues based on changes in T2* value. In vitro, USPIO, SPIO and SPIO-labelled 
cells produced a concentration-dependent reduction in T2 and T2* in agarose 
phantoms. Thirty-seven patients with asymptomatic aortic aneurysms >4.0 cm in 
diameter were recruited. Repeatability of T2* value measurement was determined in 
eight patients. Twenty-nine patients underwent MRI scanning before and 24-
36 hours after administration of USPIO. T2- and multi echo T2*W sequences were 
performed in a 3T MRI scanner. USPIO accumulation was assessed using the decay 
constant for signal intensity over time: the T2* value. Based on repeatability data, 
thresholds for absolute change (45 ms) and per cent change (59%) in T2* values 
were defined for the detection of SPIO in tissues informing colour scale map data 
presentation. Per cent changes in T2* value were highly discriminatory for detecting 
and quantifying USPIO accumulation in tissues with heterogeneous background T2* 
values.  
 
In summary we have defined a robust semi-quantitative image acquisition and data 
analysis algorithm for the detection of SPIO accumulation that has extensive 
application for clinical imaging of cellular inflammation and in vivo cell tracking. 




Superparamagnetic particles of iron oxide form a class of MRI contrast agents 
possessing much stronger paramagnetism than standard gadolinium-based agents. 
This intense paramagnetism renders SPIO exquisitely sensitive contrast agents that 
can be detected at very low concentrations. However, the analysis of the resulting 
data presents a number of challenges and a pragmatic solution is required if the 
potential of these agents is to be realised. 
 
SPIO have been used to label a variety of cell types and to track cells in vivo using 
MRI [Arbab et al 2004; de Vries et al 2005a; de Vries et al 2005b; Arbab et al 2006; 
Zhu et al 2006; Toso et al 2008b]. The ability to track cells, such as stem cells, 
would be an important tool for the further development of novel cell-based therapies, 
allowing the identification of cells reaching and remaining in the intended target 
therapeutic site. Small enough to escape immediate recognition by the 
reticuloendothelial system, USPIO can be used to study cellular inflammation within 
tissues [Corot et al 2007]. Inflammation is critical in the pathogenesis of many 
conditions including atherosclerosis and aneurysm disease. In preliminary clinical 
MRI studies, USPIO accumulated in vulnerable and ruptured carotid plaques but not 
stable plaques [Kooi et al 2003; Trivedi et al 2006; Tang et al 2009]. Magnetic 
resonance imaging with USPIO is therefore a promising method of detecting cellular 
inflammation and plaque instability.  
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Image analysis for published clinical studies using SPIO has typically involved the 
inspection of images for a reduction in signal intensity consistent with iron 
accumulation. Beyond a simple dichotomisation for the presence or absence of iron, 
it would be attractive to achieve a more objective semi-quantitative assessment of 
SPIO accumulation. The calculation of the T2* value is one such approach and is 
possible using standard clinical T2*W sequences commonly used for the assessment 
of tissue iron overload [Kirk et al 2009]. However, the acquisition parameters used 
require optimisation for SPIO detection at 3T since the reduction in T2* value 
caused by SPIO accumulation is greater at higher field strengths [Anderson et al 
2001; Storey et al 2007]. In patients with systemic iron overload, this technique 
estimates the global iron burden within tissues including the liver and myocardium. 
In contrast, when SPIO are used for clinical cell tracking studies or the identification 
of cellular inflammation, additional spatial detail is required to describe subtle 
regional variations in the distribution of iron within different tissue components with 
heterogeneous baseline T2* values. Thus, assessing focal SPIO uptake and changes 
in T2* value on a heterogeneous background presents many challenges.  
 
The aims of this study were to develop and define 3T protocols to detect SPIO 
accumulation, and to develop a robust image analysis methodology that would allow 
assessment of SPIO accumulation in different tissue components and regions. We 
here describe the development of these methods in the context of a study using 
USPIO to detect aortic wall cellular inflammation in patients with AAA.  
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3.3 MATERIALS AND METHODS 
!
3.3.1   PHANTOMS 
To mimic vascular tissue, phantoms were generated using 50 mL 0.15% agarose gel 
with 0.11 mM gadolinium EDTA [Walker et al 1989]. Two different preparations of 
superparamagnetic iron oxide nanoparticles stabilised with dextran and citrate were 
incorporated into these phantoms: ferumoxide (Endorem, Guerbet, France; SPIO; 
mean hydrodynamic particle diameter 80-150 nm) and ferumoxtran (Sinerem, 
Guerbet, France; USPIO; mean hydrodynamic particle diameter 10-30 nm) 
respectively. In addition, human mononuclear cells were labelled with SPIO 
according to the Edinburgh protocol. Free USPIO, free SPIO or SPIO-labelled cells 
were added to the gel in a range of concentrations.    
 
Phantoms were placed in a water bath and scanned using a 3T Siemens Magnetom 
Verio MRI scanner (Siemens, Erlangen, Germany) with a 12-channel receive head 
matrix coil. A T2W spin echo sequence was applied to a 5 mm coronal slice with a 
TR of 4000 ms (to avoid T1 saturation effects) and multiple echo time values ranging 
from 7.7 to 250 ms. A T2*W multi gradient echo sequence with TR of 4000 ms and 
echo times of 4.9, 7.7, 10.5 and 13.3 ms was applied to the same slice. Values for T2 
and T2* were calculated from regression of log signal intensity versus echo time 
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3.3.2   CLINICAL STUDIES 
Patients (n=37) with asymptomatic AAA (4.0-9.0 cm) were recruited from the AAA 
surveillance programme at the Royal Infirmary in Edinburgh between August 2009 
and July 2010. All patients had an asymptomatic AAA with diameter >4.0 cm on 
ultrasound scanning. Eight patients were recruited to obtain repeatability data for 
baseline T2* measurement in the absence of USPIO and twenty-nine patients were 
recruited to receive the USPIO contrast agent.  
 
3.3.3   CONTRAST AGENT ADMINISTRATION 
The weight-adjusted dose (2.6 mg/kg) of Sinerem (Guerbet, France) was diluted in 
100 mL of 0.9% sodium chloride and administered as a slow infusion over 
30 minutes. 
 
3.3.4   MAGNETIC RESONANCE IMAGING 
Magnetic resonance imaging was undertaken in a clinical whole-body 3T Siemens 
Magnetom Verio MRI scanner (Siemens, Erlangen, Germany) using a combination 
of body and spine matrix coil elements to optimise image acquisition in the 
abdominal aorta. 
 
Coronal and sagittal breath-held T2W HASTE localiser sequences were used to 
define the extent of the aneurysm and plan slice positions for subsequent scans. A 
respiratory-gated electrocardiogram-triggered axial T2W turbo spin echo sequence 
was used to acquire detailed anatomical data (TR/TE 2R-R intervals/72 ms; flip 
angle 180°; matrix 192 ! 256; field of view 400 ! 400 mm; slice width 5 mm). A 
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multi gradient echo T2*W sequence (TE 4.9, 7.7, 10.5, 13.3 ms; TR 133 ms; flip 
angle 15°; matrix 192 ! 256; field of view 400 ! 400 mm; slice width 5 mm) was 
used to acquire images of the aneurysm with slice positions corresponding to those 
of the T2W images. T2W images give excellent discrimination of the boundaries 
between the flow lumen, thrombus, wall and surrounding tissues. T2*W sequences, 
have less distinct soft tissue contrast, but are exquisitely sensitive to the effects of 
USPIO accumulation. The echo times for the T2*W sequences were selected such 
that fat and water were in phase for each echo to minimise phase shift artefact and 
subsequent errors in T2* calculation. The field of view used for both sequences was 
typically 400 ! 400 mm, but was adjusted for larger subjects to minimise phase wrap 
artefacts. 
 
For the eight patients recruited to determine the repeatability of T2* measurements, 
the aneurysm was sampled over five adjacent slices. Sequences were repeated up to 
three times. A T2W sequence was applied and T2*W sequences were acquired 
(run 1) and repeated (run 2). The study subject then came out of the scanner and got 
off the table before returning immediately to undergo a repeat scan to simulate the 
pre-and post-contrast acquisitions in patients receiving USPIO. The localiser 
sequences were repeated and slice positions were selected to match those used in 
runs 1 and 2 using the position in relation to the vertebral bodies to guide slice 
placement. The T2W and T2*W sequences (run 3) were then repeated.  
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In the twenty-nine patients recruited to receive USPIO, MRI scanning was performed 
before and 24-36 hours after the administration of the contrast agent. T2W and 
T2*W sequences were applied to the entire extent of the aneurysm. With reference to 
position in relation to the vertebral bodies, axial slice positions on the post-contrast 
scan were matched to those used for the pre-contrast scan. 
 
For calculation of the T2* value, the signal intensity was sampled at four echo times 
within the multi echo sequence. For accurate T2* value calculation, it is important 
that the signal intensity is always higher than the background noise, even at the 
longest echo time [Miller and Joseph 1993]. If, following administration of the 
contrast agent, the signal intensity decays to the level of the noise, the reduction in 
T2* value may be underestimated and the sensitivity to detect USPIO accumulation 
is reduced. To confirm the appropriate selection of echo times in the multi echo 
sequence, a ROI was selected to measure the mean signal intensity at each echo time 
in areas of high and low USPIO uptake in a subset (n=6) of the post-USPIO scans, 
and in corresponding areas of the pre-contrast scans. The noise level was calculated 
according to Edelstein’s approximation as 1/0.66 times the standard deviation of the 
signal intensity in extracorporeal air free from artefact [Edelstein et al 1984]. 
 
3.3.5   REGISTRATION 
T2W images give excellent discrimination of the boundaries between the flow 
lumen, thrombus, aortic wall and surrounding tissues (Figure 3.1) [Kramer et al 
2004]. T2*W sequences have less distinct soft tissue contrast but are exquisitely 
! !95
 








Figure 3.1   T2W image (a) and T2*W image (b) with echo time of 4.9 ms. The different components of the aneurysm are clearly seen on both images but the 
T2W image has superior soft tissue contrast. 
T2W -  T2 weighted. 
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sensitive to the effects of USPIO accumulation. To utilise the strengths of both of 
these image weightings, the T2W and T2*W images were co-registered. Subsequent 
images were registered to the base image using a well-established semi-automatic 
rigid 3-dimensional voxel registration protocol (Analyze, Mayo Clinic) utilising a 
normalised mutual information algorithm [Studholme, 1998]. The use of a 
multi echo T2*W sequence avoided the need to register the individual echoes for 
T2* map generation. The first echo (TE 4.1 ms) was used for registration since it 
provided the best structural definition.  
 
Registration of the entire imaging volume was found to compromise the quality of 
registration of the aorta itself due to bowel and abdominal wall motion. Therefore, to 
minimise the contribution of bowel and abdominal wall motion within this algorithm, 
a region for registration was selected to include the aorta, vertebrae and spinal 
musculature, which remain fairly static during the respiratory cycle, but exclude the 
more mobile abdominal wall and bowel as far as possible. Following the initial 
automatic step, registration was further optimised manually where necessary 
following visual inspection of a blend of the two images. The registration process 
generated a transformation matrix that was applied to the original images to align 
them with the pre-contrast T2W image. The transformed images were used for the 
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3.3.6   IMAGE ANALYSIS 
At 3T, the predominant effect of SPIO accumulation is to induce small local 
magnetic field inhomogeneities resulting in rapid dephasing of coherent transverse 
magnetisation. In the presence of SPIO, the rate of decay of signal is increased with a 
corresponding reduction in T2*. The T2* value is the decay constant for the 
exponential decay of signal intensity with increasing echo time. Since SPIO contrast 
agents have T1 as well as T2/T2* effects, comparison was made between the pre- 
and post-contrast T2* value, rather than using the signal intensity at a single echo 
time thereby negating the positive signal enhancement caused by the T1 shortening 
effect. From the four individual echoes in the multi echo T2*W sequence, a T2* map 
was generated in which each voxel represented the T2* value calculated by the 
equation S(t)=S(0)exp-(t/T2*), where S(t) is the signal intensity at time t, and S(0) is 
the signal intensity at time 0. 
 
A 3 x 3 voxel Gaussian filter was applied to the individual echoes to minimise the 
effect of noise on subsequent image processing steps. Then, for each voxel position a 
plot of the natural log of the signal intensity versus the corresponding echo time was 
produced with the negative inverse gradient giving the T2* value. A straight line was 
fitted to the four data points using a standard least squares method. The coefficient of 
variation and the SSE were used to exclude data that did not have an acceptable 
straight line fit. The thresholds for r
2 
(>0.4) and SSE (<0.2) were determined 
experimentally by examining a subset of the data (Matlab, The Mathworks Inc, 
USA). 
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A ROI, including the aortic wall and ILT but excluding the lumen, was drawn on the 
T2W base image and applied to the transformed T2* maps. The change in T2* value 
may be expressed as the absolute change or as the per cent change relative to the 
baseline T2* value. Given the anticipated heterogeneity of baseline T2* of different 
plaque components [Kramer et al 2004], we assessed both absolute change and per 
cent change in T2* for vascular imaging using USPIO.  
 
3.3.7   OUTPUT IMAGE GENERATION 
The absolute or per cent change in T2* was displayed using colour scale maps. SPIO 
agents result in negative contrast on T2*W MRI, and a reduction in T2* value on a 
T2* map, both of which are difficult to detect by visual inspection of grey-scale 
images. Presentation of data using a hot-cold (red-blue) colour scale map retains 
spatial information alongside quantitative T2* data to facilitate data interpretation. 
The repeatability data were used to define the colour scale by establishing a 
threshold for !T2* above which a change could be attributed to SPIO accumulation. 
 
3.3.8   STATISTICAL ANALYSIS 
The Bland and Altman method was used to evaluate the repeatability of the T2* 
measurements [Bland and Altman 1986]. Statistical analysis using Minitab was 
performed where appropriate with two-tailed Student t-test and statistical 
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3.4 RESULTS 
 
3.4.1   PHANTOMS 
There was a concentration-dependent reduction in both T2 and T2* values with 
increasing concentrations of USPIO, SPIO and SPIO-labelled cells (Figure 3.2).  
 
3.4.2   CLINICAL STUDIES 
Thirty-seven patients with aneurysm diameter 4.0-9.0 cm were recruited to the trial 
of whom 29 received the USPIO contrast agent. There were no side-effects relating 
to the administration of the USPIO contrast agent which was generally well 
tolerated. 
 
The excellent soft tissue contrast on high-resolution T2W imaging of the aorta at 3T 
allowed ready discrimination of the different components (lumen, wall and 
thrombus) for the majority of the aneurysm volume (Figure 3.1). The use of 5 mm 
thick slices enabled coverage of the entire aneurysm, but in a few patients with 
particularly tortuous regions of vasculature (e.g. aneurysm neck and iliac 
bifurcation), there was a partial volume effect that compromised distinction of the 
outer wall from surrounding tissues and required the use of thinner slices. Elsewhere 
the outer wall of the vessel was generally readily identified since the interface with 
visceral fat gave high contrast. However delineation of the vessel wall was more 
difficult if the wall was particularly thin or was adjacent to other structures, such as 
the vena cava or vertebral column that provided less contrast. Excellent registration 



















Figure 3.2   Change in T2 and T2* with increasing iron concentration for free USPIO (a), free SPIO 
(b) and SPIO-labelled cells (c). Histology of the aortic wall from a patient with an abdominal aortic 
aneurysm showing intracellular USPIO uptake and accumulation (blue; Perl’s iron stain x100) (d).  
Cytospin of mononuclear cells following ex vivo labelling with SPIO showing intracellular iron 
accumulation (blue; Perl’s iron stain x100) (e). 
A dose-dependent reduction in both T2 and T2* was observed for free USPIO, SPIO and SPIO-
labelled cells. For free SPIO, at a given concentration of iron, T2 and T2* were similar. In contrast, 
when SPIO was compartmentalised within cells, the effect on T2* was greater than the effect on the 
T2, consistent with the induction of local magnetic field inhomogeneities by clustered SPIO. For 
phantoms with SPIO-labelled cells, T2 was higher and T2* was lower than for phantoms containing 
the equivalent concentration of free SPIO. 
USPIO - Ultrasmall superparamagnetic particles of iron oxide; SPIO - Superparamagnetic particles of 
iron oxide. 
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patients. This patient moved slightly during scanning although acceptable 
registration was still achievable by registering each slice separately.  
 
3.4.3   T2* CALCULATION 
For accurate estimation of the T2* value, multiple data points were obtained by 
sampling the signal intensity at several echo times (Figure 3.3). It is important that 
the signal intensity at the longest echo time is higher than the background noise both 
pre- and post-contrast administration to avoid underestimation of the T2* value 
[Miller and Joseph 1993]. We have avoided this potential noise corruption of the T2* 
value calculation by using a multi echo sequence with a maximum echo time of 
13.3 ms such that, even in regions with the highest USPIO uptake, the mean signal 
intensity at the longest echo time (13.3 ms) was 109.5 ± 26.1 ms: well above the 
mean noise level of 0.88 ms. Less than 10% of the data did not have an acceptable 
straight line fit and were excluded from the T2* map. 
 
Repeatability and threshold of T2* 
The repeatability of the measurement of the T2* value was determined by 
comparison of data from two T2*W sequences (run 1 versus run 2) performed in 
quick succession without moving the patient. This analysis was performed on a 
voxel-by-voxel basis with a total of 24,698 data points, of which 1.1% were affected 
by artefact and discarded. Using the Bland and Altman method [Bland and Altman 
1986], there was a mean bias of -0.21 ms and standard deviation of the difference of 
16.4 ms. 














Figure 3.3   Signal intensity as percentage of first echo time (TE=4.9 ms) within the multi echo 
sequence of pre-contrast and post-contrast images in areas of high and low USPIO uptake. The signal 
intensity decays more rapidly where there is high USPIO uptake, but even at the longest echo time 
(TE=13.3 ms), the signal intensity is well above the noise level (0.88 ms). T2* values for pre-contrast, 
low uptake and high uptake were 28.8, 19.8 and 10.5 ms respectively. 
TE - Echo time; USPIO - Ultrasmall superparamagnetic particles of iron oxide. 
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We wanted to assess the between-scan variability in T2* in the absence of USPIO in 
order to establish a threshold above which an observed !T2* could be attributed to 
USPIO accumulation. For each patient in the reproducibility series, the T2* value 
was measured (run 1) and repeated (run 3) having moved the patient out of the 
scanner, repositioned the patient and repeated the localiser sequences. The absolute 
change and per cent change in T2* value between run 1 and run 3 were calculated for 
each voxel giving an indication of the composite variability in T2* value resulting 
from the measurement itself and from registration. The 95
th
 percentile value for the 
absolute and per cent !T2* was calculated for individual patients and averaged for 
all eight patients giving an absolute threshold of 45.0 ms and relative threshold of 
59.1% for !T2* values. 
 
USPIO and change in T2* 
The change in T2* value may be expressed as the absolute or per cent change from 
the baseline value. The frequency distribution for the absolute !T2* values was 
similar for those who did or did not receive USPIO although, as anticipated, it did 
show a small rightward shift of 19!ms (P <0.0001) for those receiving USPIO 
(Figure 3.4). In contrast, there was a marked non-uniform shift in frequency 
distribution with USPIO when considering the per cent !T2* (Figure 3.4). A focal 
area of USPIO uptake is difficult to distinguish on a colour map of absolute !T2* 
but is clearly seen on a per cent !T2* colour map (Figure 3.5). There is a reduction 
in signal intensity in the same area on the post-USPIO T2*W scans but this is more 
obvious when the same data are displayed as a colour map. 










Figure 3.4   T2*W sequences were performed (run 1) and repeated (run 3) having moved the patient 
out of the scanner, repositioned the patient and repeated the localiser sequences. The absolute change 
and per cent change in T2* between run 1 and run 3 were calculated for each voxel giving an 
indication of the composite variability in T2* resulting from the measurement itself and from 
registration. (a) Absolute Change in T2*: Frequency of voxels with absolute change in T2* for 
patients who did or did not receive USPIO. The upper 95% threshold of change in T2* in the absence 
of USPIO was 45 ms. (b) Per cent Change in T2*: Frequency of voxels with per cent change in T2* 
for patients who did or did not receive USPIO. The upper 95% threshold of per cent change in T2* in 
the absence of USPIO was 59%. 








Figure 3.5   Patient with focal uptake of USPIO in the anterior wall of the aneurysm. (a) T2W anatomical image, (b) colour map of the per cent change in T2*, (c) 
colour map of the per cent change in T2* with a threshold of 59%, and (d) colour map of the absolute change in T2* with a threshold of 45 ms. (e)-(h) Pre-USPIO 
T2*W images with echo times of 4.9, 7.4, 10.7, 13.3 ms. (i)-(l) Post-USPIO T2*W images with echo times of 4.9, 7.4, 10.7, 13.3 ms. 
USPIO -  Ultrasmall superparamagnetic particles of iron oxide; T2W - T2 weighted 




We have defined a robust semi-quantitative method for the detection of iron 
nanoparticle accumulation in humans using 3T MRI. Using precise tissue registration 
and per cent change in T2* (!T2*), we can identify USPIO accumulation against a 
highly heterogeneous tissue background. This technique is highly sensitive to the 
magnitude and spatial distribution of SPIO, and holds major promise as an in vivo 
method of detecting cellular inflammation and tracking SPIO-labelled cells. 
 
We used !T2* following contrast administration to evaluate SPIO accumulation 
semi-quantitatively because SPIO have some T1 as well as T2/T2* effects that could 
confound data interpretation if signal intensity measures are used. Analysis of data in 
previous clinical studies employing USPIO has been largely qualitative and used 
dichotomous assessments of signal voids or reductions in signal intensity in the 
target tissue relative to control tissue (e.g. adjacent muscle or fat) at a single echo 
time [de Vries et al 2005b; Zhu et al 2006; Toso et al 2008a; Tang et al 2009]. Our 
method has the major advantage that it is objective and calibrated against 
repeatability data rather than assuming that the signal intensity of control tissue is 
unchanged by SPIO administration. We have shown a correlation between iron 
concentration and T2* for USPIO, SPIO and SPIO-labelled cells in phantom studies, 
and a linear correlation exists between iron concentration and the R2* value 
(R2*=1/T2*) [Kuhlpeter et al 2007; Rad et al 2007]. The R2* value also correlates 
with hepatic iron concentration in patients with transfusion-related hepatic iron 
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overload. However, quantification of iron concentration in tissues can be challenging 
and it is worth considering that the relationship between R2 and R2* values may not 
be linear in situations where cells are present in large clumps as the effect of iron 
nanoparticles on the magnetic field is magnified in this scenario [Bowen et al 2002]. 
 
Rather than look at a single T2* value, we chose to scan patients before and after 
USPIO administration so that signal voids resulting from USPIO accumulation could 
be distinguished from calcification and other artefacts. Relaximetry-based methods, 
such as T2* mapping, depend on resolution and can be subject to partial volume 
effects if the voxel size is much larger than the spatial extent of the magnetic 
influence of the SPIO particles. If image analysis depends on visual inspection for 
signal deficits alone, this can lead to false negatives [Toso et al 2008b]. Conversely, 
the very high susceptibility of clustered SPIO particles causes a concentration-
dependent ‘blooming’ artefact where the magnetic effects of the SPIO particles 
extends well beyond the area occupied by the particles themselves. This effect is 
more pronounced at 3T and may lead to overestimation of the spatial extent of SPIO 
uptake. Compared to 1.5T MRI, 3T MRI offers improved signal-to-noise ratio, 
greater spatial resolution and higher sensitivity for detecting low concentrations of 
iron with additional benefits including improved signal-to-noise ratio and greater 
spatial resolution.  
 
In the presence of high concentrations of iron, the signal intensity decays very 
rapidly such that at the shortest echo time the signal intensity is of a similar 
magnitude to the background noise. In this situation the data become categorical for 
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the presence or absence of iron as the T2* value cannot be calculated. We found that 
3T MRI is ideally suited to USPIO imaging of AAA since tissue iron concentrations 
were within the quantitative range. We selected the echo times for the multi echo 
T2*W sequences such that even at the longest echo time the signal intensity was 
considerably greater than the background noise enabling quantitative analysis. 
 
We showed that in the aortic wall and in other tissues with heterogeneous baseline 
T2* values, the use of per cent !T2* was more discriminatory than absolute !T2* 
for the detection of USPIO accumulation. On the basis of T2* repeatability 
measurements, we were able to define a threshold based on the 95
th
 percentile of the 
per cent !T2*. This enabled us to attribute large changes in T2* to the accumulation 
of USPIO rather than to artefactual changes in T2*. 
 
Registration is a critical part of the analysis process for focal SPIO uptake. With 
precise anatomical detail and a voxel size of 1.4 x 1.4 mm, we achieved excellent 
and robust registration, retaining single voxel spatial resolution. This allowed us to 
determine whether SPIO uptake was within the wall or the thrombus. However a 
multivoxel grid could be applied in situations where fine resolution is not essential or 
registration is sub-optimal. For AAA, we would advocate the use of thinner slices in 
tortuous areas to avoid partial volume effects and improve delineation of ROI and 
registration. 
 
The use of a colour map rather than numeric data to present !T2* is advantageous 
since important spatial information is retained alongside the quantitative data for 
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!T2*. It also overcomes the difficulty of identifying areas of uptake of SPIO that 
cause signal voids on standard grey-scale T2*W images. Observer interpretation of 
colour maps and inter-observer agreement are facilitated by application of a 
threshold of significance for per cent !T2* as described above. 
 
The method described here is not fully quantitative and this is the main limitation of 
this technique. This is because the magnetic effects of iron nanoparticles is 
dependent not only on their concentration but also on the homogeneity of their 
distribution. Further phantom and in vivo tissue work may clarify this further. 
However we believe that this semi-quantitative approach does enable the use of 
SPIO and USPIO for a range of clinical applications. The process could be 
streamlined by the development of semi-automatic methods for image registration 
and hotspot detection. 
 
Towards improved detection of iron in tissues, a number of novel positive contrast 
imaging sequences has been proposed including susceptibility-weighted imaging, 
ultrashort echo time sequences, selective radiofrequency pulse methods (such as 
Inversion Recovery with ON-resonant water suppression, IRON) and off-resonance 
imaging [Seppenwoolde et al 2003; Mani et al 2006; Stuber et al 2007; Eibofner et 
al 2010]. A major advantage of the method described here, however, is the use of 
commercially available imaging sequences and image analysis techniques that are 
suitable for current clinical use. 
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For cell tracking studies, single cell imaging has been proposed as a way of 
improving quantification [Heyn et al 2006; Shapiro et al 2006]. Cells are typically 
labelled with MPIO and signal voids, each representing a single MPIO-labelled cell, 
are counted automatically. However, whilst this has been achieved in pre-clinical 
rodent models, a field strength of 7T is probably required to achieve sufficient 
resolution (200 x 200 µm in-plane) in humans to detect single cells reliably. 
Furthermore clinical scale cell tracking studies use up to 10
9
 cells and this method is 
not immediately translatable for clinical use. 
 
In conclusion, recognising both the great potential of SPIO contrast agents and the 
challenges of analysing the resulting data, we have defined a semi-quantitative image 
analysis algorithm for the detection of SPIO accumulation that has extensive 










CHAPTER  4 
!
MAGNETIC RESONANCE IMAGING 
OF ABDOMINAL AORTIC ANEURYSMS USING 





Abdominal aortic aneurysms are a major cause of death. Prediction of aneurysm 
expansion and rupture is challenging and currently relies on the simple measure of 
aneurysm diameter. Using magnetic resonance imaging, we aimed to assess whether 
areas of cellular inflammation correlated with the rate of AAA expansion. Stable 
patients (n=29; !"#male; aged 70 ± 5 years) with asymptomatic AAA (4.0-6.6 cm) 
were recruited from a surveillance programme and imaged using a 3T MRI scanner 
before and 24-36 hours after administration of USPIO. The change in T2* value on 
T2*W imaging was used to detect accumulation of USPIO within the AAA. 
Histological examination of aneurysm tissue confirmed co-localisation and uptake of 
USPIO in areas with macrophage infiltration. Patients with distinct mural uptake of 
USPIO had a 3-fold higher growth rate (n=11, 0.66 cm/yr; P=0.020) than those with 
no (n=6, 0.22 cm/yr) or non-specific USPIO uptake (n=8, 0.24 cm/yr) despite having 
similar aneurysm diameters (5.4 ± 0.6, 5.1 ± 0.5 and 5.0 ± 0.5 cm respectively; 
P#>0.05). In one patient with an inflammatory aneurysm, there was a strong and 
widespread uptake of USPIO extending beyond the aortic wall. In conclusion, uptake 
of USPIO in AAA identifies cellular inflammation and appears to distinguish those 
patients with more rapidly progressive AAA expansion. This technique holds major 
promise as a new method of risk-stratifying patients with AAA that extends beyond 







Abdominal aortic aneurysms have a prevalence of 5% in men over the age of 
65 years and acute rupture is associated with a mortality rate of 65-85%. Abdominal 
aortic aneurysms are responsible for 2-3% of deaths in men aged !65 years and 
account for over 15,000 deaths annually in the United States [Ashton et al 2002]. 
Open surgical or endovascular intervention to prevent rupture is considered when the 
perceived risk of rupture outweighs the risk of procedural complications with a 
diameter threshold of 5.5 cm being considered the appropriate time to intervene [The 
UK Small Aneurysm Trial Participants 1998; Lederle et al 2002b; Hirsch et al 2006]. 
However, up to one-fifth of ruptured AAA are less than 5.5 cm in diameter 
[Darling et al 1977], and many patients present with AAA diameters considerably 
greater than 5.5 cm without prior symptoms or rupture [Powell et al 2008]. Apart 
from the simple measurement of aneurysm diameter, there are currently no methods 
of predicting which patients with AAA are at risk of further aneurysm growth and 
rupture. We therefore need better methods to guide preventative intervention in these 
patients.  
 
Aortic aneurysms arise when the aortic wall develops excessive medial 
neovascularisation, infiltration of macrophages and lymphocytes, and irreversible 
proteolytic degradation and remodelling of the ECM. These pathological processes 
do not affect the aorta uniformly but are focal in nature with mural 
neovascularisation, inflammation and MMP activity occurring at sites of low tensile 
strength [Vallabhaneni et al 2004] and AAA rupture [Thompson et al 1996;       
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Choke et al 2006; Wilson et al 2006]. These areas of increased biological activity 
within the aortic aneurysm wall are therefore putative targets for novel imaging 
techniques.   
 
Magnetic resonance imaging is emerging as a useful investigative tool for 
cardiovascular disease that can distinguish the different atherosclerotic plaque 
components, such as the lipid-rich core and areas of calcification [Cai et al 2005]. 
Standard gadolinium-based MRI identifies areas of thrombus formation and fibrosis 
in AAA [Kramer et al 2004]. Recently a novel class of MRI contrast agents 
containing SPIO has been developed that provides additional biological and 
functional information through the detection of cellular inflammation within tissues. 
USPIO, with particle sizes in the range 10-30 nm, escape immediate recognition by 
the reticuloendothelial system and persist for longer in the bloodstream allowing 
them to be used to assess the accumulation of macrophages within vascular and 
lymphatic tissues [Harisinghani et al 2003; Kooi et al 2003; Trivedi et al 2006 
Heesakkers et al 2008; Tang et al 2009]. Current preparations are biodegradable and 
safe for clinical administration [Bourrinet et al 2006; Muller et al 2007; Bernd et al 
2009]. 
 
USPIO accumulate in the aortae of hypercholesterolaemic rabbits [Ruehm et al 
2001] and in murine models of AAA [Turner et al 2009]. In humans, USPIO 
accumulate in ruptured or rupture-prone carotid plaques rather than stable plaques 
[Kooi et al 2003; Trivedi et al 2006], and treatment with atorvastatin reduces both 
inflammation and USPIO uptake in carotid plaques [Tang et al 2009]. USPIO also 
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accumulate in AAA but to date no correlation has been made with clinical disease 
progression [Sadat et al 2011]. 
 
The aims of this study, therefore, were to determine whether USPIO uptake could be 
used to detect areas of cellular inflammation within the wall of the AAA, and to 




4.3.1   SUBJECTS 
Patients with an AAA with a diameter of greater than 4.0 cm on ultrasound 
examination of the aorta were recruited from the outpatient aneurysm surveillance 
programme.  
 
Demographic and clinical data, including past medical history and medications, were 
obtained through patient interview and source hospital records. Patients were being 
monitored in the aneurysm surveillance programme involving serial ultrasound-
based measurements of the maximum anteroposterior diameter of the AAA, usually 
at 6-monthly intervals. Scans were undertaken by accredited clinical vascular 
scientists with interobserver CV of aortic diameter measurements of 3.5% in our 
laboratory [Wilson et al 2000]. Due to the staccato growth pattern of AAA and need 
for a contemporary measurement [Kurvers et al 2004], the annual growth rate was 
determined from two ultrasound scans performed 6 months apart, with one 
conducted before and the other after the MRI examination. 
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4.3.2   CONTRAST AGENT ADMINISTRATION 
The weight-adjusted dose of USPIO (Sinerem, Guerbet, France) 2.6 mg/kg was 
diluted in 100 mL of 0.9% saline and administered through a filter as a slow 
intravenous infusion over 30 minutes. 
 
4.3.3   MAGNETIC RESONANCE IMAGING 
Participants underwent MRI in a whole body 3T Siemens Magnetom Verio scanner 
(Siemens, Erlangen, Germany) before and 24-36 hours [Trivedi et al 2004] after 
administration of the contrast agent. Routine clinical coronal and sagittal breath-held 
T2W multislice HASTE localiser sequences were used to identify the position and 
extent of the aneurysm following which a respiratory-gated, electrocardiogram-
triggered T2W turbo spin echo sequence was used to acquire detailed anatomical 
data (TR/TE 2R-R intervals/72 ms; flip angle 180°; matrix 192 ! 256; field of view 
400 ! 400 mm; slice width 5 mm). A multi echo, gradient echo T2*W sequence (TE 
4.9, 7.7, 10.5, 13.3 ms; TR 133 ms; flip angle 15°; matrix 192 ! 256; field of view 
400 ! 400 mm; slice width 5 mm) was used to acquire axial images of the entire 
aneurysm with slice positions corresponding to those of the T2W images.  
 
The echo times for the T2*W sequences were selected such that fat and water were 
in phase for each echo to minimise phase shift artefact and errors in T2* 
measurements. The field of view used for both sequences was typically 
400 ! 400 mm, but was adjusted for larger subjects to minimise phase wrap artefacts. 
T2W images give excellent discrimination of the boundaries between the flow 
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lumen, thrombus, wall and surrounding tissues. T2*W sequences, have less distinct 
soft tissue contrast, but are exquisitely sensitive to the effects of USPIO 
accumulation. At the post-contrast scan, slice positions were selected to match those 
of the pre-contrast scan as closely as possible by reference to the vertebral bodies.  
 
In a subset of nineteen patients, T1W images were acquired before and 5 minutes 
after the bolus administration of 0.!"mL/kg of gadolinium (Dotarem, Guerbet 
Pharmaceuticals, France) using a turbo spin echo acquisition (TR/TE 1 R-R 
interval/28 ms; flip angle 180°; matrix 192 ! 256; field of view 400 ! 400 mm; slice 
width 5 mm). Gadolinium-enhanced sequences were performed after the baseline 
T2W and T2*W sequences were acquired, 2 hours before USPIO administration and 
approximately 24 hours before the post-USPIO MRI scan. Since gadolinium has a 
plasma half-life in the region of 2 hours and, unlike USPIO, is not readily taken up 
into the intracellular compartment, USPIO-enhancement is unlikely to have been 
affected by pre-administration of gadolinium. 
 
4.3.4   IMAGE ANALYSIS 
In order that the soft tissue discrimination of the T2W images could be used to 
complement the iron sensitivity of the T2*W images, and to allow direct comparison 
of the pre- and post-contrast data, all the images were registered to the pre-contrast 
T2W image using a semi-automatic rigid 3-dimensional voxel registration protocol 
(Analyze, Mayo Clinic). Bowel and abdominal wall motion were found to 
compromise registration of the aorta itself and this was minimised by excluding these 
structures from the volume for registration as far as possible. A ROI encompassing 
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the aortic wall and thrombus but excluding the flow lumen was drawn on each slice 
of the pre-contrast T2W image. The four echoes in the multi echo T2*W sequence 
were combined to generate a T2* map, in which the data represented the T2* value 
for each voxel. The T2* value is the decay constant for the exponential decay of 
signal intensity with time. In the presence of USPIO, the signal decays more rapidly 
due to local field inhomogeneities and the T2* value is reduced. A 3 x 3 voxel 
Gaussian filter was applied to the individual echoes to reduce noise, and 




>0.4) and SSE <0.2 were used to 
exclude data that did not have an acceptable straight line fit when ln signal intensity 
(SI) was plotted against echo time.  
 
The previously delineated ROI was applied to the T2* maps that had been registered 
to the pre-contrast T2W scan. The per cent change in T2* value (%!T2*) following 
the administration of USPIO was calculated on a voxel-by-voxel basis and displayed 
on a colour scale (%!T2*= (T2* value scan 1 - T2* value scan 2)/(T2* value 
scan 1) x 100). From the 95
th
 percentile of the %!T2* value observed in a group of 
patients not receiving USPIO, we have established a threshold of significance for 
%!T2* of 59% above which an observed change in T2* value can be attributed to 
USPIO uptake. All voxels with values for %!T2* below this threshold appear blue 
on the colour map whilst voxels above this threshold appear on a yellow-red colour 
scale. This facilitates data interpretation and minimises observer bias. 
 
To assess the gadolinium-enhancement on T1W images, the pre- and post-contrast 
images were registered to the pre-contrast T2W image. The previously delineated 
 119 
ROI was applied to the T1 images. The per cent change in signal intensity was 
calculated (%! SI) on a voxel-by-voxel basis and displayed on a colour scale (%! 
SI= (SI scan 2 - SI scan 1)/(SI scan 1) x 100). By convention, an increase in signal 
intensity of more than 50% of the baseline value was taken to be significant. 
 
4.3.5   CLASSIFICATION OF ANEURYSMS 
Cellular inflammation is an important pathological process in the development of 
AAA with the associated proteolytic degradation of the aortic wall representing the 
key step leading to AAA expansion and rupture. We were interested to see whether 
aneurysm expansion rate is increased in aneurysms with USPIO uptake in (i) the 
aortic wall or (ii) the associated thrombus. Therefore, two independent observers, 
blinded to the patient demographics, and aneurysm diameter and growth rate, 
reviewed the colour map images and classified them into three clear pre-defined 
groups according to their appearance:  
 
Group 1 – no mural or thrombus USPIO uptake except isolated periluminal T2* 
enhancement occurring immediately adjacent to, and in continuity with, the lumen. 
Group 2 – diffuse USPIO uptake that was distinct from the periluminal thrombus and 
the aortic wall. 
Group 3 – focal areas (with at least 10 contiguous voxels) of USPIO uptake within 
the aortic wall of the aneurysm distinct from periluminal area and thrombus. 
 
Differences in classification were resolved by consensus. 
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4.3.6   HISTOLOGY  
For patients undergoing open surgical repair within 48 hours of USPIO 
administration, samples of aortic wall were obtained from the arteriotomy site on the 
anterior aspect of the aneurysm sac. Samples were fixed in formalin, embedded in 
paraffin, sectioned and stained to look at the architecture (haematoxylin and eosin, 
and elastin van Gieson) and USPIO accumulation (Prussian blue). The distribution of 
macrophages was assessed by immunohistochemical staining for macrophages 
(mouse, anti-human CD68 monoclonal antibody; DAKO).  
 
4.3.7   STATISTICAL ANALYSIS 
The data were normally distributed. Continuous data were compared with one-way 
ANOVA with Tukey’s post-test comparison (Minitab) and categorical data were 
analysed using Chi-squared test with cross-tabulation (SPSS). Statistical significance 




4.4.1   PATIENTS 
Twenty-nine patients (27 male) were recruited into the trial with a mean age of 
70 ± 5 years and mean AAA diameter of 5.2 cm (range 4.0-6.6 cm). All aneurysms 
were fusiform and confined to the abdominal aorta. One patient had an inflammatory 
aneurysm with ureteric obstruction and a raised erythrocyte sedimentation rate of 
100 mm/hour (reference range 1-10 mm/hour). The remaining patients were 
asymptomatic. As anticipated, patients had a range of cardiovascular risk factors and 
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co-morbidities (Table 4.1). During the study period, four patients underwent open 
surgical repair of their AAA (two in group 1 and two in group 3), two patients were 
treated by EVAR (one in group 2 and one in group 3) and one patient in group 3 died 
of a ruptured aneurysm having been assessed and considered unfit for operative 
intervention. It was not possible to calculate a growth rate for four patients (one in 
group 1, one in group 2 and two in group 3) who had only a single diameter 
measurement, either because they proceeded straight to surgery or had only recently 
presented to the surveillance programme. 
 
4.4.2   USPIO ADMINISTRATION 
The administration of USPIO was well tolerated with no significant adverse events. 
There was a relatively even distribution of patients within the three categories of 
USPIO uptake (Table 4.1). Patients in the three groups were similar in terms of age, 
sex, use of medications, initial aneurysm diameter and all co-morbidities except 
hypertension (P=0.024). In patients undergoing open surgical AAA repair, histology 
confirmed the accumulation of USPIO that co-located with immunohistochemical 
staining for CD68-positive macrophages (Figure 4.1). Iron deposits were not seen in 
control tissue from a patient with an aneurysmal aorta who had not received USPIO 
(Figure 1). 
 
4.4.3   MAGNETIC RESONANCE IMAGING WITH USPIO  
Patients had between 10 and 20 slices to cover the entire aneurysm with a total of 
351 slices for analysis. Registration within the main body of the aneurysm was 
excellent for all scans although 9.7 ± 1.4% of the data were discarded due to poor 
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straight-line fit when ln SI was plotted against echo time. Classification of AAA 







Figure 4.1   Representative histological sections of the aortic wall. (a) Haematoxylin and eosin (x20) of the full thickness of the aortic wall including atherosclerotic 
plaque, adherent thrombus and peri-adventitial fatty tissue. (b) Elastin van Gieson stain (x100) of the aortic wall showing complete destruction of the normal wall structure 
including fibrosis (collagen; pink) of the media and adventitia and virtual absence of intact medial elastic fibres (black). (c) Prussian blue staining for iron demonstrating co-
localisation of CD68-postive macrophages (x400; brown) with (d) USPIO particles (x400; blue). (e) High power (x1000) Prussian blue staining showing intra-cytoplasmic 
accumulation of USPIO within macrophages. (f)  Prussian blue stain of aneurysmal aorta in a patient not receiving USPIO showing no evidence of iron accumulation.   















Figure 4.2   Colour maps (a-c) showing representative abdominal aortic aneurysm (AAA) slices from 
patients in each of the three groups alongside the corresponding T2W anatomical images (d-f). The 
colour scale represents the magnitude of the change in T2* value with blue indicating minimal change 
and red indicating a large change in T2* value. We have previously defined the threshold above which 
changes in T2* value can be attributed to USPIO accumulation. Only changes in T2* value above the 
threshold are presented on the graduated (yellow-red) colour scale, whilst data below the threshold 
appear blue. A distinctive pattern is seen for each patient group: (a) group 1 shows a large change in 
T2* value only in the periluminal area; (b) group 2, diffuse patchy changes in T2* throughout the 
intraluminal thrombus, but no distinct focal area of USPIO uptake affecting the aortic wall; and (c) 
group 3, discrete focal area of USPIO uptake involving the wall of the AAA that is distinct from the 
periluminal region - this patient subsequently died suddenly from presumed ruptured AAA.   
T2W - T2 weighted; USPIO - Ultrasmall superparamagnetic particles of iron oxide. 
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excellent inter-observer agreement and a kappa statistic of 0.89. There appeared to be 
no differences in USPIO uptake whether or not patients had received pre-
administration of gadolinium. 
 
The effect of USPIO accumulation is to accelerate dephasing of transverse 
magnetisation resulting in rapid loss of signal with increasing echo time and hence a 
reduction in the decay constant, the T2* value. The magnitude of the change in T2* 
value was encoded for each voxel with a large reduction in T2* value reflecting a 
greater accumulation of USPIO. We have previously defined a threshold (59%) 
above which the change in T2* value can be attributed to USPIO accumulation 
rather than variability of the measurement. In all patients, there was non-specific 
USPIO uptake in the periluminal region consistent with transition of the particles 
from the blood pool (Figure 4.2). Interestingly the same region of the thrombus 
enhanced rapidly on T1W MRI with gadolinium (Figure 4.3). In group 3, in addition 
to the presence of focal areas of USPIO uptake (at least 10 contiguous voxels), there 
was a higher proportion of USPIO positive voxels in the aortic wall compared to the 
other two groups (P <0.0001) supporting the correct classification of patients into the 
three groups (Figure 4.4a).  
 
Patients with distinct focal areas of increased USPIO uptake in the wall of the 
aneurysm (group 3) had aneurysm growth rates that were 3-fold higher than patients 
without (group 1) or with non-specific (group 2) uptake of USPIO (P=0.020; Figure 





























Figure 4.3   The blood pool contrast agent gadolinium (a) enhances only the periluminal halo region 
of the thrombus and the fibrous cap. USPIO-enhancement (b) is seen not only in the periluminal halo 
but also in the deep layer of the thrombus and in the aortic wall.  













Figure 4.4   (a) Per cent USPIO positive voxels in the aortic wall (solid bars) and focal areas of increased USPIO uptake (open bars). USPIO positive voxels were 
higher in group 3 compared to the other two groups (P <0.001). (b) Relationship of diameter and growth rate with patient group. Initial aneurysm diameters (open bars) 
are similar for the three groups, but the aneurysm growth rates (solid bars) are higher for patients in group 3 (0.66 cm/yr) compared to those in groups 1 (0.22 cm/yr) 
and 2 (0.24 cm/yr; P=0.020). 
USPIO - Ultrasmall superparamagnetic particles of iron oxide. 
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across the three groups (Figure 4b). The percentage of USPIO positive voxels in the 
aortic wall correlated with the AAA growth rate (r=0.46; P=0.028). 
 
One patient in group 3 had an inflammatory aneurysm; a specific subtype of AAA 
characterised by systemic inflammation, a thickened, fibrosed aortic wall, and 
fibrosis and inflammation extending beyond the aorta into surrounding tissues. This 
produced a unique change in T2* pattern with intense USPIO uptake extending 




We have shown for the first time that uptake of USPIO in AAA identifies cellular 
inflammation and appears to distinguish those patients with more rapidly progressive 
AAA expansion. This technique holds major promise as a new method of risk-
stratifying patients with AAA that extends beyond the simple anatomical measure of 
aneurysm diameter. 
 
We have used a smart contrast agent that consists of 20 nm dextran-coated iron oxide 
nanoparticles. Following intravenous administration, these USPIO circulate within 
the blood pool with a long half-life and are engulfed by macrophages. They 
accumulate at sites of cellular inflammation at sufficient concentrations to cause 
signal changes on MRI. As a result of their superparamagnetic properties, they 
induce local field inhomogeneities leading to rapid dephasing of the transverse 

















Figure 4.5   (a) Distinctive appearance of an inflammatory abdominal aortic aneurysm (AAA) on 
T2W imaging. Arrows indicate the aortic wall. (b) Regions with a large per cent change in T2* value 
are present outwith the aortic wall showing inflammation extending into surrounding tissues as is 
typical of an inflammatory AAA (see colour scale; Figure 2). This patient had ureteric obstruction and 
an erythrocyte sedimentation rate of >100 mm/hr (reference range 1-10 mm/hr).  
T2W - T2 weighted. 
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agents exhibit T1 relaxivity, the predominant extravascular effect of USPIO at 3T is 
to cause a dropout of signal on T2W and especially T2*W images [Corot 2007]. Due 
to the mixed T1 and T2/T2* effects of USPIO, we chose to measure their effect on 
the rate of exponential signal decay by calculating the decay constant, T2* value, 
from the signal intensities at four echo times rather than relying on the signal 
intensity at a single echo time. This proved to be a highly sensitive technique and 
variations in the change of T2* value identified areas of cellular inflammation that 
were confirmed on subsequent histological examination of aneurysm tissue obtained 
at the time of open surgery. 
 
Within the study population, we observed distinct patterns of spatial variation in the 
change of T2* value and were able to divide patients into three groups on this basis. 
Patients in group 1 had a high change in T2* value only in the periluminal aspect of 
the aneurysm: this ‘halo effect’ being a constant finding in all study patients. 
Intraluminal thrombus is a consistent feature of AAA and usually has a laminar 
appearance with the mural component having been deposited first and subsequent 
growth of the thrombus occurring by further deposition of fibrin, platelets and red 
blood cells on the inner luminal aspect [Touat et al 2006]. The universal finding of a 
large change in T2* value in the periluminal region of the aneurysm is therefore 
likely to reflect trapping of USPIO in fresh potentially gelatinous thrombus that is 
typically friable and highly cellular because of its close proximity to flowing blood 
[Adolph et al 1997]. It was interesting to observe that this region also enhanced 
rapidly with gadolinium, consistent with a less selective and more generalised uptake 
of contrast agents in this region. A previous study using the larger SPIO particles 
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(80-150 nm) demonstrated their accumulation in the luminal layer of aortic 
thrombus, resulting in an MRI signal that correlated with histological evidence of 
leucocyte infiltration (CD68 and CD66b) and levels of MMP [Nchimi et al 2010]. As 
acknowledged by the authors, these large SPIO particles are not well suited to 
vascular tissue imaging due to their short plasma half-life that limits their sensitivity 
for detecting vessel wall inflammation. 
 
The second group of patients had a heterogeneous pattern of change in T2* signal 
within the thrombus but no uptake in the aortic wall. The role of the thrombus in 
aneurysm expansion and rupture is uncertain [Adolph et al 1997; Vorp et al 2001; 
Kazi et al 2005]. Some macrophages are present deep within the thrombus, but 
alternatively this signal pattern may reflect USPIO within the canaliculi that traverse 
the thrombus, conducting fluid, small molecules and, to a certain extent, cells from 
the lumen towards the aortic wall [Adolph et al 1997]. This pattern of USPIO uptake 
and inflammation within the thrombus is of uncertain significance but interestingly 
did not appear to be associated with accelerated aneurysm growth.  
 
In the third group of patients, we found one or more distinct focal areas of 
inflammation involving the wall itself and spatially distinct from the periluminal 
halo. This finding was associated with an increased growth rate compared to patients 
without mural USPIO uptake. This high growth rate (0.66 cm/yr) is clinically 
significant since the average aneurysm growth in screened populations is 0.26 cm/yr 
and growth rates >0.2 cm/yr are associated with increased AAA-related events 
[Lederle et al 2002a; Brady et al 2004; Thompson et al 2010]. We are unable to 
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exclude the possibility that differences in the incidence of hypertension amongst 
patients in the three groups influenced AAA growth rate, however this seems 
unlikely since the groups with the highest (group 2) and lowest (group 1) incidence 
of hypertension had similarly low growth rates. In patients with ruptured AAA, 
histology of the aneurysm wall has shown areas of increased biological activity and 
these correlate with a reduction in aortic wall tensile strength [Thompson et al 1996; 
Vallabhaneni et al 2004; Choke et al 2006; Wilson et al 2006]. It would be 
interesting to determine whether, in patients with AAA and abdominal pain of 
uncertain aetiology, USPIO imaging could distinguish between those with impending 
rupture and those with non-AAA related abdominal pain. Finally, whether this 
pattern of USPIO uptake in AAA may prove to be a marker for future AAA-related 
events is unclear and requires a large prospective study. 
 
Existing techniques for surveillance of AAA and estimation of risk of rupture rely 
solely upon diameter measurements, but clinical data from aneurysm screening and 
surveillance programmes suggest that there is considerable scope to improve on this.  
Of those aneurysms detected by screening that are less than 5.5 cm in diameter, one 
in 14 will rupture over the following 3 years [Thompson et al 2010] and together 
account for up to one-fifth of all ruptured AAA [Darling et al 1977]. However, 
simply reducing the diameter threshold for intervention would not improve mortality 
[The UK Small Aneurysm Trial Participants 1998; Lederle et al 2002b]. 
Furthermore, small aneurysms exhibit a bimodal distribution for growth with half 
remaining small and only half continuing to grow [Thompson et al 2010]. Having 
been shown to reduce AAA-related mortality by 53%, aneurysm screening is being 
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introduced in many countries across the world [Ashton et al 2002; Screening for 
abdominal aortic aneurysm 2005]. However, screening considerably increases the 
number of patients under long-term surveillance, and only around 30% of these 
patients will require future intervention [Ashton et al 2002; Thompson et al 2010]. 
Taken together, these observations support a need for a more sophisticated and 
individualised method of predicting clinical events in patients with AAA so that 
screening, surveillance and intervention can be targeted at high-risk patients, 
reducing the overall economic cost and decreasing morbidity and mortality. We 
believe USPIO imaging represents a logical and important new approach that has the 
potential to address these major unmet clinical needs. 
 
The conclusions drawn from these results are limited by the small number of patients 
and the limited duration of clinical follow-up. In succession to these interesting pilot 
results, a large prospective clinical trial with a longer duration of follow-up would be 
required to confirm the findings of the present study and assess the role of MRI and 
USPIO in the prediction of AAA-related clinical events. This would also enable a 
more sophisticated three-dimensional CT- or MRI-based assessment of growth and 
its relationship to areas of USPIO uptake. Serial examinations would provide further 
information regarding the optimum time for imaging, the time course of particle 
clearance and the dynamics of inflammatory hotspots with time. Further 
modifications of the image acquisition protocol such as reduction in slice thickness 




In conclusion we have demonstrated that assessment of USPIO uptake with MRI can 
be used to detect focal hotspots of inflammation in asymptomatic AAA, and that 
mural USPIO uptake is associated with more rapid expansion of AAA. If successful 
this technique has a number of potential highly relevant clinical applications that 
include informing selection of patients for intervention to prevent rupture, 
rationalisation of AAA screening resources to target high-risk patients, and 


















DEVELOPMENT OF A GOOD MANUFACTURING PRACTICE 
COMPLIANT PROTOCOL FOR LABELLING HUMAN MONONUCLEAR 




The ability to track cells non-invasively to a target site using magnetic resonance 
imaging would have a wide range of clinical applications including for inflammatory 
cell tracking to investigate disease biology and as an adjunct to cell-based therapies 
to determine the distribution of cells following their administration. A laboratory 
method has been described previously allowing cells to be labelled ex vivo with a 
MRI contrast agent containing SPIO using protamine sulphate to enhance cellular 
uptake. This method has here been translated successfully into a GMP compliant 
protocol for clinical scale SPIO-labelling of human mononuclear cells. SPIO-
labelling was efficient and did not affect cell viability, cytokine release or migratory 
capacity in vitro. Furthermore, SPIO-labelled cells were visualised in vitro using a 
3T clinical MRI scanner. This is therefore a promising investigative tool for clinical 





Stem cell and other cell-based therapies have emerged over recent years as potential 
novel treatment options for a wide range of diseases [Perin et al 2004; Wollert et al 
2004; Fuchs et al 2006; Gyongyosi et al 2008; Gyongyosi et al 2009; Yousef et al 
2009]. Ensuring the delivery of a sufficient number of cells to the target site is 
critical to the development and assessment of these therapies. A number of methods 
have been proposed for tracking cells in vivo but their translation into the clinical 
setting has been hampered for a number of reasons including limitations of the 
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imaging modality in humans and failure of reagents to comply with GMP standards: 
a pre-requisite for clinical use.  
 
By virtue of its high spatial resolution, excellent soft tissue contrast and avoidance of 
ionising radiation, MRI is ideally suited to human cell tracking studies. Magnetic 
resonance imaging contrast agents consisting of dextran-coated SPIO are available 
for use in humans and are in routine clinical use for liver imaging. SPIO possess 
intense superparamagnetism causing a profound reduction in signal intensity on T2- 
and particularly T2*W imaging. SPIO are readily taken up by macrophages, are not 
toxic to cells and are biodegradable in vivo [Arbab et al 2005; Ju et al 2006; Neri et 
al 2008; Farrell et al 2009; Hu et al 2009; Wang et al 2009].  
 
An effective method has been described for incorporating SPIO into phagocytic cells 
using protamine sulphate as a polycationic transfection agent to enhance its uptake 
through electrostatic interactions [Arbab et al 2004]. Since both SPIO (Endorem) and 
protamine sulphate are approved for human use, this method is potentially suitable 
for labelling cells for clinical studies.  
 
The aims of this study were (i) to translate this scientific method into a GMP 
compliant protocol for clinical scale labelling of human PBMC and (ii) to confirm 






5.3 METHODS  
 
5.3.1   OPTIMISATION OF SPIO CELL LABELLING METHODOLOGY AND 
TRANSLATION INTO A GMP COMPLIANT CLINICAL SCALE PROTOCOL 
Using the method described by Arbab et al [Arbab et al 2004] as a starting point, the 
Edinburgh protocol was established for clinical scale labelling of human 
mononuclear cells with SPIO under GMP compliant conditions. In order to guide the 
method-development process, the in vitro labelling efficiency, viability and function 
of labelled cells were determined following each iteration of the protocol.  
 
Initially, processing of high cell numbers had caused problems with cell clumping 
and loss of a substantial proportion of cells was encountered. In addition there was a 
requirement to adapt the Arbab method for use in the GMP setting and to condense 
the protocol such that cells could be procured and processed for reinfusion on the 
same working day. Particular considerations for the translation of a laboratory 
method into a GMP protocol include suitability of reagents and vessels for human 
use, access to an appropriate facility that meets GMP requirements, and suitability of 
the protocol to be performed in a reproducible way by a number of operators in 
different facilities.  
 
5.3.2   ENDOREM AND PROTAMINE CONCENTRATIONS 
In pursuit of a protocol that would minimise cell clumping, maximise cell yield and 
maintain SPIO uptake, a number of permutations of the Endorem concentration     
(10-1000 µg/mL), protamine concentration (0-40 µg/mL) and their ratio were 
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explored. We also investigated the timing of addition of Endorem and protamine to 
the cell suspension.  
 
5.3.3   LABELLING MEDIUM AND LABELLING CONTAINER 
Monocytes exhibit plastic adherence and a proportion of cells were lost during 
incubation as they became stuck to the receptacle in which labelling took place. We 
therefore evaluated a range of vessels in which to contain the cell suspension for the 
labelling process, and compared a static incubation period with continuous agitation. 
With a view to enabling cells to be infused in the medium in which they were 
labelled, comparison was made of labelling in 0.9% saline rather than cell culture 




) on cell adhesion and 
SPIO uptake was evaluated.  
 
5.3.4   LABELLING DURATION 
To accommodate the proposed MRI scanning schedule for the clinical studies, it was 
desirable to make cells available for reinfusion during the afternoon. We therefore 
looked to modify the Arbab protocol in the following ways: (i) reduction of labelling 
time to 2 hours; (ii) cells labelled and then stored overnight for reinfusion the 
following day; (iii) cells stored overnight and labelled the following day; and (iv) 





5.3.5   FINAL EDINBURGH PROTOCOL FOR LABELLING MONONUCLEAR CELLS WITH 
SPIO 
Venous blood was collected into citrate yielding 1-5 ! 10
8
 PMBC. A leucapheresis 
machine (COBE Spectra, Gambro BCT, USA) was used to collect 1-5 ! 10
9
 PBMC. 
Peripheral blood mononclear cells were isolated by density-gradient separation and 
suspended in 0.9% saline (4 ! 10
6 
cells/mL). Cells were labelled with SPIO 
according to the Edinburgh protocol. In brief, Endorem (100 µg/mL; Guerbet, 
France) and protamine sulphate (4 µg/mL; Prosulf) were added to the cell suspension 
and incubated at room temperature for 2 hours with continuous agitation.  
 
5.3.6   EFFECT OF SPIO-LABELLING ON CELL VIABILITY AND FUNCTION 
SPIO uptake 
Prussian blue staining of methanol-fixed cytospin preparations confirmed cellular 
SPIO uptake. Granularity (side scatter) of CD14+ cells was examined by flow 
cytometry as a surrogate marker of nanoparticle internalisation. Monocytes were 
isolated from the PBMC population by immunomagnetic separation and the cellular 
iron content of the resulting purified monocytes was determined using the Ferrozine 
assay (Sigma, UK). 
 
Cell viability 
SPIO-labelled and unlabelled cells were harvested at 1, 24 and 72 hours, exposed to 
FITC-annexin V and PI, and analysed by flow cytometry. The percentages of cells 
positive for annexin V-binding, PI staining, or both were combined to give the 
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percentage cytotoxicity. Viability was also assessed at 24, 48 and 72 hours using a 
LDH assay (Roche Diagnostics Ltd, UK).  
 
Cytokine release 
The concentration of the pro-inflammatory cytokines released from cells 24, 48 and 
72 hours post labelling was measured using a cytometric bead array kit (Becton 
Dickinson, Biosciences, USA).  
 
Migratory capacity 
Monocytes were isolated from the PBMC population by immunomagnetic 
separation. Labelled and unlabelled purified monocytes (2.5 ! 10
5
 cells/well) were 
allowed to migrate for 2 hours through a microporous (5 !m) membrane (Corning 
Costar, USA) towards 0 or 50 ng/mL of recombinant human MCP-1 (R&D Systems, 
UK). Transmigration was quantified by counting the cells adherent to the 
undersurface of the membrane. 
 
5.3.7   MAGNETIC RESONANCE IMAGING 
Phantoms mimicking the magnetic properties of vascular tissue were constructed 
using 50 mL of 0.15% agarose with 0.11 nM gadolinium EDTA. Labelled cells were 
added to phantoms in a range of concentrations. Phantoms were placed in a water 
bath and scanned using a 3T Siemens Magnetom Verio MRI scanner (Siemens, 
Erlangen, Germany) with a 12-channel receive head matrix coil. A T2W spin echo 
sequence was applied to a 5 mm coronal slice with a TR of 4000 ms (to avoid T1 
saturation effects) and multiple echo time values ranging from 7.7-250 ms. A T2*W 
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multi gradient echo sequence with TR of 4000 ms and echo times of 4.9, 7.7, 10.5 
and 13.3 ms was applied to the same slice. Values for R2 and R2* were calculated 
from regression of log signal intensity versus echo time (Minitab version 16, USA).   
 
5.3.8   STATISTICAL ANALYSIS 
Where appropriate data were analysed by unpaired two-tailed Student t-test. Two-




5.4.1   DEVELOPMENT OF A GMP COMPLIANT PROTOCOL FOR LABELLING HUMAN 
MONONUCLEAR CELLS WITH SPIO 
By adapting and optimising the method described by Arbab et al [Arbab et al 2004], 
the Edinburgh protocol was established for clinical scale labelling of human 
mononuclear cells with SPIO under GMP compliant conditions.  
 
Processing of the high number of cells required for clinical cell tracking studies 
according to the Arbab protocol caused problems with cell clumping (Figure 5.1a 
and b) which appeared to be multifactorial and resulted in the loss of a substantial 
proportion of cells.  
 
Similar to the Arbab protocol, concentrations of 100 µg/mL of Endorem and 
4 µg/mL protamine sulphate were found to be optimal. Adding Endorem and 










Figure 5.1   Cell clumping. Labelling a high number of cells by the original Arbab method [Arbab et al 2004] resulted in significant clumping (a). However when 




protamine complexes that occurs when the two are mixed in the absence of cells, and 
which promote clumping when cells are then added. Continuous agitation using a 
roller-mixer avoided gravitational sedimentation during incubation, exposing all cells 
to SPIO uniformly and reducing clumping. To minimise plastic adherence and 
facilitate the use of a roller-mixer, cells were labelled in a 250 mL polypropylene 
conical tube (Falcon, Becton Dickinson, Biosciences, USA). It was confirmed that 
cells could be labelled at room temperature without affecting SPIO uptake and there 
was therefore no requirement for an incubator within the GMP facility.  
 
When cells were labelled in suspension, SPIO became cell-associated almost 
immediately, initially adhering to the outer surface of the cell and subsequently being 
incorporated into the cell during the remainder of the incubation period. In contrast 
to the situation when cells are labelled whilst adherent or when allowed to settle out 
of suspension, almost no free SPIO remained at the end of the incubation period if 
continuous agitation was employed. There was therefore little to be gained by 
washing cells at the end of the labelling period since virtually no free iron remained 
to be removed, and this had the added benefit of avoiding centrifugation which 
markedly promotes clumping of SPIO-labelled cells. To allow cells to be infused in 
the medium in which they were labelled, cells were incubated in 0.9% saline rather 





) did not affect iron uptake and may have contributed to 
the reduction in clumping by inhibiting integrin-mediated cell adhesion. 
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Storage of cells overnight, either before or after labelling, resulted in excessive 
clumping. Additionally, overnight exposure to SPIO resulted in increased toxicity. 
However, the labelling duration could be reduced to 2 hours without affecting SPIO 
uptake and preserving cells in pristine condition. By procuring cells early in the 
morning, it was therefore possible to make labelled cells available for reinfusion in 
the middle of the afternoon allowing studies to be undertaken within a clinically 
acceptable timeframe. 
 
Throughout the optimisation process, attention was directed at the reagents and 
vessels tested to ensure that they met GMP requirements. In addition, the final 
protocol was thoroughly tested in the GMP facility confirming that is was highly 
compatible with GMP regulations and suitable for use by a variety of operators 
according to a comprehensive Standard Operating Procedure (Appendix 1). 
 
5.4.2  IN VITRO EVALUATION OF THE EFFECT OF SPIO-LABELLING ON CELL 
VIABILITY AND FUNCTION 
It is important that the behaviour of SPIO-labelled mononuclear cells remains 
unchanged in terms of cell viability and function so that the results of in vivo cell 
tracking studies reflect accurately the biological processes being observed. The 
results presented below represent the findings in cells labelled according to the 





Confirmation of SPIO uptake 
Prussian blue staining of labelled cells demonstrated intracellular accumulation of 
iron nanoparticles (Figure 5.2a). Although the entire PBMC population, including 
both lymphocytes and monocytes, was exposed to SPIO, SPIO uptake was 
predominantly confined to the phagocytic monocytes. The mean iron content of 
labelled monocytes was 18 ± 3 pg/cell compared to 1 ± 0.3 g/cell for unlabelled 
cells. Flow cytometric analysis showed that CD14-labelled monocytes exhibited 
greater side scatter following SPIO-labelling indicating increased granularity and 
SPIO uptake (Figure 5.2b and c). 
 
Assessment of cytotoxicity 
SPIO-labelling had no effect on cellular release of inflammatory cytokines 
(Figure 5.3). Cell viability was assessed by flow cytometric detection of PI staining 
and binding of FITC-conjugated annexin V. Cells that were negative for both 
annexin V-binding and PI staining were classified as viable. The percentages of cells 
positive for annexin V-binding, PI staining, or both were combined to give an overall 
percentage of cytotoxicity. Viability of labelled and unlabelled cells was equivalent 
up to 72 hours post labelling (Figure 5.4a). Due to the possibility that the 
electrostatic effects of protamine sulphate may have affected membrane 
permeability, we also looked at cellular release of LDH and confirmed that SPIO-























Figure 5.2   Cellular uptake of SPIO. (a) Cytospin preparation of peripheral blood mononuclear 
cells labelled with SPIO. Iron nanoparticles are seen within the cytoplasm but excluded from the 
nucleus, indicating that the SPIO is intracellular rather than adherent to the cell surface. (b) CD14 
positive cells (monocytes) increased their side scatter following SPIO labelling (c) indicating 
increased granularity and SPIO internalisation. 
SSC - Side scatter; FL - Fluorescence parameter; CD - Cluster of differentiation; PE - Phycoerythrin; 
























Figure 5.3   Effect of SPIO-labelling on cytokine release. SPIO-labelling did not affect the cytokine 
(IL-1, IL-6, IL-10, TNF, IL-12p70) release profile up to 72 hours post-labelling (P >0.05 for all 
cytokines at all timepoints; n=4). 
















Figure 5.4   Effect of SPIO-labelling on cell viability. Labelling mononuclear cells with SPIO had 
no effect on cell viability measured either by flow cytometric analysis of annexin V binding in 
combination with PI staining (a) or a colorimetric assay for LDH release (b). There was no difference 
in viability between labelled and unlabelled cells at any timepoint investigated (P >0.05 for both 
methods at all timepoints; n=3). 





Effect of SPIO-labelling on chemotaxis 
Because cell tracking studies are critically dependent on the ability of labelled cells to 
migrate to the target site, we examined the ability of labelled and unlabelled 
monocytes to migrate towards a chemotactic stimulus MCP-1 in vitro. When the 
original Arbab method was used to label a high number of cells, clumps formed and 
cells failed to migrate, even in the presence of MCP-1. However cells labelled 
according to the Edinburgh protocol remained as a single cell suspension and 
migrated in equivalent numbers to unlabelled cells (164 ± 10 SPIO-labelled cells 
versus 139 ± 20 unlabelled cells at 50 ng/mL MCP-1; P=0.29). Prussian blue staining 
confirmed the presence of SPIO in the cytoplasm of migrating labelled cells (Figure 
5.5a-g). 
 
5.4.3   MRI SCANNING IN VITRO 
SPIO-labelled cells were detectable in vitro using a clinical MRI scanner and cellular 




In this study, we have demonstrated, for the first time, that human mononuclear cells 
can be labelled with SPIO under GMP compliant conditions without affecting cell 
viability or function. Furthermore, the resulting labelled cells can be visualised in 








Figure 5.5   Effect of SPIO-labelling on chemotaxis. In an in vitro migration assay cells were allowed to migrate through a 5 µm microporous membrane towards 0 
or 50 ng/mL of the chemokine human recombinant monocyte chemoattractant protein (MCP-1). Migrated cells adhered to the undersurface of the membrane and were 
stained with DiffQuik! physiological stain (staining nuclei purple) and counterstained with Prussian blue causing SPIO particles carried in the cytoplasm to appear 
dark blue. Comparison was made of cells labelled according to the original protocol, which clumped and were unable to migrate (a and b), with cells labelled 
according to the Edinburgh protocol (c and d) that remained in single cell suspension and migrated in equivalent numbers to unlabelled cells (e and f). Quantification 
of chemotaxis (g) demonstrated that SPIO-labelling did not affect migratory capacity compared to unlabelled cells (P >0.05 for both 0 and 50 ng/mL MCP-1; n=6). 



















Figure 5.6   In vitro agarose phantoms. SPIO-labelled cells were introduced into agarose phantoms 
and scanned using T2W and T2*W sequences in a 3T clinical MRI scanner. There was a linear 
relationship between increasing iron concentration and R2* value. 
SPIO - Superparamagnetic particles of iron oxide; T2W - T2 weighted; 3T - 3 Tesla. 
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It is essential that techniques for labelling cells for cell tracking studies do not impair 
cell function. There are several mechanisms through which SPIO might logically be 
expected to affect cell viability and function. However it would appear that 
monocytes and macrophages, as professional scavengers, have an excellent capacity 
to deal with ingested iron and resist the potentially toxic effects [Pawelczyk et al 
2006]. The majority of studies have shown preservation of both viability and 
function following SPIO-labelling of a variety of cell types including mesenchymal, 
haematopoietic, neural and adipose-derived stem cells [Arbab et al 2005; Ju et al 
2006; Neri et al 2008; Farrell et al 2009; Hu et al 2009; Wang et al 2009], with only 
a few reporting adverse effects and one showing increased proliferation of SPIO-
labelled mesenchymal stem cells [Bulte et al 2004; Kostura et al 2004; Huang et al 
2009]. These studies employed a range of cell labelling protocols, including 
differences in the nature of transfection agents, which may explain such findings.  
 
We have demonstrated in vitro that viability and cytokine production are unaffected 
in PBMC labelled with SPIO according to the Edinburgh protocol. We were also 
able to demonstrate in vitro that SPIO-labelled PBMC exhibit normal migration 
towards the chemokine MCP-1 in a modified Boyden chamber. This is in contrast to 
others who have demonstrated in vitro migration in response to Regulated on 
Activation, Normal T-cell Expressed and Secreted (RANTES) but loss of MCP-1-
dependent migration in SPIO-labelled monocyte-like cells from the THP-1 cell line 
[Janic et al 2008].  
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Whilst we have demonstrated no evidence of short-term toxicity (up to 72 hours) in 
SPIO-labelled PBMC, we have not assessed longer-term effects. In addition we have 
only assessed the effects of SPIO-labelling within an in vitro culture system and we 
have not assessed the potential toxic effects of introducing SPIO-labelled cells into 
tissues in vivo. 
 
Finally we have demonstrated that cells labelled with SPIO are detectable in vitro 
using a clinical MRI scanner. The magnetic effects of SPIO are dependent on the 
field strength of the external magnetic field. There is a linear relationship between 
R2* value and field strength, and R2* values at 3T are approximately double the 
corresponding value at 1.5T [Storey et al 2007]. Magnetic resonance imaging using a 
higher field strength of 3T therefore offers increased sensitivity to detect iron 
accumulation as well as improved signal-to-noise ratio. However, at very high tissue 
iron concentrations the signal intensity may decay very rapidly so that even with 
short echo time intervals achieved through single echo acquisitions the iron 
concentration lies beyond the quantifiable range at 3T.  
 
The production of cell-based products for use in humans must be consistent with 
GMP requirements and is regulated under recent directives issued by the European 
Union and the Food and Drug Administration (FDA). Considerations include the 
suitability of reagents, receptacles, equipment and facilities used during the 
preparation of cell-products for human use. It is essential that basic scientists, clinical 
researchers and technicians liaise regarding these guidelines throughout the protocol 
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development and implementation stages to ensure that the final protocol is compliant 
with these regulations.  
 
Small numbers of samples have been used to assess the effects of SPIO cell labelling 
on cell viability and function in vitro. Furthermore, the toxicity of SPIO labelling has 
only been assessed for up to 72 hours in vitro and cells may respond differently when 
exposed to SPIO for a more prolonged period of time in vivo when influenced by 
other cell types and the surrounding cytokine milieu. This requires further evalution 
before more solid conclusions can be drawn regarding the cellular effects of SPIO 
labelling. Further phantom work may help to clarify the effects of SPIO size, iron 
concentration, cell type and cell aggregation on signal change and facilitate 
interpretation of the resulting imaging data. Future targeted agents may allow more 
specific cell labelling. 
 
In conclusion, this study has defined a GMP compliant protocol by which human 
mononuclear cells can be labelled with SPIO on a clinical scale and no adverse 
effects on cell viability or function were observed. We have also demonstrated the 
feasibility of imaging cells in vitro at clinical field strengths. This therefore 

















IN VIVO MONONUCLEAR CELL TRACKING USING  
 








Cell therapy is an emerging and exciting potential novel treatment option for a wide 
range of diseases and the success of such therapies depends on the delivery of cells 
to their target site. However, monitoring and tracking cells to ensure tissue delivery 
and engraftment is a critical step in establishing clinical and therapeutic efficacy. We 
have previously demonstrated that human mononuclear cells can be labelled with 
SPIO for clinical cell tracking studies under GMP compliant conditions without 
affecting cell viability or function. The safety of both intramuscular and intravenous 
administration of SPIO-labelled cells is demonstrated, with cells readily identifiable 
in vivo for at least 7 days using magnetic resonance imaging. We also show that 
SPIO-labelled mononuclear cells track to the reticuloendothelial system as well as an 
iatrogenic inflammatory focus in healthy human volunteers. SPIO-labelling for 
magnetic resonance cell tracking therefore appears to be a safe, feasible and 
potentially widely applicable technique that has major potential for a range of 
clinical applications including monitoring cellular inflammatory responses and 




Considerable interest surrounds stem cell and other cell-based therapies which have 
emerged as potential novel treatment options for a wide range of diseases including 
acute myocardial infarction and severe heart failure [Perin et al 2004; Wollert et al 
2004; Fuchs et al 2006; Gyongyosi et al 2009; Yousef et al 2009]. The ability to 
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track cells to the intended target therapeutic site non-invasively would be a key 
development for the assessment of these therapies as they continue to evolve.  
 
Radio imaging techniques, such as scintigraphy and PET, can be sensitive but offer 
poor spatial resolution, expose patients to ionising radiation and have the added 
disadvantage that radiotracers have a short half-life, limiting the duration of follow-
up. However MRI offers excellent spatial resolution and soft tissue contrast whilst 
avoiding ionising radiation. 
 
SPIO are part of a novel group of MRI contrast agents available for clinical use. 
SPIO induce local magnetic field inhomogeneities causing rapid dephasing of 
spinning protons and shortening of the T2* relaxation time. Compared to 
paramagnetic agents such as gadolinium, SPIO are detectable at much lower 
concentrations and are readily taken up by resident macrophages in the 
reticuloendothelial system. SPIO are biodegradable in vivo, and we (Chapter 5) and 
others have shown that they are not toxic to a variety of cell types in vitro [Arbab et 
al 2005; Ju et al 2006; Neri et al 2008; Farrell et al 2009; Hu et al 2009; Wang et al 
2009]. 
 
We have also demonstrated that human PBMC can be labelled with SPIO under 
GMP compliant conditions without affecting cell viability or function, and the 
resulting SPIO-labelled cells can be imaged in vitro in a 3T clinical MRI scanner. 
Importantly, however, the safety of intravenous administration of SPIO-labelled cells 
in humans has yet to be demonstrated, and would be critical for the development and 
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FDA approval of novel cell tracking agents for clinical use. Furthermore, whilst 
SPIO-labelled cells have been tracked to a target site following local administration, 
this has not previously been achieved following systemic administration of cells. 
 
We therefore aimed to (i) confirm the safety of both local and intravenous 
administration of labelled cells and (ii) track intravenously administered SPIO-




6.3.1   SUBJECTS 
Healthy volunteers aged >18 years were recruited by advertisement. Participants 
underwent a standard health assessment, including virology screening, to confirm 
suitability to participate in the study. Participants known to have a positive Mantoux 
test response were identified from the Department of Respiratory Medicine database 
of such patients. 
 
6.3.2   CELL PREPARATION AND LABELLING 
Blood was collected by venesection into citrate or by leucapheresis (COBE Spectra, 
Gambro BCT, USA) to yield approximately 1-5 ! 10
8





In the Scottish National Blood Transfusion Service GMP facility, PBMC were 
isolated by density-gradient separation and labelled with SPIO according to the 
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optimised Edinburgh protocol. In brief, PBMC were suspended in 0.9% saline 
(4 ! 10
6 
cells/mL) and incubated with SPIO (100 µg/mL; Endorem, Guerbet, France) 
and protamine sulphate (4 µg/mL; Prosulf) at room temperature for 2 hours with 
continuous agitation. Cells were provided for reinfusion in a low-adherence bag 
(Cryocyte, Baxter, UK). 
 
6.3.3   INTRAMUSCULAR ADMINISTRATION 
Having shown that cells can be imaged in in vitro agarose phantoms, and before 
proceeding to systemic cell tracking studies, we wanted to demonstrate the feasibility 
of imaging labelled cells in humans at clinically relevant field strengths. Six healthy 
volunteers each received three 2 mL intramuscular thigh injections of SPIO alone, 
SPIO-labelled autologous PBMC and unlabelled autologous PBMC, following which 
they underwent imaging in a 1.5T MRI scanner immediately and at 7 days. 
 
6.3.4   PHASED-DOSING PROTOCOL: SAFETY OF INTRAVENOUS ADMINISTRATION OF 
SPIO-LABELLED CELLS 
In order to establish the safety of intravenous administration of SPIO-labelled cells, 
we undertook a phased-dosing study in which two volunteers each received six 




cells) over four study 
visits. Cell infusions were carried out in a Clinical Research Facility with non-
invasive physiological monitoring (pulse oximetry, non-invasive blood pressure and 
temperature) and nurse observation during cell reinfusion and the subsequent 
observation period. Cells were administered through a giving set with a 200 µm 
macroaggregate filter. Each cell infusion lasted 30-60 minutes (depending on 
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volume) and was followed by a 60-minute observation period after which a further 
infusion of cells was commenced or the participant was discharged.  
 
Blood was sampled at each visit before reinfusion and one hour post-infusion of 
labelled cells. Blood was drawn into citrate and EDTA tubes for full blood count, 
routine biochemistry and coagulation parameters including prothrombin time, 
activated partial thromboplastin time, fibrinogen and D-dimer. Participants were 
contacted within one week of the study visit to confirm that there had been no 
delayed adverse effects following administration of labelled cells.  
 
6.3.5 INTRAVENOUS ADMINISTRATION OF SPIO-LABELLED CELLS FOR CELL 
TRACKING 
Twelve further healthy volunteers were recruited and received a low dose of SPIO-
labelled autologous PBMC obtained from a 250 mL venesection (~1-5 ! 10
8 
cells; 
n=6) or a high dose of cells obtained from a standard leucapheresis collection (~1-
5 ! 10
9 
cells; n=6). Intravenous cell infusions were carried out and blood samples 
were obtained as described above. These participants underwent MRI scanning in a 
3T scanner before and 2, 24, 48 and 168 hours following administration of cells. 
 
6.3.6   MANTOUX TEST 
A local cutaneous inflammatory response was induced in the thigh of healthy 
volunteers using the Mantoux test: an intradermal injection of 2 units of tuberculin 
purified protein derivative (PPD). In previously exposed individuals, tuberculin PPD 
stimulates a type IV delayed, cell-mediated hypersensitivity reaction involving an 
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influx of neutrophils initially (~6 hours), and subsequently of monocytes (12-
48 hours) and lymphocytes (12-96 hours) into the dermal skin layer [Vukmanovic-
Stejic et al 2006; Kumar et al 2007]. Twenty-four hours after the Mantoux test, 
participants underwent a standard leucapheresis collection and later the same day 
received an infusion of SPIO-labelled autologous PBMC. T2 and T2*W imaging was 
performed before and 2, 24 and 48 hours following the administration of cells. A 
skin biopsy was obtained from the site of the Mantoux test 96 hours following 
administration of cells (120 hours after the Mantoux test), fixed in 4% 
paraformaldehyde and stained with Prussian blue. 
 
6.3.7   MAGNETIC RESONANCE IMAGING 
Volunteers receiving cells intramuscularly underwent MRI scanning of the thigh in a 
1.5T Phillips scanner using a T2W sequence with a long echo time (137 ms). 
 
Volunteers undergoing intravenous infusion were scanned using a 3T Magnetom 
Verio scanner (Siemens, Erlangen, Germany). Routine localiser sequences were 
applied following which T2W (TE 87 ms; TR 1800 ms; matrix 256 ! 192; field of 
view 380 ! 285 mm) and T2*W (multi echo TE 4.1-22.1 ms; TR 100 ms; flip angle 
15°; matrix 282 ! 512; field of view 282 ! 410 mm; slice width 5 mm) sequences 
were used to acquire axial images of the upper abdomen.  
 
T1W (3D VIBE; TE/TR 2.0/5.5 ms; matrix 416 ! 416; field of view 210 ! 210 mm; 
slice width 5 mm) and T2*W (2D multislice gradient echo; TE 9.8, 12.3, 14.8 ms; 
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TR 120.0 ms; matrix size 312 ! 384; field of view 203 ! 250 mm; slice width 5 mm) 
images of the thigh were acquired following Mantoux testing.  
 
6.3.8   IMAGE ANALYSIS  
Following local administration of SPIO or cells, T2W axial images of the thigh were 
inspected qualitatively for evidence of a change in signal intensity.  
 
Following systemic administration of SPIO-labelled cells, transaxial abdominal 
images were analysed on the basis of the R2* value. The T2* value is the decay 
constant for the decay of signal intensity with increasing echo time, and its inverse 
the R2* value (T2*=1/R2*) has been used to evaluate tissue iron concentration 
[Wood et al 2005]. 
 
The use of all six echo times to calculate the R2* value was validated by selecting 
ROI at each echo time and plotting signal intensity against echo time. Even at longer 
echo times the signal was clearly distinct from the background noise level and 
exponential decay of signal intensity with time was confirmed. Therefore a six echo 
R2* map was generated. Regions of interest were selected on the initial 4.1 ms echo 
time image taking care to avoid major blood vessels and motion artefact. Five 
regions of consistent size (0.5 cm
2
) were selected in the spleen, liver, skeletal muscle 
(control) and background noise, and were copied to the corresponding R2* map. 
Relationship to distinctive anatomical features was used to ensure that the regions 
chosen were consistent amongst scans from each of the five study visits. 
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For cell tracking to the site of the Mantoux test, higher resolution was required to 
allow visualisation of the skin and subcutaneous tissue. The individual echoes were 
acquired separately and had to be registered together for R2* map generation using 
in-house software. Regions of interest were selected in the inflamed skin, normal 
unaffected skin (control), skeletal muscle (control), liver and spleen at each 
timepoint. 
 
6.3.9   STATISTICAL ANALYSIS 
Blood results and physiological monitoring data were compared by paired two-tailed 
Student t-test. T2* MRI data were analysed by repeated-measures, one-way ANOVA 
with post-test Bonferroni correction (GraphPad Prism, GraphPad Software, USA). 




6.4.1   CLINICAL STUDIES 
Intramuscular administration 
Injections were performed successfully in all participants without complication. A 
signal deficit was observed at the site of administration of SPIO alone and SPIO-
labelled cells (Figure 6.1a and b). Whilst an oedematous change was noted at the site 
of injection of unlabelled cells, no dropout of signal was seen (Figure 6.1c). These 



















Figure 6.1   MRI scanning following intramuscular administration of cells. T2W imaging of the thigh following intramuscular administration of 
labelled cells. A signal deficit is seen in relation to injection of SPIO alone (a) and SPIO-labelled cells (b) but not unlabelled cells (c).  These findings 
were consistent for all six participants and persisted for 7 days. 
MRI - Magnetic resonance imaging; T2W - T2 weighted; SPIO - Superparamagnetic particles of iron oxide. 
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Safety of intravenous administration of SPIO-labelled cells 
In the phased-dosing study, all cell infusions in both participants were well tolerated 
with no early or late clinical side-effects. A further twelve volunteers then received a 
low dose of SPIO-labelled autologous PBMC obtained from a 250 mL venesection 
(2.03 ± 0.18 ! 10
8 
cells; mean ± standard error of the mean (SEM); n=6) or a 
high dose of SPIO-labelled autologous PBMC obtained from a standard 
leucapheresis collection (2.23 ± 0.51 ! 10
9 
cells; n=6). Cell infusions had no effect 
on heart rate, blood pressure or temperature (Table 6.1).  
 
Although the problem of macroscopic cell clumping had been obviated using the 
Edinburgh protocol, labelled cells were administered through a macroaggregate filter 
and we aimed to demonstrate that there were no clinically significant microembolic 
events associated with cell administration. Peripheral perfusion, monitored 
continuously by digital pulse oximetry during and for an hour after cell infusion, was 
unaffected. To ensure further that labelled cells did not have a procoagulant effect in 
vivo, blood was sampled for prothrombin time, activated partial thromboplastin time 
and fibrinogen concentration before and after cell infusion, and D-dimer 
concentration was measured after cell infusion. Infusion of SPIO-labelled cells did 
not affect any coagulation variable, and there were no clinically significant effects on 
routine clinical haematological and biochemical variables (Table 6.2). 
 
MRI scanning  
Following administration of labelled cells, the signal intensity was reduced in the 







                             TABLE 6.1   Non-invasive physiological monitoring parameters before and at the end of infusion of 
                             1-5 x 10
9
 PBMC SPIO-labelled cells (n=12) 
 
 Mean pre-infusion Mean post-infusion P 
Systolic blood pressure 
(mmHg) 
 
127 123 0.10 




75 74 0.72 








36.8 36.9 0.27 




99 99 0.81 








TABLE 6.2   Haematological, biochemical and coagulation variables before and after infusion of 1-5 x 10
9
 SPIO-labelled cells (n=12) 
 
 Normal range Mean pre-infusion Mean post-infusion P 
Haemoglobin (g/L) 115 - 165 136 ± 5 132 ± 4 0.07 
White blood count (x10
9
/L) 4.0 - 11.0 7.1 ± 1.1 7.5 ± 0.6 0.68 
Platelets (x10
9
/L) 150 - 350 237 ± 19 230 ± 18 0.35 
 
Prothrombin time (s) 10.5 - 13.5 11 ± 0 12 ± 0 0.19 
Activated partial thromboplastin time (s) 26 - 36 30 ± 0 30 ± 0 0.59 
Fibrinogen (g/L) 1.5 - 4 2.8 ± 0.2 2.7 ± 0.2 0.09 
D-Dimer (ng/mL) 0 - 230 - 114 ± 22 - 
 
Urea (mmol/L) 2.5 - 6.6 4.4 ± 0.3 4.5 ± 0.2 0.84 
Creatinine (µmol/L) 60 - 120 68 ± 3 68 ± 3 0.87 
Sodium (mmol/L) 135 - 145 140 ± 0 140 ± 0 0.40 
Potassium (mmol/L) 3.6 - 5.0 4.1 ± 0.1 4.0 ± 0.1 0.22 
TCO2 (mmol/L) 20 - 30 26 ± 1 28 ± 1 0.16 
 
Bilirubin (µmol/L) 3 - 16 12 ± 2 11 ± 1 0.31 
Alanine amino transferase (U/L) 10 - 55 20 ± 2 21 ± 2 0.53 
Alkaline phosphatase (U/L) 40 - 125 70 ± 7 68 ± 7 0.88 
 












Figure 6.2   MRI scanning of the upper abdomen following systemic administration of cells. T2 weighted transaxial slice through the upper abdomen 
before (a) and after (b) intravenous administration of SPIO-labelled cells. Signal intensity is reduced in the liver (L) and spleen (S) following 
administration of cells. 
MRI - Magnetic resonance imaging; SPIO - Superparamagnetic particles of iron oxide.  
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marked increase in R2* value in the liver and in the spleen (P <0.001) following the 
administration of cells (Figure 6.3) reflecting the dose-dependent accumulation of 
SPIO-labelled cells at these sites. There was no change in the R2* value in skeletal 
muscle (negative control) and the background noise level remained constant. 
 
6.4.2   CELL TRACKING TO AN INFLAMMATORY FOCUS 
At 24 and 48 hours, an increase in the R2* value was observed in the inflamed skin 
(P <0.001) as well as the liver and the spleen but not the adjacent normal skin or 
skeletal muscle (P >0.05; Figure 6.4a-h). A skin biopsy was obtained from the site of 
the Mantoux test 96 hours following administration of cells (120 hours after the 
Mantoux test) and stained with Prussian blue. Occasional iron-laden cells were 
observed in the inflamed skin consistent with the diminishing monocyte and 
macrophage cell numbers by this stage in a type IV hypersensitivity response 
(Figure 6.5a-c). In a participant who had a negative response to the Mantoux test, 





We have shown that intravenous administration of SPIO-labelled cells is safe, and 
that cells can be visualised in vivo at clinically relevant field strengths following 
either local or systemic administration. Importantly SPIO-labelled cells can be 
tracked to a site of iatrogenic focal inflammation in healthy human volunteers. This 










Figure 6.3   Change in R2* value in the reticuloendothelial system following administration of SPIO labelled cells. Change in R2* value from baseline 2 hr, 
24 hr, 48 hr and 7 days following intravenous administration of a low dose (a; 1-5 ! 10
8
 PBMC; n=6) or a high dose (b; 1-5 ! 10
9
 PBMC; n=6) of SPIO-labelled cells. 
An increase in R2* value is seen in the spleen (P <0.0001) and liver (P <0.0001) but not skeletal muscle (control, P >0.05). 








Figure 6.4   (a) T1W axial image of the thigh 24 hr following the Mantoux test. A thick layer of aqueous jelly was applied to the skin to avoid artefact that 
would otherwise occur at the interface between the outer layer of skin and the surrounding air. (b) A magnified area of normal unaffected skin and 
subcutaneous tissue on the medial aspect of the thigh. R2* maps before (c) and after (d) infusion of SPIO-labelled cells show no change in R2* value in 
normal skin and subcutaneous tissue following cell administration. The skin and subcutaneous tissue thickens in the region of the Mantoux test on the anterior 
thigh (e). Corresponding R2* maps of this inflamed skin (f) show a marked increase in R2* value following the administration of SPIO-labelled cells (g).  











                 
Figure 6.4.  Cell tracking to a region of cutaneous inflammation. (h) Consistent with accumulation of SPIO-labelled cells, a significant increase in R2* 
value is observed 24 and 48 hr after cell administration in inflamed skin in the region of the Mantoux test (P <0.0001) as well as in the liver and the spleen 
(P <0.0001), but not in unaffected normal skin or skeletal muscle (control; P >0.05).  
















Figure 6.5   Accumulation of SPIO-labelled cells at the site of the Mantoux test. The strongly positive cutaneous response to the Mantoux test is clearly visible in 
the anterior thigh (a). SPIO-loaded cells are seen on Prussian blue staining of a skin biopsy from this area 96 hr following cell infusion (b and c). 












Figure 6.6 (a) There is no evidence of an inflammatory response at the site of the Mantoux test. R2* maps before (b) and after (c) infusion of SPIO-labelled cells show 
no change in R2* value in skin and subcutaneous tissue at the site of the Mantoux test following cell administration. Similarly, R2* maps before (d) and after (e) 
infusion of SPIO-labelled cells show no change in R2* value in skin and subcutaneous tissue at the control site (medial thigh) following cell administration. (f) The 
R2* value increased significantly in the liver and spleen (p<0.0001, all time points) but not in the skin at the site of the Mantoux test, normal skin or skeletal muscle 
(p>0.05, all timepoints) following the administration of SPIO-labelled cells. 
SPIO - Superparamagnetic particles of iron oxide. 
 176 
cells administered systemically as part of cell therapy: a critical component of the 
development of cellular therapeutic strategies, and ultimately of monitoring the 
success of treatment. 
 
It is essential that techniques for labelling cells for cell tracking studies do not impair 
cell viability or function and we have previously shown that human PBMC can be 
labelled with SPIO under GMP compliant conditions without affecting cell viability, 
cytokine release or migratory capacity in vitro. Importantly we have also shown for 
the first time that intravenous administration of SPIO-labelled cells in humans is 
safe. Although several SPIO agents have been approved for intravenous 
administration, the FDA has not approved the intravenous administration of cells into 
which SPIO has been incorporated ex vivo. These safety data are therefore critical for 
the further development and subsequent FDA approval of novel SPIO-based cell 
tracking agents, facilitating translation into the clinical setting. 
 
Several recent publications have reported tracking of labelled cells to a site of 
inflammation following both local and systemic administration in the pre-clinical 
setting [Kraitchman et al 2003; Anderson et al 2005; Cao et al 2009a; Cao et al 
2009b; Kim et al 2009; Loebinger et al 2009; Song et al 2009]. Migration of cells to 
a target site has also been demonstrated in humans following local administration. 
de Vries and colleagues labelled human dendritic cells with USPIO (particle size 
 20 nm), injected them directly into peripheral lymph nodes in patients with 
melanoma and demonstrated their migration to regional lymph nodes on MRI 
scanning and histology of surgical resection specimens [de Vries et al 2005].     
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SPIO-labelled pancreatic islet cells have been detected in the liver following portal 
venous administration and SPIO-labelled MSC have been tracked to the site of injury 
following intracerebral injection in a patient with a traumatic brain injury [Zhu et al 
2006; Toso et al 2008]. However this is the first report of successful tracking of 
SPIO-labelled cells to a target site following systemic intravenous administration. 
This finding substantially broadens the potential applications for SPIO-labelled cell 
tracking. 
 
We have shown that at clinically relevant field strengths, it is readily possible to 
image ~10
8 
mononuclear cells (containing ~1-5 ! 10
7 
monocytes) following local or 
intravenous administration, and others have imaged as few as 1.5 ! 10
5
 cells in a 
target site following local delivery of 7.5 ! 10
6 
cells [de Vries et al 2005]. If there 
was any concern regarding the effect of SPIO-labelling on the likely success of cell-
based treatments, it would therefore be possible to label a small but representative 
proportion of the total number of cells given, allowing visualisation of the fate and 
distribution of cells, but leaving the majority of cells for engraftment or other desired 
function. Alternatively, if the purpose of cell tracking was not therapeutic but, for 
example, to observe inflammatory cell tracking, a much higher dose of labelled cells 
could be administered to increase the sensitivity for detecting labelled cells in the 
target site. We have demonstrated that 1-5 ! 10
9
 SPIO-labelled autologous PBMC 




It is acknowledged that whilst MRI can detect accumulation of SPIO-labelled cells at 
a target site, further quantification of cell number is currently challenging. This is 
because clustering of iron nanoparticles magnifies their magnetic effects, 
confounding attempts at quantification. However, novel positive imaging sequences 
may address this issue in the future. Furthermore, using this method of cell labelling 
it is not clear whether cells at the target site remain viable nor whether the SPIO 
remains intracellular. Further work is required to establish the duration of specificity 
of SPIO accumulation in tissues to indicate the continued presence of delivered cells 
at the target site. In the future, antibody or enzyme conjugated SPIO may yield 
additional information regarding cell viability and behaviour within tissues. It would 
also be important to define the time course of SPIO clearance from tissues if serial 
administration of cells was considered. Larger studies are needed to confirm the role 
of SPIO in cell tracking studies. 
 
In conclusion, we have demonstrated the feasibility of imaging SPIO-labelled cells in 
humans at clinical MRI field strengths following local or systemic administration. 
This technology for in vivo cell tracking is widely applicable for monitoring cell 

























Inflammation is central to the pathophysiology of cardiovascular disease. In 
atherosclerotic plaque, high macrophage density is a feature of vulnerability and 
correlates with risk of plaque rupture and clinical events [Naghavi et al 2003].  
Similarly, in abdominal aortic aneurysm disease, hotspots of neovascularisation, 
inflammation and proteolytic activity are thought to represent regions of the 
aneurysm wall prone to further expansion and rupture [Thompson et al 1996; 
Vallabhaneni et al 2004; Choke et al 2006; Wilson et al 2006]. However, current 
cardiovascular imaging methods look only at plaque and aneurysm morphology and 
are unable to assess lesion vulnerability on the basis of inflammatory and other 
biological activity. 
 
Cell-based therapies may have the potential to contribute to regeneration following 
injury, and stabilise or even regress cardiovascular disease. When evaluating their 
efficacy, it would be advantageous to be able to determine the proportion of cells 
reaching and remaining in the intended target therapeutic site. However this is not 
currently feasible in clinical studies due to lack of a suitable method. 
 
Beyond the definition of anatomical structure that traditional imaging methods offer, 
novel cellular and molecular imaging techniques aim to allow the non-invasive 
assessment of biological activity within tissues. Superparamagnetic particles of iron 
oxide are part of a novel class of MRI contrast agents and are taken up by phagocytic 
cells including monocytes and macrophages [Corot et al 2007]. USPIO have been 
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used to distinguish stable from ruptured and rupture-prone atherosclerotic plaques 
and to demonstrate a reduction in macrophage activity in carotid plaques following 
the institution of statin therapy [Kooi et al 2003; Trivedi et al 2006; Tang et al 
2009]. Uptake of USPIO in AAA has been reported as an incidental finding but has 
not been correlated with disease progression [Sadat et al 2011]. SPIO have been used 
to label cells for in vivo cell tracking studies. In pre-clinical studies, SPIO-labelled 
cells have been tracked to a target site following both local and systemic 
administration. In humans, whilst cell tracking has been demonstrated following 
local administration close to the target tissue, the ability to track cells following 
systemic administration would increase vastly the range of potential applications of 
this technique. 
 
Using two distinct approaches, we have assessed the potential of SPIO to probe 
inflammatory activity in cardiovascular disease. Firstly we have investigated USPIO-
enhanced MRI to assess inflammation and its relationship to disease progression in 
patients with AAA. Secondly we have developed a method of labelling cells with 
SPIO ex vivo for clinical cell tracking studies. To facilitate this work we first 








7.2 SUMMARY OF THESIS FINDINGS 
 
7.2.1   CHANGES IN T2* VALUE ON CLINICAL MRI SCANNING CAN BE USED TO 
DETECT FOCAL IRON ACCUMULATION IN TISSUES 
Whilst SPIO are promising as smart contrast agents, image acquisition and data 
analysis presents a number of issues that require to be addressed if SPIO are to be 
used to their full potential for cardiovascular imaging. Data analysis for existing 
studies often involves the inspection of images for a reduction in signal intensity at 
the target site. Alternatively, ROI have been used to assess signal changes but this 
compromises spatial resolution. We aimed to address this issue by developing a 
robust, semi-quantitative method for detecting SPIO accumulation in tissues.  
 
Using a multi gradient echo T2*W sequence we have assessed SPIO accumulation in 
tissues by looking at changes in T2* and R2* values, and applied this methodology 
for USPIO imaging of AAA and SPIO cell tracking in a variety of tissues. By 
applying a threshold based on repeatability data for calculation of the T2* value in 
vascular tissue, we have been able to distinguish USPIO accumulation from 
artefactual changes in T2* value. However, the differential magnetic effects of 
clustered versus homogeneously distributed SPIO makes accurate quantification of 
tissue iron concentration challenging. Development and availability of novel positive 
contrast imaging sequences will be required for fully quantitative assessment of 
SPIO accumulation in tissues. 
 
! "#$!
With tissue-specific calibration, this methodology could be adapted for SPIO-MRI of 
a range of organs and tissues, and for a variety of applications. 
 
7.2.2   USPIO-ENHANCED MRI CAN BE USED TO DETECT INFLAMMATION IN THE 
WALL OF ABDOMINAL AORTIC ANEURYSMS AND PREDICT ANEURYSM EXPANSION 
AAA affects 5% of men over the age of 65 and causes up to 8,000 deaths annually in 
the United Kingdom [Ashton et al 2002]. The vast majority of these deaths occur as 
a result of aortic rupture, which has a mortality rate of 65-85%. Currently, maximum 
aneurysm diameter is used to assess risk of rupture, however, diameter is not the only 
determinant of rupture. Up to 20% of ruptured AAA have a diameter less than 
5.5 cm, the threshold above which risk of rupture increases considerably and 
preventative intervention is considered [Darling et al 1977]. Furthermore, many 
patients have much larger aneurysms that are asymptomatic and appear stable. With 
the implementation of aneurysm screening, the number of patients under surveillance 
is likely to increase considerably and an improved method of rupture prediction is 
required to determine more accurately the patients requiring surgical or endovascular 
intervention [Ashton et al 2002]. 
 
In aneurysm disease, the aortic wall is affected by intense areas of biological activity 
including neovascularisation, inflammation and degradation of the extracellular 
matrix by MMP. These biological hotspots are thought to be regions of the aortic 
wall at risk of aneurysm expansion and rupture. We have shown that USPIO-
enhanced MRI can detect aortic wall inflammation [Richards et al 2011]. This was 
corroborated by histological examination of aortic wall tissue samples taken from 
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patients undergoing open surgical repair of their AAA shortly after participating in 
the study. USPIO particles were found to collocate with macrophages; indeed on 
high power views the USPIO particles were identified within the macrophage 
cytoplasm. 
 
Furthermore, USPIO uptake and inflammation in the aneurysm wall appeared to 
predict accelerated aneurysm expansion and USPIO-MRI is therefore a promising 
method of identifying patients with AAA at risk of further expansion and rupture. 
We intend to conduct a larger longitudinal study to confirm these findings. 
Assessment of biological activity within aortic aneurysms may also be useful for 
developing and monitoring the response to novel pharmacological interventions. 
 
7.2.3   SPIO-LABELLING DOES NOT AFFECT VIABILITY OR FUNCTION OF 
PERIPHERAL BLOOD MONONUCLEAR CELLS 
The success of cell-based therapies is contingent upon the delivery of an adequate 
number of cells to the target therapeutic site, however this is challenging to ascertain 
in human studies. For the further development and evaluation of cell-based therapies 
it would be advantageous to have a method of determining the proportion of infused 
cells reaching the target site and we have investigated cell tracking using SPIO-
labelled cells.  
 
A GMP compliant protocol was defined for clinical scale labelling of human 
mononuclear cells with SPIO for use in clinical cell tracking studies. The viability, 
cytokine release pattern and migratory capacity of the resulting SPIO-labelled cells 
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were similar to unlabelled cells. This was important so that the observed distribution 
of SPIO-labelled cells could be extrapolated to the behaviour of mononuclear cells in 
vivo. We also showed that SPIO-labelled cells could be visualised in in vitro agarose 
phantoms in a clinical MRI scanner. This preliminary work and method development 
established a basis for subsequent healthy volunteer cell tracking studies. 
 
7.2.4   LOCAL AND SYSTEMIC ADMINISTRATION OF SPIO-LABELLED PERIPHERAL 
BLOOD MONONUCLEAR CELLS IN HUMANS IS SAFE 
We have shown that both local and systemic administration of up to 10
9
 SPIO-
labelled cells in humans is safe. This is an important finding since the FDA has been 
hesitant to approve the administration of SPIO-labelled cells in humans due to lack 
of available safety data. This in turn has limited commercial interest in developing 
suitable agents for clinical cell tracking hampering further developments in this field. 
Establishing the safety of SPIO-labelled cells is therefore important to enable further 
research into the development of novel SPIO-based cell labelling agents and tracking 
methods. It is our hope that the accumulation of relevant safety data will allow 
clinical trials to proceed. 
 
7.2.5   SPIO-LABELLED PBMC CAN BE TRACKED TO AN INFLAMMATORY FOCUS IN 
HUMANS FOLLOWING SYSTEMIC INTRAVENOUS ADMINISTRATION 
We have shown that SPIO-labelled cells can be visualised at a target site in humans 
using a clinical MRI scanner following both local and systemic administration. 
Furthermore, we have shown that SPIO-labelled cells can be tracked to an 
experimental inflammatory focus in the skin of healthy human volunteers. Following 
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cell administration, changes in R2* value in the target site indicated cell 
accumulation in the inflamed skin and SPIO-labelled cells were also detected on 
histological examination of skin biopsies. No change in R2* value was observed in 
normal skin. Thus MRI detection of SPIO-labelled cells has sufficient sensitivity to 
enable clinical cell tracking and this is the first demonstration of successful magnetic  
resonance cell tracking in humans following systemic administration of cells. This 
technology has a broad range of potential clinical applications. As well as monitoring 
the success of cell-based therapies SPIO cell tracking may allow the investigation of 
inflammatory processes and activity through dynamic leucocyte trafficking. These 
findings also support the use of SPIO as reporters for novel cell tracking agents. 
 
Having shown the feasibility of using SPIO-based cell tracking methods to determine 
the distribution of cells following infusion, it would be important to extend this 
technique to achieve specific labelling of a range of cell types further broadening the 
potential applications. 
 
7.3 FUTURE DIRECTIONS 
 
A number of questions and ideas have arisen as a result of the studies described 
within this thesis and we hope to address some of these issues with further studies. 
 
7.3.1   USPIO-MRI TO ASSESS CLINICAL OUTCOMES FOR PATIENTS UNDER 
SURVEILLANCE FOR AAA 
Ruptured AAA has an extremely high mortality and is the 13
th
 leading cause of death 
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in the United Kingdom. In this preliminary study we have demonstrated that MRI 
with USPIO can detect aortic wall inflammation and appears to predict accelerated 
aneurysm expansion. Following on from these exciting pilot results, we intend to 
undertake a large, longitudinal study with the aim of establishing definitive proof of 
clinical efficacy and the size of effect of using USPIO uptake identified on MRI to 
predict disease progression in patients with AAA. This would include prediction not 
just of growth as a surrogate risk factor for rupture, but also of actual clinical events 
including rupture and requirement for surgical repair. In a prospective, observational, 
single-centre cohort study, we will recruit two hundred and twenty-eight patients 
with AAA (anteroposterior diameter >40 mm) from the clinical surveillance 
programme. At baseline, the AAA of each subject will be imaged with (i) an 
ultrasound scanner as part of standard clinical care, (ii) a 3T MRI scanner before and 
24-36 hours after administration of 4.0 mg/kg of USPIO (ferumoxytol), and (iii) a 
320-multidetector CT scanner with contrast enhancement. Thereafter, subjects will 
be followed-up every 6 months with clinical and ultrasound scanning as part of the 
clinical surveillance programme. At 2 years, a repeat CT scan will be performed to 
assess 3-dimensional growth of the aneurysm.  
 
The primary research question of the study will be whether mural aortic uptake of 
USPIO predicts the composite endpoint of aneurysm rupture or need for elective 
surgical repair. Secondary endpoints will include aneurysm growth rate and clinical 
events including aneurysm rupture, aneurysm repair and aneurysm-related mortality. 
If successful we anticipate that USPIO-MRI could become a useful clinical tool of 
major benefit to patients under surveillance for AAA.  
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7.3.2   CORRELATION BETWEEN INFLAMMATORY ACTIVITY AND BIOMECHANICAL 
FORCES IN AAA 
Evidence that regions of the aneurysm wall featuring intense biological activity are 
weakened and prone to further expansion and rupture is the basis of using USPIO-
MRI to predict clinical disease progression. Biomechanical modelling can identify 
areas of the aortic wall exposed to particularly high tissue stresses and, when used in 
conjunction with USPIO-MRI, may improve further our ability to distinguish 
patients at increased risk of AAA expansion and rupture. Furthermore, 
biomechanical factors may be important in initiating and perpetuating inflammation 
in vascular tissue. Through collaboration with our medical physics colleagues we 
will use the CT and MRI 3D datasets collected as part of the longitudinal study 
described above to explore the relationship between biomechanical and biological 
factors in AAA pathophysiology, expansion and rupture.    
 
7.3.3   CORRELATION BETWEEN USPIO-MRI AND PET-CT WITH 
FLUORODEOXYGLUCOSE (
18
F-FDG) AND SODIUM FLUORIDE (
18
F-NAF) FOR THE 
ASSESSMENT OF INFLAMMATORY ACTIVITY IN CARDIOVASCULAR DISEASE 
Of the imaging modalities currently available, PET-CT with FDG is the best 
established for the assessment of inflammation in the cardiovascular system. FDG 
uptake has been shown to correlate with tissue macrophage density in carotid 
atherosclerotic plaque, and FDG uptake is greater in symptomatic atherosclerotic 
plaques [Davies et al 2007; Rudd et al 2007]. However, little is known of the 
correlation between USPIO uptake and FDG uptake. USPIO accumulation is reliant 
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upon macrophage phagocytosis, whilst FDG assesses cellular metabolic activity. A 
small study of two patients has shown similar uptake patterns for USPIO and FDG in 
carotid atherosclerotic plaque, suggesting that both modalities indicate similar 
disease processes [Tang et al 2008b]. We plan to extend this comparison by scanning 
patients with AAA. This will allow us to compare FDG and USPIO uptake in 
aneurysmal disease in the abdominal aorta, and by selecting an area of adjacent 
thoracic aorta we will be able to assess atherosclerotic disease in the same patients. 
 
18
F-NaF is an alternative PET ligand that is incorporated into hydroxyapatite crystals 
in bone and has been used to detect areas of new bone formation and active 
calcification. Calcification is a feature of advanced atherosclerotic disease and 
‘spotty’calcification is recognised as an imaging marker for plaque vulnerability. Our 
group has recently shown the potential of 
18
F-NaF for cardiovascular imaging.        
18
F-NaF uptake correlated with disease severity in patients with aortic stensosis and a 
correlation was observed between coronary artery 
18
F-NaF uptake and the 
Framingham cardiovascular risk score [Dweck et al 2012]. Interestingly, 
18
F-NaF 
uptake occurred at the periphery of FDG-avid areas, suggesting that its uptake may 
indicate the early phase of inflammation. We propose to investigate 
18
F-NaF uptake 
as a marker of inflammation and vulnerability in symptomatic carotid atherosclerotic 
disease as well as in AAA, and to assess its use for stratifying cardiovascular event 





7.3.4   USE OF USPIO-MRI TO ASSESS INFLAMMATORY ACTIVITY FOLLOWING 
MYOCARDIAL INFARCTION 
Beyond aneurysm disease we have looked to apply the image acquisition and data 
analysis methodology developed for USPIO-MRI to assess inflammatory activity in 
other cardiovascular tissues and diseases. Following reperfusion of an infarct-related 
coronary artery, the myocardium subtended by it may recover rapidly or become 
apoptotic/necrotic. Recruitment of monocytes to the affected area is important for 
myocardial healing and remodelling, but excessive or disordered inflammatory 
activity may have deleterious effects. 
 
We are currently using USPIO-MRI to assess inflammatory activity following 
myocardial infarction and primary coronary intervention and have generated some 
interesting preliminary results (Figure 7.1). If successful we hope to establish the 
relationship between the inflammatory response and infarct size, and to assess the 
effects of pharmacological intervention to limit myocardial inflammation using 
USPIO-MRI. 
 
7.3.5   USE OF ANTIBODY-TARGETTED SUPERPARAMAGNETIC MICROBEADS FOR IN 
VIVO CELL TRACKING 
Cell tracking has a wide range of potential clinical applications. Using SPIO and 
protamine sulphate we were able to label phagocytic cells for clinical cell tracking 
studies and successfully tracked intravenously delivered SPIO-labelled cells to an 
experimental inflammatory focus in healthy human volunteers. However, it would be 








Figure 7.1   USPIO uptake in the myocardium following myocardial infarction and primary coronary revascularisation. Following myocardial infarction and 
primary coronary revascularisation, patients (n=10) underwent MRI scanning immediately before and 24 and 48 hours after administration of USPIO. A further group 
of patients (n=6) acted as controls and did not receive USPIO. Colour maps indicate the R2* value before and after USPIO administration. Regions of interest were 
drawn on the following areas indicated by coloured arrows: red=infarct; purple=microvascular obstruction (if present); green=myocardium remote from infarct; 
blue=liver. In control patients no difference in R2* value was observed in any of these areas at baseline (a) and at 24 hours (b). This was confirmed on qualitative 
analysis (c). In patients receiving USPIO, compared to baseline (d) the R2* value was increased in the infarcted myocardium (e) (from 0.041 ± 0.012 s
-1
 at baseline to 
0.155 ± 0.045 s
-1
 (p <0.001) and 0.124 ± 0.035 s
-1
 (p <0.05) at 24 and 48 h respectively). As expected the R2* value was also increased in the liver following USPIO 
administration. Intriguingly, following USPIO administration, a small change in R2* value was observed in the myocardium remote from the infarct (f). 
USPIO - Ultrasmall superparamagnetic particles of iron oxide; MRI - Magnetic resonance imaging. 
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non-phagocytes. This would allow tracking of cells including stem cells, and in 
addition would allow investigation of specific aspects of cellular inflammatory 
activity in vivo.  
 
There now exists the possibility to label cells using targeted antibody-coupled 
superparamagnetic iron dextrose microbeads (Miltenyi Biotech). These GMP grade 
microbeads have been developed and used extensively within the field of cell therapy 
for isolation of a variety of cell types. There are a number of potential advantages to 
labelling cells using microbeads rather than SPIO. The processing time is 
significantly reduced since the isolation and labelling steps are combined. To 
encourage uptake of SPIO into cells, a transfection agent must be used (e.g. 
protamine sulphate) which can lead to cell clumping. Furthermore, using antibody-
targeted microbeads discrete cell populations can be labelled whereas Endorem is 
taken up non-specifically by any cell with phagocytic capacity. Finally non-
phagocytic cells can readily be labelled using antibody-targeted microbeads. 
 
When microbeads are used for immunomagnetic separation of different cell types, 
the aim is to achieve highly specific cell surface labelling with the minimum number 
of microbeads required to separate labelled from unlabelled cells in a magnetic 
separation column. We have modified this method to maximise cellular iron uptake 
by encouraging microbead phagocytosis, and in the first instance intend to use in 




7.4 CLINICAL PERSPECTIVE 
 
With strong evidence for a relationship between biological activity and 
cardiovascular events, the use of molecular imaging to assess pathophysiological 
processes is an enticing concept for improving risk stratification in patients with 
cardiovascular diseases. This in turn could enable individualised pharmacological 
therapy and risk factor control for high-risk individuals, which may be a more 
effective way to reduce the risk of cardiovascular events. There is also considerable 
interest in cellular and molecular imaging modalities from the pharmaceutical 
industry since these may provide intermediate measures for the assessment of 
efficacy of novel drugs and therapeutic targets. 
 
In aneurysm disease, it would be beneficial to have an improved method of assessing 
risk of aneurysm rupture to facilitate decision-making regarding the necessity and 
urgency of surgical or endovascular intervention. If shown to predict aneurysm 
rupture, MRI scanning with USPIO could address this need for more accurate risk 
stratification. In particular there may be patients with AAA smaller than the current 
threshold of 5.5 cm who are identified as being at increased risk of rupture using 
USPIO-MRI but who would not currently be considered for intervention. 
Furthermore, patients with large AAA whose aneurysm appears to be stable with 
little inflammatory activity may be spared surgery and its associated risks. In patients 
with AAA presenting with abdominal pain and tenderness it can be difficult to 
distinguish whether the symptoms indicate an aneurysm at risk of imminent rupture 
or whether the symptoms are explained by an alternative pathology. USPIO-MRI 
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may be useful in this group of patients to determine whether urgent aneurysm 
surgery is required. 
 
By assessing inflammatory activity in the aneurysm wall, MRI with USPIO may also 
be a useful way of assessing novel pharmacological agents in aneurysm disease both 
in terms of assessing their efficacy at the drug development stage, and to monitor and 
titrate dose on an individual patient basis.  
 
Regenerative medicine and cell-based therapies may become important treatment 
options to limit and even reverse cardiovascular and other diseases. Currently, the 
results of clinical trials can be difficult to interpret because there is no method of 
establishing the proportion of cells retained in the target therapeutic site following 
infusion. We have shown that using MRI, SPIO-labelled cells can be tracked to an 
experimental inflammatory focus in vivo following systemic administration. In the 
field of cell therapy, SPIO cell labelling could enable the proportion of cells reaching 
the target site to be determined non-invasively following administration. This would 
be critical for the assessment of the success of such cell-based therapies. 
 
In summary we have demonstrated the current use and future potential of SPIO in 
cardiovascular disease. USPIO allow correlation between biological activity and 
clinical disease progression in abdominal aortic aneurysm disease, and may become 
an invaluable clinical tool for the assessment of these patients. SPIO cell labelling 
enables clinical inflammatory cell tracking which has the potential to be a huge asset 
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as an investigative tool for assessing inflammatory activity in vivo and as a clinical 
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This document describes the procedure for isolation of Mononuclear 
Cells (MNC) from a venesection (whole) blood collection, labelling 
with Supraparamagnetic Iron Oxide (SPIO/Endorem) and preparation 
of the cells for infusion. All stages of the process to the point of final 
packaging of cells are performed aseptically within a Microbiological 
Safety Cabinet in the GMP Clean Room Facility (Grade A 
environment within a Grade B background). Clean Rooms 1 and 2 
within the TS Laboratory area or the Stem Cell Development Clean 
Room within the TS Cellular Therapy Suite may be used for the 
process. 
 
Changes from previous version: 
 
Time for incubation of cells with Endorem on roller mixer reduced from 
2 hours to 30 minutes, therefore all of procedure performed in single 
session in clean room. Amendments to SOP made accordingly. 
Addition of option to issue 2ml aliquot of labelled cells for 
intramuscular injection where required. 
 Ficoll now poured into accuspin tubes. 
Addition of method for cleaning sample racks, centrifuge and roller 
mixer. 
 Minor reformatting to improve clarity. 
 
1. Health and Safety 
 
Refer to the Departmental Health & Safety Manual for general health 





Lasair Particle Counter (if required) 
Hettich Rotafix 32 Centrifuge & 4-place rotor  
Roller mixer (Fisher Scientific MPR-465-010B) 
Tube Sealer (Sebra: Model: Omni) 
Bag Sealer (Astrapac: Model: SD 250) 
Gilson Pipetting Aid  
20µl /50-200µl /1,000µl Pipettes  
Light Microscope and x10/x40 objectives 
Improved Nebauer Haemocytometer & Coverslip   
Staedler Fine Waterproof Marker 
Sample Racks for Universal Containers and 225ml Containers 
1 x Yellow Clinical Waste Bag     
Calculator 
Sterile 50ml Leucosep Containers (Greiner Bio-One Code:227290) 
 
 224 
Sterile BD-Falcon 50ml Conical Tubes (Becton Dickinson Code: 
352077) 
Sterile BD-Falcon 225ml Conical Tubes (Becton Dickinson Code: 
352075) 
Sterile 3ml Pasteur Pipettes (VWR Code: 1612-1747) 
Sterile 5ml Cellstar Serological Pipettes (Greiner Bio-One Code: 
606180) 
Sterile 25ml Cellstar Serological Pipettes (Greiner Bio-One Code: 
760180) 
Sterile 200µl Pipette Tips (Eppendorf Code: 154006) 
Sterile 1ml Pipette Tips (Eppendorf Code: 323106) 
Sterile Plasma Transfer Set (Baxter Code: VMC 2240) 
Sterile 50ml Syringes (BD Code: 300866) 
Sterile 2ml Syringes (BD Code: 300185) 
Sterile Syringe Caps  
Sterile Universal 13cm Filling Tube (Bunzl Healthcare Code: UN 888) 
Sterile 500ml Cryocyte Freezing Containers (Baxter Code: R4R9955) 
Sterile Origen O-Wraps (Quest Biomedical Code: 6ORW1430)  
Sterile Scissors (In-House) 
1.8ml Cryovials (Nunc Code: LW3434) 
Sterile Drape (Molnlycke Healthcare Code: 700530) 
Sterile Klercide 70/30 IPA Spray (Shield Medicare Code: 3035800) 
Sterile Klerwipe 70% IPA Wipes –Sachet (Shield Medicare Code: 
3036040) 
Sterile Klerwipe 70% IPA Wipes – Pouch (Shield Medicare Code: 
3035960) 
Sterile Klerwipe Dry Wipe – Sachet (Shield Medicare Code: 3036060)  
Sterile Klerwipe Biocide B Pouch Wipes (Shield Medicare Code: 
3035900) 
Sterile Microseal 3000 Polyester Wipes (Berkshire Code: 
785000120S) 
8 x 90mm TSA plates (Oxoid Code: PO0821B) 
x 90mm SAB plates (Oxoid Code: PO 0410B) 
x 55mm TSA + Lecithin + Tween Contact Plates (Oxoid Code: PO 
0479D) 
x Microbiology Sample Container Packs (Cherwell Code: 211987) 
Venesection pack containing whole blood              
 
2.2. Reagents 
1 x 8ml ampoule Endorem (SPIO/Fe) (11.2mg/ml)(Guerbet:code 
013873)1  
1 x 5ml ampoule Protamine Sulphate  50mg in 5ml (10mg/ml) 
Wockhardt Code: FP3404 2 
x 100ml Sterile Ficoll-Paque (GE Healthcare:code 17-5442-02) 
1 x 1,000ml Sodium Chloride for Intravenous Infusion BP 0.9% w/w 
 
Ordered and supplied by Cardiovascular Group 










All staff undertaking this procedure must be appropriately trained and 
assessed.   
 
4. Bacteriology Testing 
Samples for bacteriology testing are taken into TSB & Thioglycollate broth 
from the following during the procedure: 
Sample Type Sample Size  
Session 1:Venesection Sample 0.5ml 
Session 1:Post Ficoll Supernatant 1ml 
Session 1:Post Wash Supernatant 1ml 
Session 2:Post Incubation Cell 
Suspension 
1ml 
4.1. Samples must be labelled with the donation number, date of 
sampling, sample type and processed as described in LIBS TSD 248. 
4.2. A record of sterility samples taken throughout the procedure is made 
on LIBF TSD 602. 
4.3. The Bacteriology Lab Book must be checked to ensure that all 
samples taken for sterility testing during the procedure are received 
by microbiology and logged correctly.  
LIBS TSD 201: Environmental Monitoring of the Clean Room Suite and Associated 
Areas 
LIBS TSD 208: Operation and Cleaning of Class II Microbiological Safety Cabinets 
LIBS TSD 213: Clothing procedure for entering the TS General Lab and Cleanroom 
Suite 
LIBS TSD 217: Introduction of Materials and Equipment into the General 
Laboratory and Clean Room and Disposal of Waste Materials 
LIBS TSD 223: Disposal of Clinical Waste 
LIBS TSD 248: Bacteriological Screening of Tissue Samples 
LIBS TSD 307: Operation of Sebra Tube Sealers 
LIBS TSD 308: Operation of Lasair Particle Counter 
LIBS TSD 439: Preparation of Cellular Therapy Product Labels 
LIBS TSD 601:  Operation and Cleaning of Class II Microbiological Safety Cabinets 
in the Cellular Therapy Suite 
LIBS TSD 603: Clothing Procedure for Entering the Tissue Services Cellular 
Therapy Suite 
LIBS TSD 604: Introduction of Consumables, Reagents and Equipment into the 
Tissue Services Cellular Therapy Suite and Disposal of Waste 
Materials 
LIBF TSD 602: Venesection Collection: Isolation & SPIO Labelling of MNC: Clean 
Room Batch Record 
LIBF TSD 603: Venesection Collection: Isolation & SPIO Labelling of MNC: Cell 




5. Preparation for Procedure in Clean Room 
5.1. Prepare processing record with forms. Print blank labels for labelling 
final product. 
5.2. If using the CTS Clean Room check that the clean room air pressure 
is within limits before entering the clean room. Record outcome on 
LIBF TSD 424. 
5.3. If using TS Clean Room 1/2, check that clean room air pressures are 
within limits and that the Airnet Particle Monitoring system is 
operational before entering the clean room suite. Record outcome on 
LIBF TSD 602. 
5.4. All reagents, materials & equipment are introduced to the transfer 
hatch as described in LIBS TSD 604/217.  
 
6. Clean Room Procedure 
6.1. Operator and assistant don cleanroom clothing as described in LIBS 
TSD 603/213 and enter the clean room. 
6.2. Environmental monitoring for the procedure must be performed as 
described   in LIBS TSD 201. Where require the Lasair Particle 
counter must be switched on as described in LIBS TSD 308. 
6.3. Ensure the MSC is operating safely before proceeding. Record 
outcome on LIBF TSD 602. Clean the MSC as described in LIBS TSD 
601/208. Record cleaning in appropriate cleaning record. Take Pre-
Procedure contact plates from the MSC as described in LIBS TSD 
201. 
6.4. Ensure that the microscope is operating correctly before proceeding. 
6.5. Clean the centrifuge, centrifuge buckets, inserts and lids with Sterile 
Klercide Biocide B wipes, leave for 5 minutes, then wipe all surfaces 
with Sterile IPA spray and dry with sterile dry wipes. Record cleaning 
in centrifuge cleaning record. 
6.6. Clean the roller mixer with Sterile Klercide Biocide B wipes, leave for 
5 minutes, then wipe all surfaces with Sterile IPA spray and dry with 
sterile dry wipes. Record cleaning in roller mixer cleaning record. 
6.7. Clean the sample racks with Sterile Biocide B wipes, leave for 5 
minutes, then wipe all surfaces with Sterile IPA spray and dry with 
sterile dry wipes. 
6.8. Clean all pipettes with Sterile Klercide Biocide B wipes, leave for 5 
minutes, then wipe all surfaces with Sterile IPA spray and dry with 
sterile dry wipes. 
6.9. The assistant will unload the materials from the hatch, & pass the 
materials as required into the operator in the MSC as described in 
LIBS TSD 604/217. All consumable and reagent batch numbers must 
be recorded on LIBF TSD 602. 
 
6.10. Check pack and product details before commencing: 




Patient information, product details and donation number on 
pack label matches information on consent forms. Checks must 
be recorded on LIBF TSD 602. 
 
6.11. Spray operator & assistant gloves with Sterile IPA before 
commencing procedure in MSC.  
6.12. The assistant passes a sterile drape to the operator who 
prepares a sterile field in the MSC. 
6.13. The assistant will then place environmental monitoring plates at 
the appropriate positions as described in LIBS TSD 201 and record 
the procedure start time on LIBF TSD 602. 
 
6.14. Separate MNC from Whole Blood by Density Gradient 
Centrifugation using Ficoll. 
6.14.1. N.B All spikes and ports must be wiped with sterile 
alcohol wipes before connecting. All bottle/container necks 
must be wiped with sterile alcohol wipes before pouring. 
6.14.2. Pour approx. 18mls of ficoll-paque into the appropriate 
number of 50ml accuspin tubes. The number of accuspin tubes 
will depend on the volume of blood collected. The maximum 
amount of blood that can be processed is 280mls (8 x tubes @ 
35mls/tube). 
6.14.3. Place accuspin tubes in sample rack. Pass the accuspin 
tubes to the assistant.  
6.14.4. Centrifuge the tubes for 30 secs @ 400g (2,000 r.p.m) to 
allow the ficoll to settle to the bottom of the tube. Wipe the 
accuspin tubes and rack with sterile alcohol wipes before 
transferring to operator. 
6.14.5. Using a Pasteur pipette remove excess ficoll above the 
scinter and discard to waste. 
6.14.6. Transfer blood from the venesection pack into a 225ml 
conical tube by cutting the tail of bag with sterile scissors and 
allowing the blood to pour into the tube.  
6.14.7. Remove 1ml aliquot of venesection sample using a 
pasteur pipette for sterility testing as described in Section 5.0.  
6.14.8. Carefully pour blood directly onto the scinter in the 
accuspin tubes. Distribute the blood evenly between the first 4 
tubes, up to a maximum of 35mls of blood per tube.  
6.14.9. Pass accuspin tubes to assistant. Centrifuge the 
accuspin tubes for 30 minutes @ 400g (2,000 r.p.m).  
6.14.10. After 25 mins, repeat from 7.13.7 above for remaining 
tubes. 
6.14.11. The original pack must be retained to allow final 




6.15.  Wash MNC x2 in Saline. 
6.15.1. Wipe the sample rack followed by the tubes with sterile 
alcohol wipes and return to the operator. 
6.15.2. After centrifugation, the MNC form a distinct band at the 
sample/medium interface. Using a 25ml volumetric pipette, 
carefully remove supernatant to within 2cm of the mononuclear 
layer and discard the supernatant into a 225ml conical tube 
labelled WASTE. 
6.15.3. Remove 2mls post ficoll supernatant using a pasteur 
pipette for sterility testing as described in Section 5.0.  
6.15.4. Carefully remove the MNC layer at the interfaces, 
loosening any cells adhering to the walls of the tubes. 
6.15.5. Distribute the MNC equally between 4 x 50ml universal 
containers.  
6.15.6. Insert a plasma transfer set into the saline bag. Make up 
the volume in each tube to 50mls with saline.  Replace the caps 
and invert the tubes three times. Pass MNC samples to assistant.  
6.15.7. Centrifuge the MNC samples for 10 minutes @ 300g 
(1500 rpm). Wipe the sample rack followed by the tubes with 
sterile alcohol wipes and return to operator. 
6.15.8. MNC will form a pellet at the base of the tube. Using a 
25ml volumetric pipette initially, followed by a pastette carefully 
remove all supernatant from the cell pellet and discard the 
supernatant into the waste container. 
6.15.9. Gently resuspend each of the pellets in 5-10mls of saline 
and pool the pellets into one 50ml tube. Mix thoroughly and 
make up to an exact final volume of 30mls. N.B All volumes 
must be checked by the assistant. 
6.15.10. Remove 500µl of the cell suspension and place into a 
cryovial for cell counting. Label with date and donation number 
and prefix “Pre”. 
6.15.11. Repeat wash procedure from 7.14.6 x1. 
 
6.16. Perform a Manual White Cell Count 
6.16.1. Perform a white cell count as described in Appendix 1. 
6.16.2. All cell counts and calculations must be performed 
independently by the operator and assistant. Record calculations 





6.17. Calculate the Volume of Saline, Endorem and Protamine 
Sulphate to add to the Cells.  
Note: The final volume of Endorem infused must not exceed 
0.075mls/kg  of recipient body weight and the final volume of cells 
infused must not exceed 500mls. If required, the volume of cells 
labelled  initially must be adjusted to achieve this.  
 
6.17.1. Saline is added to the cell suspension to achieve a 
final cell concentration of 4 x 106 cells/ml.  
Example: If the total cell count is 200 x 106, then the total volume of 
saline  required to be added to the cell pellet to achieve a final cell 
concentration of  4x106/ml will be: 
200 x 106  = 50 mls saline x106 
 
6.17.2. Endorem is added to the cell suspension to give a 
final concentration of Fe: 100ug/ml. Endorem contains 11.2mg 
Fe/ml therefore 8.9!l of Endorem solution will contain 100!g Fe.  
Example: For 50 mls of cell suspension at a concentration of 4 x 
106/ml, 445µl (50 x 8.9!l) of Endorem is added. Ensure that the 
volume of endorem is within the limit of 0.075mls/kg of recipient body 
weight. (The recipient’s current weight will be recorded on LIBF TSD 
210) 
Example: For a 60kg donor, the maximum amount of Endorem for 
 infusion  will be 60 x 0.075mls = 4.5mls. 
 
Protamine Sulphate is added to the cell suspension to give a final 
concentration of Protamine: 4!g/ml. Protamine Sulphate contains 
10mg Protamine/ml therefore 0.4!l of Protamine Sulphate will contain 
4!g of Protamine. 
Example: For 50 mls of cell suspension 20!l (50x0.4) of Protamine 
Sulphate is added. 
 
6.17.3. Record calculations and results on LIBF TSD 603. All 
calculations must be performed independently by the operator 
and assistant. 
 
6.18. Add Saline, Endorem and Protamine Sulphate to Cells 
6.18.1. Spray operator & assistant gloves with Sterile IPA before 
continuing procedure in MSC.  
6.18.2. Clean the roller mixer with sterile alcohol wipes and 
transfer into the MSC. 
6.18.3. Wipe the sample rack followed by the tube with sterile 
alcohol wipes and return to the operator. 
6.18.4. Remove 2mls post wash supernatant using a pasteur 
pipette for sterility testing as described in Section 5.0.  
6.18.5. Remove all of the remaining supernatant from the cell 
pellet and discard the supernatant into the waste container.  
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6.18.6. Using a 25ml pipette, resuspend the pellet initially in 
30mls of saline and transfer suspension into a 225ml conical 
tube. Add required additional volume of saline to achieve final cell 
concentration of 4 x 106 cells/ml. Mix the cell suspension. 
6.18.7. Using a pipette, add the correct volume of Endorem 
directly to the cell suspension.  
6.18.8. Using a pipette, add the correct volume of Protamine 
Sulphate directly to the cell suspension. Mix.  
6.18.9. Record the final volume of suspension (including 
endorem and protamine) to the nearest ml on LIBF TSD 603. 
6.18.10. Place the tube immediately on the roller mixer. The 
cells are mixed at ambient room temperature for 30 minutes. 
Note the incubation start/finish time on LIBF TSD 602. 
 
6.19. Perform a Manual White Cell Count 
Spray operator & assistant gloves with Sterile IPA before continuing 
procedure in MSC.  
6.19.1. Using a pipette remove 500µl of the cell suspension and 
place into a cryovial for cell counting. Label with date and 
donation number and prefix “Post”. 
6.19.2. Perform a white cell count as described in Appendix 1. 
6.19.3. Operator and assistant must perform all cell counts and 
calculations independently. Record the results on LIBF TSD 603.  
 
6.20. Prepare Pack/Syringe labels with Patient and Product 
Details.  
6.20.1. All pack/syringe labels must be checked for accuracy 
independently by the operator and assistant against the original 
venesection pack label and the cell dose calculations on LIBF 
TSD 603. 
 
6.21. Package Cells for Infusion 
6.21.1. Spray operator & assistant gloves with Sterile IPA before 
continuing procedure in MSC.  
6.21.2. The entire volume of cells remaining post incubation will 
be infused, but must not exceed 500mls. The cells are 
transferred into the required number of 500ml cryocyte containers 
depending on the final volume.  If required a 2ml aliquot of 
labelled cells is prepared for intramuscular injection. 
6.21.3. Remove 1ml post incubation cell suspension using a 
pasteur pipette for sterility testing as described in Section 5.0. 
6.21.4. Remove 2ml aliquot of cell suspension (if required), cap 
with syringe cap. Pass to assistant.  
6.21.5. Visually check the integrity of the cryocyte container and 
port and tubing closures. Do not use container if port and/or 




6.21.6. Close the roller clamps on 1 x male and 1 x female luer 
lines on each of the containers, leaving 1 x female line open to 
access the container. The roller clamps should be positioned on 
the line as near to the container as possible. 
6.21.7. Using a sterile filling tube attached to a 50ml syringe, 
withdraw all remaining cell suspension and introduce the 
suspension into the cryocyte bag via the luer line.  
6.21.8. Carefully remove excess air from the cryocyte container 
by applying gentle    pressure to the pack until all the air in the 
container has been expelled and close the roller clamp on the 
line. 
6.21.9. Clean the jaws and lever assembly of the Sebra Heat 
Sealer using a sterile alcohol wipe. Pass to the operator. Refer to 
LIBS TSD 307 for operating instructions for the Sebra Heat 
Sealer. 
6.21.10. Dry the line and jaws of the sealer using a sterile lint free 
wipe. Ensure there is no fluid in the line (tap gently to return fluid 
to container if required). 
6.21.11. Seal the line to the cryocyte container as close as 
possible to the container, ensuring that the seal is parallel to the 
plane of the container and centred on the tubing.  
6.21.12. Make a 2nd seal 0.5cm above the 1st seal, but not above 











6.21.13. Cut the middle of the 2nd seal using sterile blunt-ended 
scissors and discard the excess line. Do not pull the line ends to 
separate. This could cause a small hole in the seal compromising 
the sterility and integrity of the contents. 
6.21.14. Check the integrity of the seals both visually and by 
inverting the container and applying gentle pressure. If there is 
any evidence of leakage, the contents of the container must be 
transferred to a fresh cryocyte container and resealed. 
6.21.15. Pass the container to the assistant. 
6.21.16. The sterile procedure is now complete. Operator and 
assistant must take finger plates as described in LIBS TSD 201. 
 
6.22. Label and Package Containers/Syringe. 
6.22.1. Place the correct identification label in the label pocket of 




label are accurate. Seal the label pocket x3 with the Sebra Tube 
Sealer. 
6.22.2. Place the bag in an O-wrap outer bag and seal x1 using 
the bag sealer. 
6.22.3. Wrap an identification label around the syringe and place 
the syringe in a 225ml conical tube. Label the outside of the conical 
tube with an identification label. 
6.22.4. Place labelled containers/syringe in CR or Product 
Dispatch hatch. 
 
6.23. The MSC must be cleaned as described in LIBS TSD 601/208 
and “Post Clean “ contact plates taken. 
6.24. The centrifuge, roller mixer, sample racks and pipettes must be 
cleaned post procedure as described in 7.5 -7.8. 
6.25. All waste must be handled as described in LIBS TSD 604/223 
and returned to the hatch for disposal. 
6.26. Ensure all documentation is complete and signed by the 
operator/assistant before leaving the clean room. 
6.27. Medical release and issue of the cells for infusion is described in 
LIBS TSD.  
 
 233 
Appendix 1  
 









• Ensure that both the haemocytometer and coverslip are clean by wiping 
over with sterile alcohol wipe. Breathe on to the surface of the 
haemocytometer and quickly place the coverslip in position so that it is 
centred over the counting chamber.  
• Gently, but firmly press down the coverslip, using a thumb placed either 
side, holding the haemocytometer firmly between both hands, until 
Newton’s rings (refraction rings of light of a rainbow/oil slick colouration) 
are seen.  
• Take up a 20µl of the cell suspension into the tip of a 100µl Gilson. Gently 
touch the tip against the side of the coverslip where it touches the base of 
the   depression. Press down the plunger of the Gilson and a drop of the 
suspension will be drawn out of the pipette into the chamber and will fill 
one of the chambers.  
• Ensure that the counting chamber is filled with a single action and that no 
fluid  
flows into the surrounding depression.  
• It is important to carry out the following steps as quickly as possible to 
ensure that the chamber does not dry out: 
• Place the haemocytometer under the microscope. Turn the microscope 
on and under low power (x5/x10) focus on the grid area of the counting 
chamber.  
• The grid area can be seen to be formed of 9 large squares in a 3x3 grid. 
Each of these squares covers an area of 1mm2, which, with the depth of 
the chamber being 0.1mm, means that the volume of each large square is 
0.1mm3.  
• The central area of the grid (3) is made up of triple ruled lines that in the 
centre form a 5x5 grid of 25 squares with a total volume of 0.1mm3. Each 
of these 25 squares have an area of 0.04mm2 and a volume of 
0.004mm3. 
• Turn to the x40 objective and count the four corner and one central 
0.04mm2 squares. Cells falling on the bordering triple lines should only be 
counted if they are on either the top or the left lines only. Exclude those 
touching the bottom and the right hand side lines.  
• The most accurate count is achieved when 120-200 cells are counted. If 
there are more cells than this the suspension should be further diluted 
and counted again, noting the dilution factor in the calculation.  
• If there are fewer cells turn the objective to x10 and count all 25 squares 
in the central grid. 
• Count the cells and make a note of the count on LIBF TSD 603.  
• The counts will be performed by two individuals and the mean of the two 




• Calculate the number of cells using the following calculation: 
 
If you have counted 5 of the 25 squares in the central triple ruled grid 
the calculation will be as follows: 
• The central triple ruled grid has a volume of 0.1mm3. You have counted 5 
squares, so to convert to the number of cells in 0.1mm3, divide by 5 then 
multiply by 25.  
• To convert from cells/ 0.1mm3 to cells/ml, multiply by 10,000 and then by 
the dilution factor (if applicable). 
        
No of Cells/ml =   Cell Count   x  25  x  10,000 x Dilution Factor 
                                     5 
 
If you have counted all 25 squares (0.1mm3) in the central grid, to allow 
for a low density cell population the calculation will be: 
 
• The central triple ruled grid has a volume of 0.1mm3. To convert from 
cells/ 0.1mm3 to cells/ml, multiply by 10,000 and then by the dilution 
factor (if applicable). 
 
 No of Cells /ml = Cell Count  x 10,000 x Dilution Factor 





Departmental Manager must consider staff training and re-training requirements associated 
with the introduction of this SOP; and initial as appropriate the statements below for its 
application within their department: 
 
Training required for all staff in the department carrying out 
procedure.  
 
Familiarisation with SOP content required for staff trained and 
competent in the procedure. 
 






Staff Signature Date 
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   












1.1 MAGNETIC RESONANCE IMAGING 
 
1.1.1   ATOMIC STRUCTURE  
Atoms are made up of a central cluster of nucleons in the nucleus surrounded by a 
cloud of orbiting, spinning electrons. The mass of an atom is concentrated in the 
nucleus which consists of particles called nucleons: protons which are positively 
charged and neutrons which have no charge. The mass number of an atom is the sum 
of the number of protons and neutrons. To maintain overall electrical neutrality, the 
number of electrons must be equal to the number of protons. The mass of an electron 
is negligible when compared to that of the nucleus. 
 
1.1.2   MAGNETIC NUCLEI 
Protons and neutrons spin about their own axis and have a paired nucleon which 
spins in the opposite direction. In most atoms, protons and neutrons are present in 
equal number so overall the spins of pairs of particles cancel each other out. 
Therefore, when considered as a whole, the nucleus has no net spin. In some atoms, 
however, the number of neutrons is one more or one fewer than the number of 
protons. In this situation the spin of one of the nucleons is unopposed conferring the 
property of angular momentum or spin to the atom. Such atoms are described as 
magnetically active and examples of these include hydrogen, carbon, nitrogen, 
oxygen, fluorine, sodium and phosphorous. Any of these nuclei can be utilised for 
magnetic resonance imaging (MRI). Hydrogen, which consists of a single proton, is 
most commonly used for in vivo imaging due to its relative abundance in the human 
body and large magnetic moment. 
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Magnetic nuclei (the electron cloud is ignored here) such as hydrogen are positively 
charged and possess angular momentum. According to the laws of electromagnetic 
induction, a moving, charged particle generates a magnetic field around it and is said 
to have a magnetic moment. In the absence of an external magnetic field the axes of 
different spinning protons are randomly orientated. 
 
1.3   CLASSICAL AND QUANTUM MECHANICS 
 
According to the laws of classical mechanics, in the presence of an external magnetic 
field (B0), a proton experiences a torque force and tends to align its own field with 
that of the stronger external field. The proton is unable to align itself exactly and its 
own magnetic moment orbits around B0. This phenomenon is called precession and 
is analogous to the wobbling of a spinning top (Figure A2.1). The precessional 
frequency is proportional to the field strength of B0 and is described by the Larmor 
equation  
!0 = B0 x " 
 
where !0 is the precessional frequency, B0 is the strength of the external magnetic 
field and " is the gyromagnetic ratio (angular momentum/magnetic moment of a 
particular nucleus). 
 
Under the laws of quantum mechanics, there are two states in which individual 
protons can align with B0. Low-energy protons will align in approximately the same 
direction as the field (parallel or spin up) and high-energy protons will align in the 
opposite direction (anti-parallel or spin down) (Figure A2.2). Both of these states are 
stable but protons may swap between the two states by gaining or losing a photon. 




















Figure A2.1 Precession 
When an external magnetic field (B0) is applied magnetic nuclei attempt to align with B0, but do so 











Figure A2.2 Quantum theory and energy levels 
According to quantum theory, magnetic nuclei lie in either the low energy (spin up or parallel) state or in the high energy (spin down or anti-parallel) state. In the 
resting state a small excess of nuclei lie in the parallel state creating a small NMV in the same direction as B0. 
NMV - Net magnetisation vector; B0 - External magnetic field. 
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The proportion of protons in each state depends on the temperature and the strength 
of the external field. At a higher temperature, a higher proportion of protons have 
sufficient energy to oppose B0 and exist in the anti-parallel or spin down state. In 
clinical imaging, however, the temperature is not subject to manipulation and the 
only important factor is the external field strength.  
 
When a patient lies in a clinical MRI scanner, the small majority of hydrogen protons 
aligning in the parallel direction generate the Net Magnetisation Vector (NMV or 
M0), the size of which reflects the balance of protons in the parallel and anti-parallel 
states (Figure A2.2). As the strength of B0 increases, fewer nuclei have enough 
energy to oppose the external field and more protons lie in the parallel or spin up 
state. The NMV is therefore of greater magnitude at higher field strengths and this 
explains why there is more signal when imaging in higher tesla MRI scanners.  
 
Whilst individual protons behave in accordance with the laws of quantum theory, the 
average behaviour of a group of protons conforms to the laws of classical mechanics. 
 
1.4   RESONANCE AND PHASE 
Resonance occurs when particles are excited by energy of the same frequency as 
their own oscillation (i.e. the Larmor frequency). For protons precessing at clinical 
field strengths, the frequency of energy required to induce resonance is within the 
radiofrequency (RF) range of the electromagnetic spectrum. The exact frequency 
required for resonance is specific to individual MRI active atomic nuclei. 
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When protons are excited by a RF pulse, a proportion will gain sufficient energy to 
move into the high energy spin down or anti-parallel state (Figure A2.3). The effect 
on the NMV is deflection away from B0. The angle between the NMV and B0 is the 
flip angle. The flip angle depends on the size and duration of the RF pulse. The flip 
angle is more easily understood if a fixed frame is considered rather than a rotating 
frame (Figure A2.4). 
 
Under the influence of an external magnetic field, protons precess at the same 
frequency but are out of phase with each other. The other effect of application of a 
resonant RF pulse is to cause all the protons to precess in phase. The concept of 
phase-coherence can be understood when compared to the hour hand of a clock 
(Figure A2.5). All over the world the hour hand takes 12 hours to complete a 
revolution of the clock face (i.e. they have the same frequency), but depending on 
which time-zone you are in the hour hand will be pointing at a different time (i.e. 
they are out of phase with each other). If, however, you consider all of the clocks in 
the same country, the hour hands will all be pointing to the same time (i.e. they are 
in phase). When all the protons are in phase they are said to have phase-coherence 
and the resulting MR signal is greater. When phase-coherence is lost the signal 
becomes indetectable. 
 
1.5   TRANSVERSE MAGNETISATION AND SIGNAL 
 
According to Faraday’s Law of electromagnetic induction, a voltage is induced in a 
conductive coil placed in a fluctuating magnetic field. Because resonance causes the 










Figure A2.3 Resonance and transverse magnetisation 
When the radiofrequency pulse is applied, resonance is induced. Some nuclei gain energy and move into the high energy state (*) deflecting the NMV into the 
transverse plane at an angle to B0. 









Figure A2.4 Longitudinal and transverse magnetisation 
When considering the “fixed frame”, precession is ignored and only the x and y components of the NMV are considered. At baseline (a) the NMV is aligned with 
B0. When a radiofrequency pulse is applied (b), the NMV is deflected into the transverse plane inducing a signal in the receiver coil. 
NMV - Net magnetisation vector; B0 - External magnetic field. 
















Figure A2.5 Phase coherence 
The hour hands of clocks all over the world have the same frequency. The hour hands of all clocks in 
the United Kingdom are at the same position (ie they are in phase) but in other countries point to 
different times (ie they are out of phase). 
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precesses about B0, a coil placed in the transverse plane is exposed to an oscillating 
magnetic field. The resulting voltage induced in the coil constitutes the signal. The 
frequency is equal to the Larmor frequency and the magnitude is determined by the 
magntitude of the transverse component of the NMV. 
 
1.6   RELAXATION 
 
At the end of the radiofrequency pulse the NMV tends to realign with B0. This 
process of relaxation involves a proportion of protons in the spin down, high-energy 
state returning to the spin up, low-energy state by emitting some of the energy that 
they had gained from the RF pulse. The second component of relaxation is loss of 
phase-coherence of spinning protons. 
 
During relaxation longitudinal magnetisation is regained and this is called T1 
recovery. There is also a loss of transverse magnetisation called T2 decay that occurs 
simultaneously with but independently of T1 recovery (Figure A2.6a). 
 
As a result of the decay of transverse magnetisation, the signal in the receiver coil 
decreases with time after the end of the RF pulse and this is called free induction 
decay (FID). FID is influenced by a number of factors including interactions between 
spinning nuclei and their environment, and inhomogeneities in the magnetic field 
which cause nuclei to precess at slightly different frequencies. 
 
T1 recovery occurs when spinning nuclei emit energy to the surrounding 
environment or lattice (spin-lattice relaxation). Recovery of longitudinal 
magnetisation is an exponential process described by a tissue-specific constant called 














Figure A2.6 (a) T1 recovery and (b) T2 decay 
T1 recovery occurs as a result of spin-lattice interactions and longitudinal magnetisation is regained 
(a). The T1 value is the time taken for 63% of longitudinal magnetisation to be recovered. T2 decay is 
loss of transverse magnetisation and occurs as a result of spin-spin interactions between magnetic 
nuclei (b). The T2 value is the time taken for transverse magnetisation to decay to 37% of its original 
value.  
T1 recovery and T2 decay occur simultaneously but are independent of each other.  
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the T1 relaxation time which represents the time taken to recover 63% of the 
longitudinal magnetisation. 
 
Transfer of energy to neighbouring nuclei (spin-spin relaxation) results in 
exponential T2 decay of coherent transverse magnetisation (Figure A2.6b). Spinning 
nuclei exhibit random motion and as they come into close proximity with each other 
there is a small change in the local magnetic field which in turn causes a small 
change in the precessional frequency. As they move apart again they return to the 
Larmor frequency but are now slightly out of phase with each other. As a result of 
serial interactions with other nuclei there is complete loss of phase-coherence. Note 
that there is no net loss of energy from the population of spinning nuclei but rather a 
transfer of energy amongst nuclei. The T2 relaxation time is the time taken for the 
transverse magnetisation to decay to 37% of its original value. 
 
Since loss of phase-coherence occurs much more rapidly than realignment with B0, 
the T2 relaxation time is much shorter than the T1 relaxation time for a particular 
tissue. 
 
T2* decay is the combination of T2 decay (spin-spin interaction) and loss of phase-
coherence due to small magnetic field inhomogeneities. If the local magnetic field 
strength around a spinning proton is slightly higher or lower than B0, the proton will 
spin slightly faster or slower than its neighbours because the precessional frequency 
given by the Larmor equation is proportional to field strength. This results in very 
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rapid loss of phase-coherence occurring immediately after application of the RF 
pulse. The T2* value is always shorter than the T2 value.  
 
The T1 and T2 relaxation rates of a tissue depend on three key factors: inherent 
energy of the tissue, how tightly packed the molecules are and how closely the 
molecular tumbling rate matches the Larmor frequency. Energy transfer between 
nuclei (i.e. spin-spin energy transfer) is more efficient if the molecules are closely 
related to each other and T2 relaxation time is short. If the molecular tumbling rate 
and the Larmor frequency are similar, efficient transfer of energy occurs between 
spinning nuclei and the surrounding lattice resulting in rapid T1 relaxation. In 
addition, tissues such as fat with low inherent energy can readily absorb energy 
dissipated into the lattice. 
 
In fat the molecules are large, densely packed and have a low tumbling rate which is 
similar to the Larmor frequency. They also have low inherent energy. There is 
therefore efficient transfer of energy between nuclei and the surrounding lattice  
(spin-lattice relaxation) resulting in rapid T1 recovery (short T1 time) 
(Figures A2.7 and 8). There is also efficient transfer of energy amongst the hydrogen 
nuclei (spin-spin relaxation) and the T2 decay is rapid (short T2 time). 
 
Water, by comparison, consists of small, high-energy molecules with a high 












Figure A2.7  T1 recovery in fat and water 
T1 recovery is faster in fat than in water because there is efficient transfer of energy between the spinning nuclei and the surrounding lattice. 
 




















Figure A2.8 T2 decay in fat and water 
T2 decay in fat is rapid and in water occurs more slowly because the molecules are closely packed 
together, the molecular tumbling rate is similar to the Larmor frequency and the molecules have low 
inherent energy. These factors favour transfer of energy between spinning nuclei resulting in a short 
T2 time. Water, by comparison, consists of small, high energy molecules with a high tumbling rate 




resulting in slow T1 recovery (long T1 time) and slow T2 decay (long T2 time) 
(Figures A2.7 and 8). 
 
1.7   BASIC SIGNAL PARAMETERS 
A simple sequence consists of a series of RF pulses followed by a period of 
relaxation during which the signal is sampled.  
 
The repetition time (TR) is the time between the radiofrequency pulses and 
determines the degree of T1 recovery that is allowed to occur. The TR therefore 
gives the T1 weighting of the sequences. 
 
The echo time (TE) is the time that elapses between application of the RF pulse and 
sampling of the signal which determines the amount of T2 decay that is allowed to 
occur. Using a long echo time therefore increases the T2 weighting of the sequence. 
 
1.8   CONTRAST AND WEIGHTING 
T1, T2 and T2* decay occur to a certain extent in all MR images. However by 
manipulating the echo time and TR it is possible to weight the image so that one of 
these weightings predominates. This increases the contrast between different tissues 
and enables image interpretation. 
 
In a T1 weighted (T1W) image the difference in T1 times between fat and water is 
maximised. This is achieved by using a short TR so that there is a large difference in 









Figure A2.9 T1 weighted and T2 weighted imaging 
In a T1 weighted image (a), the TR is short to maximise the contrast between water and fat. The T2 
effects are minimised by using a short TE. 
In T2 weighted imaging (b), the TE is long to maximise the contrast between water and fat by 
allowing the signals in both water and fat to decay. In addition, the T1 effects are minimised by using 
a long TR. 
TR - Repetition time; TE - Echo time. 
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vectors from both fat and water would have realigned fully with B0 and no difference 
would be detected. In conjunction with a short TR, a short echo time is used to 
minimise the T2 weighting. 
 
In a T2 W image the difference in T2 times between fat and water is maximised 
(Figure A2.9b). This is achieved by using a long echo time so that both fat and water 
signals have an opportunity to decay and a difference between them can be detected. 
To minimise the T1 weighting of the image the TR is long so that full T1 relaxation 
has occurred in both fat and water. 
 
To obtain a proton density image both the T1 and T2 effects are minimised so that 
the image reflects the proton density of tissues. To achieve this a long TR and a short 
echo time are used. 
 
1.9   SPIN ECHO SEQUENCES 
T2* decay is very rapid and without compensation the signal would reach zero 
before T1 and T2 weighting had been achieved. Following application of a RF pulse, 
spinning protons begin to precess at different rates due to local magnetic field 
inhomogeneities and phase-coherence is lost.  
 
This situation is commonly likened to racing cars driving at different speeds on a 
circular track (Figure A2.10). At a specified time, t (where t=TE/2), the faster cars 









Figure A2.10 Spin echo sequences 
Spin echo sequences can be understood using the analogy of a car race. All cars start at the same point on the track (a) but travel at different speeds and at the half 
way stage in the race (t=TE/2) are at different points on the track (b). If they then stop and start driving the other way round the track (c) they will reach the 
finishing line together at a time 2t (where 2t=TE) (d).  
TE - Echo time. 
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at the same speed the opkposite way round the track they would all cross the line 
simultaneously at a time 2t (where 2t=TE). 
 
A spin echo sequence uses a similar principle (Figure A2.11). A 90
o
 RF pulse is 
applied flipping the NMV into the transverse plane. The precessing protons begin to 
dephase immediately due to T2* effects and phase-coherence is lost. At a time 
t (where t=TE/2), a further 180
o
 RF pulse is applied which reverses the direction of 
the NMV. The protons which are precessing more rapidly ‘catch up’ with the slowly 
precessing protons and at a time, 2t (where 2t=TE), the protons are back in phase and 
the signal is sampled. 
 
1.10   GRADIENT ECHO SEQUENCES 
A magnetic field gradient is induced by a current passing through a magnetic coil in 
the bore of the magnet. It interacts with the main magnetic field such that the 
composite field strength varies along the axis of B0. At the magnetic isocentre the 
field strength is equal to that of B0, but away from the isocentre in one direction it 
increases and in the other direction it decreases (Figure A2.12). Since the 
precessional frequency is proportional to the magnetic field strength, protons in 
different parts of the magnetic field will precess at different frequencies resulting in 
gradual dephasing of coherent transverse magnetisation (Figure A2.13). A second 
equal but opposite gradient can be applied to rephase the individual magnetic 
moments restoring phase-coherence. The signal induced in the receiver coil at this 








Figure A2.11 Spin echo sequences 
An excitatory 90° radiofrequency pulse is applied and flips the NMV into the transverse plane (a). There is spontaneous rapid loss of phase coherence as a result of 
T2* decay (b and c). A 180° radiofrequency pulse is applied which inverts the NMV (d). Rephasing occurs (e) with restoration of phase coherence and the spin 
echo is sampled at TE (f). 









Figure A2.12 Gradient echo 
In a gradient echo sequence a gradient magnetic field is applied at an angle to B0. Magnetic nuclei in different parts of the imaging volume experience different 
field strengths of magnitude slightly greater or less than B0. Because precessional frequency is proportional to field strength, some nuclei slow down and some 
speed up so that they are all slightly out of phase.  








Figure A2.13  Gradient echo 
Spinning nuclei align with B0 and are in phase (a). When a gradient magnetic field is applied, protons begin to spin at different frequencies depending upon the 
composite field strength that they are exposed to and dephasing occurs (b). A second equal but opposite gradient is applied which rephases the spins (c) and phase 
coherence is restored (d). The signal sampled at this point is called the gradient echo.  
B0 - External magnetic field. 
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Whilst spin echo sequences always use excitatory RF pulses that flip the NMV 
through 90°, gradient echo sequences can use smaller flip angles. By using a smaller 
flip angle, full recovery of longitudinal magnetisation occurs more rapidly and the 
TR can be shorter. In addition, rephasing is faster using a gradient compared to a 
180º RF pulse allowing shorter echo time to be used. These factors mean that the 
scanning time is shorter compared to spin echo sequences. 
 
Compared to images acquired using spin echo sequences, gradient echo images are 
acquired much more quickly but have a poorer signal-to-noise ratio due to the short 
TR and small flip angle. Furthermore, gradient echo sequences make no 
compensation for T2* decay making them highly sensitive to magnetic field 
inhomogeneities. T2* weighting is maximised by the use of long echo time and long 
TR (although in practice TR is still much shorter than that used in spin echo 
sequences).   
 
1.11   MULTI ECHO SEQUENCES AND T2* VALUE 
 
In a multi echo gradient echo sequence the signal is sampled at multiple echo times 
following a single RF pulse. Compared to acquiring the echoes individually 
following separate RF pulses, the use of a multi echo sequence reduces the 
acquisition time and, because the echoes are collected only milliseconds apart, 
avoids the need to register sequential images to each other. 
 
The signal decays exponentially with increasing echo time. The rate of decay of 
signal intensity is determined by the decay constant the T2* value calculated by the 
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equation S(t)=S(0)exp-(t/T2*), where S(t) is the signal intensity at time t, and S(0) is 
the signal intensity at time 0. 
 
Endogenous iron and iron nanoparticle-based MRI contrast agents induce local 
magnetic field inhomogeneities resulting in rapid dephasing of coherent transverse 
magnetisation. The rate of decay of signal intensity with echo time is increased with 
a corresponding reduction in T2* value. Changes in T2* value have been exploited 
for the detection of endogenous iron accumulation such as occurs in 
haemochromatosis and transfusion-related iron overload in patients with 
thalassaemia major. Using multi echo sequences, a reduction in T2* value is 
observed in the myocardium and the liver in patients with systemic iron overload. 
[Anderson et al 2001; Wood et al 2005; Storey et al 2007]. 
 
1.12   CONTRAST AGENTS 
Contrast agents may be used to enhance the differences between different tissue 
components and increase the specificity of MRI to distinguish normal from 
pathological tissue. The choice of agent is contingent upon the diagnostic question.  
 
Paramagnetic substances such as gadolinium shorten the T1 relaxation time in tissues 
in which they accumulate. Consequently these tissues appear bright on T1W images. 
 
Superparamagnetic contrast agents such as superparamagnetic particles of iron oxide 
(SPIO) induced local magnetic field inhomogeneities leading to a rapid loss of 
phase-coherence amongst magnetic nuclei. The effect of this is a shortening of the 
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T2 and T2* relaxation times and a profound reduction in the signal intensity on T2W 
and particularly T2*W images. As a result, tissues in which SPIO accumulate appear 
dark on T2W and T2*W scans. SPIO also have a T1 shortening effect which is most 
obvious at low concentrations whilst at higher concentrations T2* susceptibility 
effects predominate [Canet et al 1993; Torabi et al 2004]. 
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Abdominal Aortic Aneurysm Growth Predicted by Uptake
of Ultrasmall Superparamagnetic Particles of Iron Oxide
A Pilot Study
Jennifer M.J. Richards, MD; Scott I. Semple, PhD; Thomas J. MacGillivray, PhD; Calum Gray, PhD;
Jeremy P. Langrish, MD; Michelle Williams, MD; Marc Dweck, MD; William Wallace, MD;
Graham McKillop, MD; Roderick T.A. Chalmers, MD; O. James Garden, MD; David E. Newby, MD
Background—Abdominal aortic aneurysms are a major cause of death. Prediction of aneurysm expansion and rupture is
challenging and currently relies on the simple measure of aneurysm diameter. Using MRI, we aimed to assess whether
areas of cellular inflammation correlated with the rate of abdominal aortic aneurysm expansion.
Methods and Results—Stable patients (n!29; 27 male; age, 70"5 years) with asymptomatic abdominal aortic aneurysms
(4.0 to 6.6 cm) were recruited from a surveillance program and imaged using a 3-T MRI scanner before and 24 to 36
hours after administration of ultrasmall superparamagnetic particles of iron oxide (USPIO). The change in T2* value
on T2*-weighted imaging was used to detect accumulation of USPIO within the abdominal aortic aneurysm.
Histological examination of aneurysm tissue confirmed colocalization and uptake of USPIO in areas with macrophage
infiltration. Patients with distinct mural uptake of USPIO had a 3-fold higher growth rate (n!11, 0.66 cm/y; P!0.020)
than those with no (n!6, 0.22 cm/y) or nonspecific USPIO uptake (n!8, 0.24 cm/y) despite having similar aneurysm
diameters (5.4"0.6, 5.1"0.5, and 5.0"0.5 cm, respectively; P#0.05). In 1 patient with an inflammatory aneurysm,
there was a strong and widespread uptake of USPIO extending beyond the aortic wall.
Conclusions—Uptake of USPIO in abdominal aortic aneurysms identifies cellular inflammation and appears to distinguish
those patients with more rapidly progressive abdominal aortic aneurysm expansion. This technique holds major promise
as a new method of risk-stratifying patients with abdominal aortic aneurysms that extends beyond the simple anatomic
measure of aneurysm diameter.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00794092.
(Circ Cardiovasc Imaging. 2011;4:274-281.)
Key Words: abdominal aortic aneurysm ! inflammation ! MRI
Abdominal aortic aneurysms (AAA) have a prevalence of5% in men over the age of 65 years, and acute rupture
is associated with a mortality rate of 65% to 85%. AAAs are
responsible for 2% to 3% of deaths in men age !65 years and
account for #15 000 deaths in the United States.1–3 Open
surgical or endovascular intervention to prevent rupture is
considered when the perceived risk of rupture outweighs the
risk of procedural complications with a diameter threshold of
5.5 cm being considered the appropriate time to intervene.4–6
However, up to one-fifth of ruptured AAA are $5.5 cm in
diameter,7 and many patients present with AAA diameters
considerably #5.5 cm without prior symptoms or rupture.8
Apart from the simple measurement of aneurysm diameter,
there are currently no methods of predicting which patients
with AAA are at risk of further aneurysm growth and rupture.
We therefore need better methods to guide preventative
intervention in these patients.
Clinical Perspective on p 281
Aortic aneurysms arise when the aortic wall develops
excessive medial neovascularization, infiltration of macro-
phages and lymphocytes, and irreversible proteolytic degra-
dation and remodeling of the extracellular matrix. These
pathological processes do not affect the aorta uniformly but
are focal in nature with mural neovascularization, inflamma-
tion, and matrix metalloproteinase (MMP) activity occurring
at sites of low tensile strength9 and AAA rupture.10–12 These
areas of increased biological activity within the aortic aneu-
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rysm wall are therefore putative targets for novel imaging
techniques.
MRI is emerging as a useful investigative tool for cardio-
vascular disease that can distinguish the different atheroscle-
rotic plaque components, such as the lipid-rich core and areas
of calcification.13 Standard gadolinium-based MRI identifies
areas of thrombus formation and fibrosis in abdominal aortic
aneurysms.14 Recently, a novel class of MRI contrast agents
containing superparamagnetic particles of iron oxide (SPIO)
has been developed that provides additional biological and
functional information through the detection of cellular in-
flammation within tissues. Ultrasmall SPIO (USPIO), with
particle sizes in the range 10 to 30 nm, escape immediate
recognition by the reticulo-endothelial system and persist for
longer in the bloodstream allowing them to be used to assess
the accumulation of macrophages within vascular and lym-
phatic tissues.15–19 Current preparations are biodegradable
and safe for clinical administration.20–22
USPIO accumulate in the aortas of hypercholesterolemic
rabbits23 and in murine models of AAAs.24 In humans,
USPIO accumulate in ruptured or rupture-prone carotid
plaques rather than stable plaques,17,18 and treatment with
atorvastatin reduces both inflammation and USPIO uptake in
carotid plaques.19 However, the use of USPIO has not been
explored in patients with AAAs. The aims of this study were
to determine whether USPIO uptake can be used to detect
areas of cellular inflammation within the wall of the AAA and




Patients were recruited from the outpatient aneurysm surveillance
program at the Royal Infirmary of Edinburgh between August 2009
and December 2009. Patients had an AAA with a diameter !4.0 cm
on ultrasound examination of the aorta. Patients who were under the
age of 40 years or pregnant and those who had active systemic
inflammatory or malignant disease, renal dysfunction (estimated
glomerular filtration rate "25 mL/min), hepatic cirrhosis (Child
Pugh score B or C), or a contraindication to MRI scanning were
excluded from the study. The research ethics committee and the
Medicines and Healthcare Products Regulatory Agency approved the
study, which was conducted in accordance with the Declaration of
Helsinki. All participants gave written informed consent.
Demographic and clinical data, including medical history and
medications, were obtained through patient interview and source
hospital records. Patients were being monitored in the aneurysm
surveillance program involving serial ultrasound-based measure-
ments of the maximum anteroposterior diameter of the AAA, usually
at 6-month intervals. Scans were undertaken by accredited clinical
vascular scientists with interobserver coefficient of variation of
aortic diameter measurements of 3.5% in our laboratory.25 Because
of the stacatto growth pattern of AAA and need for a contemporary
measurement,26 the annual growth rate was determined from 2
ultrasound scans performed 6 months apart, with one conducted
before and the other after the MRI examination.
Contrast Agent Administration
The preparation containing USPIO (Sinerem, Guerbet, France)
consists of iron oxide nanoparticles stabilized with dextran and
sodium citrate. Supplied as a dry powder, it was first reconstituted in
10 mL of 0.9% saline and then the weight-adjusted dose of 2.6 mg/kg
was diluted further in 100 mL of 0.9% saline. The USPIO was then
administered through a filter as a slow infusion over 30 minutes
through a peripheral 20G intravenous cannula.
Magnetic Resonance Imaging
Participants underwent MRI in a whole-body, 3-T Siemens Magne-
tom Verio scanner (Siemens, Erlangen, Germany) before and 24 to
36 hours27 after administration of the contrast agent. Routine clinical
coronal and sagittal breath-held T2-weighted multislice HASTE
localizer sequences were used to identify the position and extent of
the aneurysm, after which a respiratory-gated, ECG-triggered T2-
weighted (T2W) turbo spin-echo sequence was used to acquire
detailed anatomic data (TR/TE 2R-R intervals/72 ms; flip angle,
180°; matrix, 192#256; field of view, 400#400 mm; slice width,
5 mm). A multi-echo, gradient-echo T2*W sequence (TE, 4.9, 7.7,
10.5, 13.3 ms; TR, 133 ms; flip angle, 15°; matrix 192#256; field of
view 400#400 mm; slice width 5 mm) was used to acquire axial
images of the entire aneurysm with slice positions corresponding to
those of the T2W images. The echo times for the T2*W sequences
were selected such that fat and water were in-phase for each echo to
minimize phase shift artifact and errors in T2* measurements. The
field of view used for both sequences was typically 400#400 mm
but was adjusted for larger subjects to minimize phase-wrap artifacts.
T2W images give excellent discrimination of the boundaries between
the flow lumen, thrombus, wall, and surrounding tissues. T2*W
sequences have less distinct soft tissue contrast but are exquisitely
sensitive to the effects of USPIO accumulation. At the postcontrast
scan, slice positions were selected to match those of the precontrast
scan as closely as possible by reference to the vertebral bodies.
In a subset of 19 patients, T1W images were acquired before and
5 minutes after the bolus administration of 0.2 mg/kg of gadolinium
(Dataram, Guerbet Pharmaceuticals, France), using a turbo spin-echo
acquisition (TR/TE 1 R-R interval/28 ms; flip angle, 180°; matrix,
192#256; field of view, 400#400 mm; slice width, 5 mm).
Gadolinium-enhanced sequences were performed after the baseline
T2W and T2*W sequences were acquired, 2 hours before USPIO
administration and approximately 24 hours before the post-USPIO
MRI scan. Because gadolinium has a plasma half-life in the region of
2 hours and, unlike USPIO, is not readily taken up into the
intracellular compartment, USPIO enhancement is unlikely to have
been affected by preadministration of gadolinium.
Image Analysis
So that the soft tissue discrimination of the T2W images could be
used to complement the iron sensitivity of the T2*W images, and to
allow direct comparison of the precontrast and postcontrast data, all
the images were registered to the precontrast T2W image using a
semiautomatic rigid 3D voxel registration protocol (Analyze, Mayo
Clinic). Bowel and abdominal wall motion were found to compro-
mise registration of the aorta itself and this was minimized by
excluding these structures from the volume for registration as far as
possible. A region of interest (ROI) encompassing the aortic wall and
thrombus but excluding the flow lumen was drawn on each slice of
the precontrast T2W image. The 4 echoes in the multi-echo T2*W
sequence were combined to generate a T2* map, in which the data
represented the T2* value [S(t)$S(0)exp%(t/Ts*)] for each voxel.
The T2* value is the decay constant for the exponential decay of
signal intensity with time. In the presence of USPIO, the signal
decays more rapidly due to local field inhomogeneities and the T2*
value is reduced. A 3#3 voxel gaussian filter was applied to the
individual echoes to reduce noise, and experimentally determined
thresholds for the coefficient of determination (r2!0.4) and sum of
squared deviations due to error (SSE "0.2) were used to exclude
data that did not have an acceptable straight-line fit when ln signal
intensity (SI) was plotted against echo time.
The previously delineated ROI was applied to the T2* maps that
had been registered to the precontrast T2W scan. The percent change
in T2* value (%&T2*) after the administration of USPIO was
calculated on a voxel-by-voxel basis and displayed on a color scale
(%&T2*$(T2* value scan 1%T2* value scan 2)/(T2* value scan
1)#100). From the 95th percentile of the %&T2* value observed in
a group of patients not receiving USPIO, we established a threshold
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of significance for %!T2* of 59%, above which an observed change
in T2* value can be attributed to USPIO uptake. All voxels with values
for %!T2* below this threshold appear blue on the color map, whereas
voxels above this threshold appear on a yellow-red color scale. This
facilitates data interpretation and minimizes observer bias.
To assess the gadolinium enhancement on T1W images, the
precontrast and postcontrast images were registered to the precon-
trast T2W image. The previously delineated ROI was applied to the
T1 images. The percent change in SI was calculated (%! SI) on a
voxel-by-voxel basis and displayed on a color scale (%! SI"(SI
scan 2#SI scan 1)/(SI scan 1)$100). By convention, an increase in
SI of %50% of the baseline value was taken to be significant.
Classification of Aneurysms
Cellular inflammation is an important pathological process in the
development of AAA, with the associated proteolytic degradation of the
aortic wall representing the key step leading to AAA expansion and
rupture. We were interested to see whether aneurysm expansion rate is
increased in aneurysms with USPIO uptake in (1) the aortic wall or (2)
the associated thrombus. Therefore, 2 independent observers, blinded to
the patient demographics, and aneurysm diameter, and growth rate,
reviewed the color map images and classified them into 3 clear
predefined groups according to their appearance:
Group 1 had no mural or thrombus USPIO uptake, except for
isolated periluminal T2* enhancement occurring immediately adja-
cent to, and in continuity with, the lumen.
Group 2 had diffuse USPIO uptake that was distinct from the
periluminal thrombus and the aortic wall.
Group 3 had focal areas (with at least 10 contiguous voxels) of
USPIO uptake within the aortic wall of the aneurysm distinct from
periluminal area and thrombus.
Differences in classification were resolved by consensus.
Histology
For patients undergoing open surgical repair within 48 hours of
USPIO administration, samples of aortic wall were obtained from the
arteriotomy site on the anterior aspect of the aneurysm sac. Samples
were fixed in formalin, embedded in paraffin, sectioned, and stained
to look at the architecture (hematoxylin and eosin and elastin–van
Gieson) and USPIO accumulation (Prussian blue). The distribution
of macrophages was assessed by immunohistochemical staining for
macrophages (mouse, anti-human CD68 monoclonal
antibody; DAKO).
Statistical Analysis
The data were normally distributed. Continuous data were compared
with 1-way ANOVA with Tukey post test comparison (Minitab), and
categorical data were analyzed using the !2 test with cross-tabulation
(SPSS). Statistical significance was taken as 2-sided P&0.05.
Results
Patients
Twenty-nine patients (27 male) were recruited into the trial, with
a mean age of 70'5 years and mean AAA diameter of 5.2 cm
(range, 4.0 to 6.6 cm). All aneurysms were fusiform and
confined to the abdominal aorta. One patient had an inflamma-
tory aneurysm with ureteric obstruction and a raised erythrocyte
sedimentation rate of 100 mm/h (reference range, 1 to 10 mm/h).
The remaining patients were asymptomatic. As anticipated,
patients had a range of cardiovascular risk factors and comor-
bidities (Table). During the study period, 4 patients underwent
open surgical repair of their AAA (2 in group 1 and 2 in group
3), 2 patients were treated by endovascular aneurysm repair (1 in
group 2 and 1 in group 3), and 1 patient in group 3 died of a
ruptured aneurysm, having been assessed and considered unfit
for operative intervention. It was not possible to calculate a
growth rate for 4 patients (1 in group 1, 1 in group 2, and 2 in
group 3) who had only a single diameter measurement, either
because they proceeded straight to surgery or had only recently
presented to the surveillance program.
USPIO Administration
The administration of USPIO was well tolerated, with no
significant adverse events. There was a relatively even distribu-
tion of patients within the three categories of USPIO uptake
(Table). Patients in the 3 groups were similar in terms of age,
sex, use of medications, initial aneurysm diameter, and all
comorbidities except hypertension (P"0.024). In patients under-
going open surgical AAA repair, histology confirmed the accu-
mulation of USPIO that colocated with immunohistochemical
staining for CD68-positive macrophages (Figure 1).
MRI With USPIO
Patients had between 10 and 20 slices to cover the entire
aneurysm with a total of 351 slices for analysis. Registration
within the main body of the aneurysm was excellent for all
scans although 9.7'1.39% of the data were discarded due to
poor straight-line fit when ln SI was plotted against echo
time. Classification of AAA according to USPIO uptake
(Figure 2) was consistent and reproducible with excellent
interobserver agreement and a " statistic of 0.89. There
appeared to be no differences in USPIO uptake whether or not
patients had received preadministration of gadolinium.
The effect of USPIO accumulation is to accelerate dephasing
of transverse magnetization, resulting in rapid loss of signal with










Age, y 70'4 72'6 69'6 70'5
Male:female, % men 7:0 (100) 9:0 (100) 11:2 (85) 27:2 (93)
Cigarette smokers
Current 2 (29) 2 (22) 6 (46) 10 (34)
Previous 5 (71) 7 (78) 7 (54) 19 (66)
Diabetes mellitus 2 (29) 1 (11) 1 (8) 4 (14)
Hypertension 7 (100) 3 (33) 7 (54) 17 (59)
Hypercholesterolemia 6 (86) 7 (78) 8 (62) 21 (72)
Ischemic heart disease 4 (57) 2 (22) 6 (46) 12 (41)
Peripheral arterial disease 2 (29) 1 (11) 1 (8) 4 (14)
Cerebrovascular disease 1 (14) 1 (11) 1 (8) 3 (10)
Active systemic inflammatory
disease
0 (0) 0 (0) 0 (0) 0 (0)
Active malignancy 0 (0) 0 (0) 0 (0) 0 (0)
Drugs
Aspirin'clopidogrel 4 (57) 6 (67) 9 (69) 19 (66)
Warfarin 2 (29) 2 (22) 0 (0) 4 (14)
Statin 6 (86) 9 (100) 11 (85) 26 (90)
#-blocker 3 (43) 2 (22) 6 (46) 11 (38)
ACE inhibitor/ARB 3 (43) 2 (22) 4 (31) 9 (31)
Values are mean ' SD or n (%).
ACE indicate angiotensin-converting enzyme inhibitor; ARB, angiotensin II
receptor blocker.
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increasing echo time and hence a reduction in the decay
constant, the T2* value. The magnitude of the change in T2*
value was encoded for each voxel, with a large reduction in T2*
value reflecting a greater accumulation of USPIO. We have
previously defined a threshold (59%) above which the change in
T2* value can be attributed to USPIO accumulation rather than
variability of the measurement. In all patients, there was non-
specific USPIO uptake in the periluminal region consistent with
transition of the particles from the blood pool (Figure 2).
Interestingly the same region of the thrombus enhanced rapidly
on T1W MRI with gadolinium (Figure 3). In group 3, in addition
to the presence of focal areas of USPIO uptake (at least 10
contiguous voxels), there was a higher proportion of USPIO-
positive voxels in the aortic wall compared with the other 2
groups (P!0.0001), supporting the correct classification of
patients into the 3 groups (Figure 4A).
Patients with distinct focal areas of increased USPIO
uptake in the wall of the aneurysm (group 3) had aneurysm
growth rates that were 3-fold higher than patients without
(group 1) or with nonspecific (group 2) uptake of USPIO
Figure 1. Representative histological
sections of the aortic wall. A, Hematoxy-
lin and eosin ("20) of the full thickness
of the aortic wall including atheroscle-
rotic plaque, adherent thrombus and
periadventitial fatty tissue. B, Elastin–van
Gieson stain ("100) of the aortic wall
showing complete destruction of the
normal wall structure including fibrosis
(collagen, pink) of the media and adven-
titia and virtual absence of intact medial
elastic fibers (black). C, Prussian blue
staining for iron demonstrating colocal-
ization of CD68-postive macrophages
("400; brown) with D, Ultrasmall super-
paramagnetic particles of iron oxide par-
ticles ("400;blue). E, High-power
("1000) Prussian blue staining shows
intracytoplasmic accumulation of USPIO
within macrophages.
Figure 2. Color maps (A through C)
showing representative abdominal aortic
aneurysm (AAA) slices from patients in
each of the 3 groups alongside the cor-
responding T2W anatomic images (D
through F). The color scale represents
the magnitude of the change in T2*
value, with blue indicating minimal
change and red indicating a large
change in T2* value. We have previously
defined the threshold above which
changes in T2* value can be attributed
to ultrasmall superparamagnetic particles
of iron oxide particles (USPIO) accumu-
lation. Only changes in T2* value above
the threshold are presented on the grad-
uated (yellow-red) color scale; data
below the threshold appear blue. A dis-
tinctive pattern is seen for each patient
group: A, Group 1 shows a large change
in T2* value only in the periluminal area;
B, group 2, diffuse patchy changes in
T2* throughout the intraluminal thrombus
but no distinct focal area of USPIO
uptake affecting the aortic wall; and C,
group 3, discrete focal area of USPIO
uptake involving the wall of the AAA that
is distinct from the periluminal region.
This patient subsequently died suddenly
from presumed ruptured AAA.
Richards et al AAA Growth and USPIO Uptake 277
 by guest on May 9, 2013circimaging.ahajournals.orgDownloaded from 
(P!0.020; Figure 4B). Interestingly, there was no difference
in baseline aneurysm diameter across the three groups (Figure
4B). The percentage of USPIO positive voxels in the aortic
wall correlated with the AAA growth rate (r!0.46;
P!0.028).
One patient in group 3 had an inflammatory aneurysm; a
specific subtype of AAA characterized by systemic inflam-
mation, a thickened, fibrosed aortic wall, and fibrosis and
inflammation extending beyond the aorta into surrounding
tissues. This produced a unique change in T2* pattern with
intense USPIO uptake extending beyond the wall of the AAA
(Figure 5).
Discussion
We have shown for the first time that uptake of USPIO in
AAAs identifies cellular inflammation and appears to distin-
guish those patients with more rapidly progressive abdominal
aortic aneurysm expansion. This technique holds major prom-
ise as a new method of risk-stratifying patients with AAAs
that extends beyond the simple anatomic measure of aneu-
rysm diameter.
We used a smart contrast agent that consists of 20-nm
dextran-coated iron oxide nanoparticles. After intravenous
administration, these USPIO circulate within the blood pool
with a long half-life and are engulfed by macrophages. They
accumulate at sites of cellular inflammation at sufficient
concentrations to cause signal changes on MRI. As a result of
their superparamagnetic properties, they induce local field
inhomogeneities leading to rapid dephasing of the transverse
magnetization of spinning protons and thus loss of coherent
signal. Although these agents exhibit T1 relaxivity, the
predominant extravascular effect of USPIO at 3T is to cause
a dropout of signal on T2W and especially T2*W images.28
Because of the mixed T1 and T2/T2* effects of USPIO, we
chose to measure their effect on the rate of exponential signal
decay by calculating the decay constant, T2* value, from the
signal intensities at 4 echo times rather than relying on the
signal intensity at a single echo time. This proved to be a
highly sensitive technique, and variations in the change of
T2* value identified areas of cellular inflammation that were
confirmed on subsequent histological examination of aneu-
rysm tissue obtained at the time of open surgery.
Within the study population, we observed distinct patterns
of spatial variation in the change of T2* value and were able
to divide patients into 3 groups on this basis. Patients in group
1 had a high change in T2* value only in the periluminal
Figure 3. The blood pool contrast agent
gadolinium (A) enhances only the perilu-
minal halo region of the thrombus and
the fibrous cap. Ultrasmall superpara-
magnetic particles of iron oxide particles
(B) enhancement is seen not only in the
periluminal halo but also in the deep
layer of the thrombus and in the aortic
wall.
Figure 4. A, Percent ultrasmall superparamagnetic particles of iron oxide particles (USPIO)-positive voxels in the aortic wall (solid bars)
and focal areas of increase USPIO uptake (open bars). USPIO-positive voxels were higher in group 3 compared with the other 2 groups
(P"0.001). B, Relationship of diameter and growth rate with patient group. Initial aneurysm diameters (open bars) are similar for the 3
groups, but the aneurysm growth rates (solid bars) are higher for patients in group 3 (0.66 cm/y) compared with those in groups 1 (0.22
cm/y) and 2 (0.24 cm/y; P!0.020).
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aspect of the aneurysm, this “halo effect” being a constant
finding in all study patients. Intraluminal thrombus is a
consistent feature of AAA and usually has a laminar appear-
ance with the mural component having been deposited first
and subsequent growth of the thrombus occurring by further
deposition of fibrin, platelets, and red blood cells on the inner
luminal aspect.29 The universal finding of a large change in
T2* value in the periluminal region of the aneurysm is
therefore likely to reflect trapping of USPIO in fresh poten-
tially gelatinous thrombus that is typically friable and highly
cellular because of its close proximity to flowing blood.30 It
was interesting to observe that this region also enhanced
rapidly with gadolinium, consistent with a less selective and
more generalized uptake of contrast agents in this region. A
previous study using the larger SPIO particles (80 to 150 nm)
demonstrated their accumulation in the luminal layer of aortic
thrombus, resulting in an MRI signal that correlated with
histological evidence of leukocyte infiltration (CD68 and
CD66b) and levels of matrix metalloproteinases.31 As ac-
knowledged by the authors, these large SPIO particles are not
well suited to vascular tissue imaging because of their short
plasma half-life that limits their sensitivity for detecting
vessel wall inflammation.
The second group of patients had a heterogeneous pattern
of change in T2* signal within the thrombus but no uptake in
the aortic wall. The role of the thrombus in aneurysm
expansion and rupture is uncertain.30,32,33 Some macrophages
are present deep within the thrombus, but, alternatively, this
signal pattern may reflect USPIO within the canaliculi that
traverse the thrombus, conducting fluid, small molecules and,
to a certain extent, cells from the lumen toward the aortic
wall.30 This pattern of USPIO uptake and inflammation
within the thrombus is of uncertain significance but interest-
ingly did not appear to be associated with accelerated
aneurysm growth.
In the third group of patients, we found 1 or more distinct
focal areas of inflammation involving the wall itself and
spatially distinct from the periluminal halo. This finding was
associated with an increased growth rate compared to patients
without mural USPIO uptake. This high growth rate (0.66
cm/y) is clinically significant because the average aneurysm
growth in screened populations is 0.26 cm/y, and growth rates
!0.2 cm/y are associated with increased AAA-related
events.34–36 We are unable to exclude the possibility that
differences in the incidence of hypertension among patients
in the 3 groups influenced AAA growth rate; however, this
seems unlikely because the groups with the highest (group 2)
and lowest (group 1) incidence of hypertension had similarly
low growth rates. In patients with ruptured AAA, histology of
the aneurysm wall has shown areas of increased biological
activity and these correlate with a reduction in wall tensile
strength.9–12 It would be interesting to determine whether, in
patients with AAA and abdominal pain of uncertain etiology,
USPIO imaging could distinguish between those with im-
pending rupture and those with non–AAA-related abdominal
pain. Finally, whether this pattern of USPIO uptake in AAA
may prove to be a marker for future AAA-related events is
unclear and requires a large, prospective study.
Existing techniques for surveillance of AAA and estima-
tion of risk of rupture rely solely on diameter measurements,
but clinical data from aneurysm screening and surveillance
programs suggest that there is considerable scope to improve
on this. Of those aneurysms detected by screening that are
"5.5 cm in diameter, 1 in 14 will rupture over the following
3 years34 and together account for up to one-fifth of all
ruptured AAA.7 However, simply reducing the diameter
threshold for intervention would not improve mortality.4,6
Furthermore, small aneurysms exhibit a bimodal distribution
for growth with half remaining small and only half continuing
to grow.34 Having been shown to reduce AAA-related mor-
tality by 53%, aneurysm screening is being introduced in
many countries across the world.1,37 However, screening
considerably increases the number of patients under long-
term surveillance, and only around 30% of these patients will
require future intervention.1,34 Taken together, these observa-
tions support a need for a more sophisticated and individu-
alized method of predicting clinical events in patients with
AAA so that screening, surveillance, and intervention can be
targeted at high-risk patients, reducing the overall economic
cost and decreasing morbidity and mortality. We believe
USPIO imaging represents a logical and important new
approach that has the potential to address these major unmet
clinical needs.
In conclusion, we have demonstrated that assessment of
USPIO uptake with MRI can be used to detect focal hotspots
Figure 5. A, Distinctive appearance of an inflammatory abdomi-
nal aortic aneurysm (AAA) on T2W imaging. The aortic wall is
indicated by arrows. B, Regions with a large percent change in
T2* value are present outwith the aortic wall showing inflamma-
tion extending into surrounding tissues as is typical of an
inflammatory AAA (see color scale Figure 2). This patient had
ureteric obstruction and an erythrocyte sedimentation rate of
!100 mm/h (reference range, 1 to 10 mm/h).
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of inflammation in asymptomatic AAA and that mural
USPIO uptake is associated with more rapid expansion of
AAA. A large prospective clinical trial with a longer duration
of follow-up would be required to confirm the findings of the
present study and assess the role of MRI and USPIO in the
prediction of AAA-related clinical events. This would also
enable a more sophisticated MRI-based assessment of growth
and its relationship to areas of USPIO uptake. If successful,
this technique has a number of potential highly relevant
clinical applications that include informing selection of pa-
tients for intervention to prevent rupture, rationalization of
AAA screening resources to target high-risk patients, and
application as a biomarker to investigate the utility of novel
therapeutic interventions for AAA.
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CLINICAL PERSPECTIVE
Abdominal aortic aneurysm (AAA) rupture is a catastrophic event associated with a very high mortality rate. Patients with
known AAA are therefore enrolled in a surveillance program involving serial ultrasound scanning to monitor changes in
aneurysm diameter, taken as a surrogate for risk of rupture. Patients with an aneurysm !5.5 cm in diameter are perceived
to be at high risk and are offered surgical or endovascular aneurysm repair. Although AAA diameter is the best predictor
of rupture currently available, up to 20% of ruptured AAA are "5.5 cm. Large studies have shown no mortality benefit
for early surgery over continued surveillance in this group of patients. Conversely, many patients have AAA considerably
larger than 5.5 cm without rupture. We therefore need an improved method of predicting rupture for individual patients.
Rupture is thought to occur in regions of the aortic wall featuring intense inflammation and proteolytic activity. We used
MRI with a novel contrast agent consisting of ultrasmall superparamagnetic particles of iron oxide (USPIO) to identify
focal inflammation within the aortic wall. The key finding is that USPIO uptake within the aortic wall was associated with
a rate of aneurysm expansion (0.66 cm/y) 3-fold higher than AAA with no mural USPIO uptake. If confirmed in larger
longitudinal studies, these results suggest that USPIO-enhanced MRI may be a more accurate way to predict disease
progression than diameter alone in patients with AAA, facilitating selection of patients for preventative surgery.
Richards et al AAA Growth and USPIO Uptake 281




American Heart Association. All rights reserved. Print ISSN: 1941-9651. Online ISSN: 2012 Copyright ©
Avenue, Dallas, TX 72514
Circulation: Cardiovascular Imaging is published by the American Heart Association. 7272 Greenville
DOI: 10.1161/CIRCIMAGING.112.972596
 2012;5;509-517; originally published online July 10, 2012;Circ Cardiovasc Imaging
Turner and David E. Newby
Graham McKillop, Thomas A. Connolly, Giora Z. Feuerstein, G. Robin Barclay, Marc L.
Kev Dhaliwal, A. John Simpson, William A. Wallace, Adam T. Hill, P. Huw Roddie, 
Anne P.M. Atkinson, Elaine K. Forrest, Carol Bienek, Nicholas L. Mills, Anne Burdess,
I.K. Semple, Thomas J. MacGillivray, Calum Gray, Julie H. Crawford, Shirjel R. Alam, 
Jennifer M.J. Richards, Catherine A. Shaw, Ninian N. Lang, Michelle C. Williams, Scott
: Feasibility and Safety in Humans





on the World Wide Web at: 




Data Supplement (unedited) at: 
 http://www.lww.com/reprints




Health, 351 West Camden Street, Baltimore, MD 21201-2436. Phone: 410-528-4050. Fax: 
Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters Kluwer
 
 http://circimaging.ahajournals.org/site/subscriptions/
Subscriptions: Information about subscribing to Circulation: Cardiovascular Imaging is online at
 by guest on May 9, 2013circimaging.ahajournals.orgDownloaded from 
509
Stem cell and other cell-based therapies have emerged as potential, novel treatment options for a wide range 
of diseases including acute myocardial infarction and 
severe heart failure.1–5 Ensuring the delivery of a sufficient 
number of cells to the target site is critical to the devel-
opment and assessment of these therapies. Several meth-
ods have been proposed for tracking cells in vivo, but their 
translation into the clinical setting has been hampered for 
many reasons including limitations of the imaging modality 
in humans and the failure of reagents to comply with Good 
Manufacturing Practice (GMP) standards: a prerequisite for 
clinical use.
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Background—Cell therapy is an emerging and exciting novel treatment option for cardiovascular disease that relies on the 
delivery of functional cells to their target site. Monitoring and tracking cells to ensure tissue delivery and engraftment is 
a critical step in establishing clinical and therapeutic efficacy. The study aims were (1) to develop a Good Manufacturing 
Practice–compliant method of labeling competent peripheral blood mononuclear cells with superparamagnetic particles 
of iron oxide (SPIO), and (2) to evaluate its potential for magnetic resonance cell tracking in humans.
Methods and Results—Peripheral blood mononuclear cells 1–5!109 were labeled with SPIO. SPIO-labeled cells had similar 
in vitro viability, migratory capacity, and pattern of cytokine release to unlabeled cells. After intramuscular administration, 
up to 108 SPIO-labeled cells were readily identifiable in vivo for at least 7 days using magnetic resonance imaging 
scanning. Using a phased-dosing study, we demonstrated that systemic delivery of up to 109 SPIO-labeled cells in humans 
is safe, and cells accumulating in the reticuloendothelial system were detectable on clinical magnetic resonance imaging. 
In a healthy volunteer model, a focus of cutaneous inflammation was induced in the thigh by intradermal injection of 
tuberculin. Intravenously delivered SPIO-labeled cells tracked to the inflamed skin and were detectable on magnetic 
resonance imaging. Prussian blue staining of skin biopsies confirmed iron-laden cells in the inflamed skin.
Conclusions—Human peripheral blood mononuclear cells can be labeled with SPIO without affecting their viability or 
function. SPIO labeling for magnetic resonance cell tracking is a safe and feasible technique that has major potential for 
a range of cardiovascular applications including monitoring of cell therapies and tracking of inflammatory cells. (Circ 
Cardiovasc Imaging. 2012;5:509-517.)
Clinical Trial Registration—URL: http://www.clinicaltrials.gov; Unique identifier: NCT00972946, NCT01169935. 
Key Words: inflammation " macrophages " magnetic resonance imaging
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Radio-imaging techniques, such as scintigraphy and posi-
tron emission tomography, can be sensitive but offer poor 
spatial resolution and expose patients to ionizing radiation. 
In addition, although some radiotracers have a long half-life 
(eg, 89-Zircuronium 78.4 h, 124-Iodine 100.3 h) those that are 
most widely available have a short half-life (eg, 18-Fluorine), 
limiting the duration of follow-up. By virtue of its high spa-
tial resolution, excellent soft tissue contrast, and avoidance 
of ionizing radiation, magnetic resonance imaging (MRI) is 
ideally suited to human cell-tracking studies. MRI contrast 
agents consisting of dextran-coated superparamagnetic par-
ticles of iron oxide (SPIO) are available for use in humans 
and have been used for clinical liver imaging. SPIO possess 
intense superparamagnetism and, by inducing local mag-
netic field inhomogeneities, cause rapid dephasing of spin-
ning protons. The T2* relaxation time is shortened, causing a 
profound reduction in signal intensity on T2- and particularly 
T2*-weighted (T2*W) imaging. Compared with paramag-
netic agents such as gadolinium, SPIO are detectable at much 
lower concentrations and are readily taken up by resident 
macrophages in the reticuloendothelial system. SPIO are not 
toxic to cells and are biodegradable in vivo.6–11 It is important 
to note, however, that the safety of intravenous administration 
of SPIO-labeled cells in humans has yet to be demonstrated, 
and would be critical for the development and Food and Drug 
Administration approval of novel clinical cell-tracking agents.
An effective method has been described for incorporat-
ing SPIO into phagocytic cells using protamine sulphate as a 
polycationic transfection agent to enhance its uptake through 
electrostatic interactions.12 We have modified and translated 
this method into a GMP-compliant protocol and successfully  
(1) labeled human peripheral blood mononuclear cells 
(PBMC), (2) confirmed normal cell viability and function, and 
(3) delivered and tracked SPIO-labeled cells in vivo in humans.
Methods
Ethical and Regulatory Considerations
Clinical studies (NCT00972946; NCT01169935) were approved by 
the local research ethics committee and conducted in accordance with 
the Declaration of Helsinki with the written informed consent of all 
participants.
Cell Labeling With SPIO
Cell Collection
Blood was collected by venesection into citrate or by leukapheresis 
(COBE Spectra; Gambro BCT, Lakewood, CO) to yield 1–5!108 or 
1–5!109 PBMC, respectively.
Edinburgh Protocol for Labeling Mononuclear  
Cells With SPIO
A GMP-compliant protocol for labeling PBMC with SPIO was op-
timized (online-only Data Supplement Methods and online-only 
Data Supplement Figure I). PBMC were isolated by density-gradient 
separation and suspended in 0.9% saline (4!106 cells/mL). Endorem 
(100 "g/mL; Guerbet, Villepinte, France) and protamine sulphate 
(4 "g/mL; Prosulf) were added to the cell suspension, which was in-
cubated at room temperature for 2 hours with continuous agitation.
For clinical studies, cell preparation and labeling was undertaken 
in a GMP facility. At the end of the incubation period, labeled cells 
were supplied in a low-adherence bag (Cryocyte; Baxter, Deerfield, IL) 
for reinfusion.
Evaluation of the Effects of SPIO Labeling  
on Cell Viability and Function
Isolation of Monocytes From PBMC
Monocytes were isolated from PBMC suspensions using indirect im-
munomagnetic selection (Monocyte Isolation Kit II; Miltenyi Biotec, 
Auburn, CA).
Cellular Iron Uptake
Cellular SPIO uptake was confirmed by Prussian blue staining of 
methanol-fixed cytospin preparations. Cellular iron content was 
determined using the Ferrozine assay (Sigma-Aldrich, Gillingham, 
Dorset, United Kingdom).
Cell Viability
Monocytes were allowed to adhere for 1 hour in 24-well tissue cul-
ture plates (106 cells per well; 37°C; 5% CO2) after which the super-
natant was harvested and exchanged to prevent continued uptake of 
SPIO and to avoid interference of excess SPIO with assays.
SPIO-labeled and unlabeled cells were harvested at 1, 24, and 72 
hours, exposed to fluorescein isothiocyanate-annexin V and propidium 
iodide, and analyzed by flow cytometry. The percentages of cells posi-
tive for annexin V binding, propidium iodide staining, or both were com-
bined to give the percentage cytotoxicity. Viability was also assessed 
at 24, 48, and 72 hours using a colorimetric lactate dehy drogenase 
assay (Roche Diagnostics Ltd, West Sussex, United Kingdom).
Cytokine Release
Cells were plated out as described in the preceding section. The con-
centration of the proinflammatory cytokines released from cells 24, 
48, and 72 hours postlabeling was measured using a cytometric bead 
array kit (Becton Dickinson, Franklin Lakes, NJ).
Migratory Capacity
In vitro migratory capacity was assessed using a modified Boyden 
chamber. Labeled and unlabeled purified monocytes (2.5!105 cells 
per well) were allowed to migrate for 2 hours through a microporous 
(5 "mol/L) membrane (Corning Costar, Corning, NY) toward mono-
cyte chemoattractant protein-1 (R&D Systems, Abingdon, United 
Kingdom). Transmigration was quantified by counting the cells 
adherent to the undersurface of the membrane.
Figure 1. Cellular uptake of superparamagnetic particles of iron 
oxide (SPIO). Cytospin preparation of peripheral blood mononu-
clear cells (PBMC) labeled with SPIO and stained with Prussian 
blue and Nuclear Fast red. Iron nanoparticles are seen within the 
cytoplasm.
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Clinical Studies
Participants underwent formal clinical assessment and were exclud-
ed if they had renal dysfunction (estimated glomerular filtration rate  
<25 mL/min), hepatic dysfunction (Childs-Pugh score B or C), positive 
virology screen, pregnancy, breastfeeding, blood dyscrasia, anemia 
(hemoglobin concentration <12 g/dL), iron storage disorder, active ma-
lignancy, chronic inflammatory condition, risk factors for protamine 
allergy, intercurrent illness, or contraindication to MRI scanning.
Intramuscular Administration
Six healthy volunteers received three 2-mL intramuscular thigh injec-
tions of unlabeled autologous PBMC (107), SPIO-labeled autologous 
PBMC (107), and SPIO alone. Participants underwent MRI scanning 
in a 1.5 T scanner immediately and at 7 days.
Phased-Dose Intravenous Administration of Labeled Cells
To establish the safety of intravenous administration of SPIO-labeled 
cells, we undertook a phased-dosing study in which 2 volunteers 
each received 6 increasing doses of SPIO-labeled autologous PBMC 
(104–109 cells) over 4 study visits. Cell infusions were performed in 
a clinical research facility with noninvasive physiological monitoring 
(pulse oximetry, noninvasive blood pressure, and temperature) and 
clinical observation during cell reinfusion and the subsequent obser-
vation period. Cells were administered through a blood giving set 
with a 200-!mol/L macroaggregate filter. Each cell infusion lasted 
30 to 60 minutes (depending on volume) and was followed by a 
60-minute observation period.
Blood was sampled at each visit before reinfusion and 1 hour 
postinfusion of labeled cells. Blood was drawn for full blood 
count, routine biochemistry, and coagulation parameters including 
prothrombin time, activated partial thromboplastin time, fibrinogen, 
and D-dimer.
Intravenous Administration of Labeled Cells
Twelve healthy volunteers were recruited and received a low dose of 
SPIO-labeled autologous PBMC obtained from a 250-mL venesec-
tion ("1–5#108 cells; n=6) or a high dose of cells obtained from a 
standard leukapheresis collection ("1–5#109 cells; n=6). Intravenous 
cell infusions were performed, and blood samples were obtained as 
described earlier in the article. These participants underwent MRI 
scanning in a 3T scanner before and 2 hours, 24 hours, 48 hours, and 
7 days after administration of cells.
Mantoux Test
A local cutaneous inflammatory response was induced in the thigh 
of healthy volunteers using the Mantoux test: intradermal injection 
of 2 units of tuberculin purified protein derivative. In previously ex-
posed individuals, tuberculin purified protein derivative stimulates a 
type IV delayed, cell-mediated hypersensitivity reaction involving an 
influx of neutrophils initially ("6 hours), and subsequently of mono-
cytes (12–48 hours) and lymphocytes (12–96 hours) into the dermal 
skin layer.13,14 Twenty-four hours after the Mantoux test, participants 
underwent a standard leukapheresis collection and later the same 
day received an infusion of "109 SPIO-labeled autologous PBMC. 
T2-weighted and T2*W imaging was performed before and 2, 24, and 
48 hours after the administration of cells. A skin biopsy was obtained 
from the site of the Mantoux test 96 hours after administration of cells 
(120 hours after the Mantoux test), fixed in 4% paraformaldehyde and 
stained with Prussian blue.
Magnetic Resonance Imaging
Volunteers receiving cells intramuscularly underwent MRI scanning 
of the thigh in a 1.5 T Phillips scanner using a T2-weighted sequence 
with a long echo time (TE; 137 ms).
Volunteers undergoing intravenous infusions were scanned using a 
3T Magnetom Verio scanner (Siemens, Erlangen, Germany). Routine 
localizer sequences were applied after which T2-weighted (TE 87 ms; 
repetition time 1800 ms; matrix 256#192; field of view 380#285 mm) 
and T2*W (multiecho TE, 4.1–22.1 ms; repetition time, 100 ms; flip 
angle, 15°; matrix, 282#512; field of view, 282#410 mm; slice width, 
5 mm) breath-hold sequences were used to acquire axial images of 
the upper abdomen.
T1-weighted (3-dimensional volumetric interpolated breath-hold 
examination; TE/repetition time, 2.0/5.5 ms; matrix, 416#416; field of 
view, 210#210 mm; slice width, 5 mm) and T2*W (2-dimensional mul-
tislice gradient echo; TE, 9.8, 12.3, 14.8 ms; repetition time, 120.0 ms; 
matrix size, 312#384; field of view, 203#250 mm; slice width, 5 mm) 
axial images of the thigh were acquired after Mantoux testing.
Image Analysis
After local administration of SPIO or cells, T2-weighted axial im-
ages of the thigh were inspected for evidence of a change in signal 
intensity.
After systemic administration of SPIO-labeled cells, transaxial 
abdominal images were analyzed on the basis of R2*. T2* is the 
decay constant for the decay of signal intensity with increasing TE, 
and its inverse R2* (T2*=1/R2*) has been used to evaluate tissue iron 
concentration.15
From the multiecho T2*W data, a 6-echo R2* map was generated. 
Regions of interest were selected on the initial echo (4.1 ms) taking 
care to avoid major blood vessels and motion artifact. Five regions 
of consistent size (0.5 cm2) were selected in the spleen, liver, skeletal 
muscle (control), and background noise, and copied to the R2* map. 
Relationship to distinctive anatomical features was used to ensure 
that regions chosen were consistent across the 5 study visits.
For cell tracking to the site of the Mantoux test, higher spatial reso-
lution was required to allow visualization of the skin and subcutaneous 
tissue. The individual echoes were acquired separately and had to be 
registered together for R2* map generation using in-house software. 
Regions of interest were selected in the inflamed skin, normal unaf-
fected skin (control), skeletal muscle (control), liver, and spleen.
Statistical Analysis
In vitro data were analyzed by Mann-Whitney U test. Blood results 
and physiological monitoring data were compared by Wilcoxon signed 
rank test (SPSS Inc, Chicago, IL). R2* MRI data were analyzed by the 
Friedman test with Dunn correction. Exact testing was used through-
out, and 2-sided P<0.05 was regarded as statistically significant.
Results
In Vitro Evaluation of the Effect of SPIO Labeling 
on Cell Viability and Function
It is important that the behavior of SPIO-labeled mononuclear 
cells remains unchanged in terms of cell viability and function 
so that the results of in vivo cell-tracking studies accurately 
reflect the biological processes being observed. See online-
only Data Supplement Methods section for more detail.
Confirmation of SPIO Uptake
Prussian blue staining of labeled cells demonstrated intracel-
lular accumulation of iron nanoparticles (Figure 1). The entire 
PBMC population, including both lymphocytes and monocytes, 
was exposed to SPIO but SPIO uptake was predominantly con-
fined to phagocytic monocytes (online-only Data Supplement 
Figure II). The median (interquartile range) iron content of 
labeled monocytes was 17 (14–22) pg per cell compared with 
1.3 (0.7–1.4) pg per cell for unlabeled monocytes (P=0.03).
Assessment of Cytotoxicity
SPIO labeling had no effect on cellular release of inflam-
matory cytokines (Figure 2). Viability of labeled and 
unlabeled cells was equivalent up to 72 hours postlabeling 
(Figure 3A and 3B).
Effect of SPIO Labeling on Chemotaxis
Cell-tracking studies are critically dependent on the ability of 
labeled cells to migrate to the target site. Cells labeled accord-
ing to the optimized Edinburgh protocol migrated in equivalent 
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numbers to unlabeled cells (154 [150–184] SPIO-labeled cells 
versus 112 [105–188] unlabeled cells at 50-ng/mL monocyte  
chemoattractant protein-1; median [interquartile range]; P=0.29). 
Prussian blue staining confirmed the presence of SPIO in the 
cytoplasm of migrating labeled cells. (Figure 3C–3I)
Clinical Studies
Intramuscular Administration
Injections were performed successfully in all participants without 
complication. A signal deficit was observed at the site of adminis-
tration of SPIO alone and SPIO-labeled cells (Figure 4). Although 
an edematous change was noted at the site of injection of unla-
beled cells, no dropout of signal was seen. These findings were 
consistent for all 6 participants and persisted for at least 7 days.
Safety of Intravenous Administration of  
SPIO-Labeled Cells
In the phased-dosing study, all cell infusions in both partici-
pants were well tolerated with no early or late clinical side 
effects. A further 12 volunteers then received a low dose 
(2.03±0.18!108 cells; n=6) or a high dose of SPIO-labeled 
autologous PBMC obtained from a standard leukapheresis 
collection (2.23±0.51!109 cells; n=6).
Cell infusions had no effect on heart rate, blood pressure, 
or temperature (Table 1), and there were no clinically signifi-
cant microembolic events after cell administration. Peripheral 
perfusion, monitored continuously by digital pulse oximetry 
during and for an hour after cell infusion, was unaffected. 
Demonstrating further that labeled cells did not have a proco-
agulant effect in vivo, infusion of SPIO-labeled cells did not 
affect any coagulation variable, and there were no clinically 
significant effects on routine clinical hematological and bio-
chemical variables (Table 2).
MRI Scanning
After administration of labeled cells, the signal intensity was 
reduced in the liver and spleen on T2- (Figure 5) and T2*W 
imaging.
The use of 6 TEs for R2* value calculation was validated by 
plotting signal intensity against TE. Even at longer TE, the sig-
nal was clearly distinct from the background noise level, and 
exponential decay of signal intensity with time was confirmed.
There was a marked increase in R2* in the liver and spleen 
(P<0.001) after administration of cells (Figure 5) reflecting dose-
dependent accumulation of SPIO-labeled cells at these sites. 
There was no change in R2* in skeletal muscle (negative control).
Figure 2. Effect of superparamagnetic particles of iron oxide (SPIO) labeling on cytokine release. SPIO labeling did not affect the cytokine 
(interleukin-1 [IL-1], IL-6, IL-10, tumor necrosis factor [TNF], IL-12p70) release profile up to 72 hours postlabeling (P>0.05 for all cytokines, 
at all time points; n=4).
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Cell Tracking to an Inflammatory Focus
At 24 and 48 hours after administration of SPIO-labeled cells, 
an increase in R2* was observed in inflamed skin (P<0.001) 
but not adjacent normal skin or skeletal muscle (P>0.05; 
Figure 6). Prussian blue staining of skin biopsies obtained 
from the site of the Mantoux test 96 hours after adminis-
tration of cells, revealed occasional iron-laden cells in the 
inflamed skin consistent with the diminishing monocyte/
macrophage cell numbers by this stage in a type IV hypersen-
sitivity response. In controls (negative Mantoux response), 
Figure 3. Effect of superparamagnetic particles of iron oxide (SPIO) labeling on cell viability and chemotaxis. Labeling mononuclear cells 
with SPIO had no effect on cell viability measured either by flow cytometric analysis of annexin V binding in combination with propidium 
iodide (PI) staining (A) or a colorimetric assay for lactate dehydrogenase release (B). There was no difference in viability between unla-
beled and labeled cells at any time point investigated (P>0.05 for both methods at all time points; n=3). In an in vitro migration assay, 
cells were allowed to migrate through a 5-!mol/L microporous membrane toward 0 or 50 ng/mL of the chemokine human recombinant 
monocyte chemoattractant protein-1 (MCP-1). C, Quantification of chemotaxis demonstrated that SPIO labeling did not affect migratory 
capacity compared with unlabeled cells (P>0.05 for both 0 and 50 ng/mL MCP-1; n=6). Migrated cells adhered to the undersurface of 
the membrane and were stained with DiffQuik physiological stain (staining nuclei purple) and counterstained with Prussian blue causing 
SPIO particles carried in the cytoplasm to appear blue. Comparison was made of cells labeled according to the original protocol, which 
clumped and were unable to migrate (D and E), with cells labeled according to the Edinburgh protocol (F and G) that remained in single 
cell suspension and migrated in equivalent numbers to unlabeled cells (H and I).
Figure 4. Magnetic resonance imaging scanning after intramuscular administration of cells. T2-weighted imaging of the thigh after  
intramuscular administration of labeled cells. A signal deficit is seen in relation to injection of superparamagnetic particles of iron oxide 
(SPIO) alone (A) and SPIO-labeled cells (B) but not unlabeled cells (C). These findings were consistent for all 6 participants.
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there was no change in R2* in the skin at the site of the 
Mantoux test, in adjacent normal skin, or in skeletal muscle 
(P>0.05; Figure 7).
Discussion
In the present study, we have demonstrated, for the first time, 
that human mononuclear cells can be labeled with SPIO under 
GMP-compliant conditions without affecting cell viability or 
migratory capacity. Furthermore, labeled cells can be visualized 
in vivo at clinically relevant field strengths after local or 
systemic administration, and it is important to note that SPIO-
labeled cells can be tracked to a site of focal inflammation 
in humans. This technique therefore has the potential to track 
the distribution, time course, and fate of cells administered systemically as part of cell therapy: a critical component of the 
Table 1. Noninvasive Physiological Monitoring Parameters 
(Median and IQR) Before and at the End of Infusion of  





Systolic blood pressure, 
mm Hg
126 (120–133) 121 (114–130) 0.13
Diastolic blood pressure, 
mm Hg
74 (68–85) 74 (67–79) 0.69
Heart rate, beats per minute 67 (58–78) 68 (58–76) 0.20
Temperature, °C 36.9 (36.4–37.0) 36.9 (36.7–37.2) 0.42
Oxygen saturations on air, % 99 (98–100) 99 (98–100) 1.00
IQR indicates interquartile range; PBMC, peripheral blood mononuclear cells; 
and SPIO, superparamagnetic particles of iron oxide.
Table 2. Hematological, Biochemical, and Coagulation 








Hemoglobin, g/L 115–165 133 (120–148) 130 (120–140) 0.06
White blood 
count,!109/L
4.0–11.0 5.9 (5.2–7.6) 7.4 (5.4–9.7) 0.28
Platelets,!109/L 150–350 259 (195–274) 235 (194–280) 0.33




26–36 29 (29–32) 30 (27–32) 0.67
Fibrinogen, g/L 1.5–4 2.9 (2.3–3.4) 2.7 (2.3–3.2) 0.10
D-Dimer, ng/mL 0–230 — 67 (52–200) —
Urea, mmol/L 2.5–6.6 4.4 (3.6–5.2) 4.4 (4.0–5.1) 0.68
Creatinine, µmol/L 60–120 64 (58–78) 67 (52–78) 0.67
Sodium, mmol/L 135–145 140 (139–141) 140 (138–141) 0.40
Potassium, mmol/L 3.6–5.0 4.1 (3.8–4.4) 4.0 (3.9–4.2) 0.26
TCO2, mmol/L 20–30 27 (25–28) 27 (25–30) 0.16
Bilirubin, µmol/L 3–16 11 (9–15) 10 (8–15) 0.31
Alanine amino 
transferase, U/L
10–55 20 (16–22) 19 (14–30) 0.57
Alkaline  
phosphatase, U/L
40–125 72 (53–82) 68 (48–89) 0.67
PBMC indicates peripheral blood mononuclear cells; SPIO, superparamagnetic 
particles of iron oxide; IQR indicates interquartile range; and TCO2, total CO2.
Figure 5. Magnetic resonance imaging of the upper abdomen after systemic administration of cells. T2-weighted transaxial slice through 
the upper abdomen before (A) and after (B) intravenous administration of superparamagnetic particles of iron oxide (SPIO)-labeled cells. 
Signal intensity is reduced in the liver (L) and spleen (S) after administration of cells. Change in R2* from baseline 2 hours, 24 hours,  
48 hours, and 7 days after intravenous administration of a low dose (C; 1–5!108 peripheral blood mononuclear cells [PBMC]; n=6) or a 
high dose (D; 1–5!109 PBMC; n=6) of SPIO-labeled cells. An increase in R2* is seen in the spleen (P<0.001) and liver (P<0.001) but not 
skeletal muscle (control; P>0.05).
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development of cellular therapeutic strategies, and ultimately 
of monitoring the success of treatment.
It is essential that techniques for labeling cells for cell- 
tracking studies do not impair cell function. We were able to 
demonstrate in vitro that cells labeled according to the Edinburgh 
protocol were viable and exhibit normal in vitro migration 
toward the chemokine monocyte chemoattractant protein-1.
There are several mechanisms through which SPIO might 
logically be expected to affect cell viability and function. 
However, it would appear that monocytes and macrophages, 
as professional scavengers, have an excellent capacity to deal 
with ingested iron and resist potentially toxic effects.16 We 
have demonstrated in vitro that viability, cytokine produc-
tion, and migratory capacity are unaffected by SPIO labeling. 
This is consistent with the majority of studies that have shown 
preservation of both viability and function after SPIO label-
ing of a variety of cell types including mesenchymal, hema-
topoietic, neural, and adipose-derived stem cells,6–11 with only 
a few reporting adverse effects and 1 showing increased pro-
liferation of SPIO-labeled mesenchymal stem cells.17–19 It is 
worth recognizing the diversity in cell-labeling protocols used 
across these studies that may explain such findings.
It is important to note that we have shown for the first 
time that intravenous administration of SPIO-labeled cells 
in humans is safe. Although several SPIO agents have been 
approved for intravenous administration, the Food and Drug 
Administration has not approved the intravenous administration 
of cells labeled with SPIO ex vivo. These safety data are 
therefore critical for the further development and subsequent 
Food and Drug Administration approval of novel SPIO-based 
cell-tracking agents, facilitating translation into the clinical 
setting. Although ferumoxide (Endorem, Feridex) is no longer 
clinically available, several alternative agents are currently 
being developed for clinical use. We have here shown the 
feasibility of SPIO cell tracking and established the potential 
use of SPIO as reporters for novel cell-tracking agents.20
Several recent publications have reported tracking of labeled 
cells to a site of inflammation after both local and systemic 
administration in the preclinical setting.21–26 Migration of cells 
to a target site has also been demonstrated in humans after local 
administration. de Vries et al27 labeled human dendritic cells 
with ultrasmall SPIO (20 nm diameter), injected them directly 
into peripheral lymph nodes in patients with melanoma, and 
demonstrated their migration to regional lymph nodes on 
MRI scanning and histology of surgical resection specimens. 
Figure 6. Cell tracking to a region of cutaneous inflammation. A, T1-weighted axial image of the thigh 24 hours after the Mantoux test 
and (B) a magnified area of normal unaffected skin/subcutaneous tissue. A thick layer of aqueous jelly was applied to the skin to mini-
mize artifact occurring at the interface between the outer layer of skin and the surrounding air. R2* maps before (C) and 2 hours (D), 
24 hours (E), and 48 hours (F) after infusion of superparamagnetic particles of iron oxide (SPIO)–labeled cells show no change in R2* in 
normal skin/subcutaneous tissue on the medial aspect of the thigh after cell administration. The skin and subcutaneous tissue thickens 
in the region of the Mantoux test on the anterior thigh (G). Corresponding R2* maps of this inflamed skin (H) show a marked increase in 
R2* 2 hours (I), 24 hours (J), and 48 hours (K) after administration of SPIO-labeled cells. Consistent with accumulation of SPIO-labeled 
cells, a significant increase in R2* is observed 24 and 48 hours after cell administration in inflamed skin in the region of the Mantoux test 
(L; P<0.001) as well as in the liver and the spleen (P<0.001), but not in unaffected normal skin or skeletal muscle (control; P>0.05). No 
change in R2* was seen if labeled cells were administered in the absence of a positive Mantoux response (M). The strongly positive cuta-
neous response to the Mantoux test is clearly visible in the anterior thigh (N). SPIO-loaded cells are seen on Prussian blue staining of a 
skin biopsy from this area 96 hours after cell infusion (O and P).
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SPIO-labeled pancreatic islet cells have been detected in the 
liver after portal venous administration, and SPIO-labeled 
mesenchymal stem cells have been tracked to the site of injury 
after intracerebral injection in a patient with a traumatic brain 
injury.28,29 However, this is the first report of successful track-
ing of SPIO-labeled cells to a target site after systemic intra-
venous administration. This finding substantially broadens the 
potential applications for SPIO-labeled cell tracking.
We have shown that at clinically relevant field strengths, it 
is readily possible to image !108 mononuclear cells (contain-
ing !1–5!107 monocytes) after local or intravenous admin-
istration, and others have imaged as few as 1.5!105 cells in 
a target site after local delivery of 7.5!106 cells.27 If there 
was any concern regarding the effect of SPIO labeling on 
the likely success of cell-based treatments, it would therefore 
be possible to label a small but representative proportion of 
the total number of cells given, allowing visualization of the 
fate and distribution of cells, but leaving the majority of cells 
for engraftment or other desired function. For nontherapeu-
tic applications such as inflammatory cell tracking, a much 
higher dose of labeled cells could be administered to increase 
the sensitivity for detecting labeled cells in the target site. We 
have demonstrated that 1–5!109 SPIO-labeled autologous 
PBMC can be given safely: 100-fold greater than that needed 
for detection on MRI scanning.
An alternative control for the Mantoux component of the pres-
ent study would have been to administer saline or unlabeled cells 
to participants with a positive Mantoux response, and this could 
be undertaken as part of a future study. It is acknowledged that 
although MRI can detect accumulation of SPIO-labeled cells at 
a target site, further quantification of cell number is currently 
challenging because clustering of iron nanoparticles magnifies 
their magnetic effects, confounding attempts at quantification. 
However, novel positive imaging sequences may address this 
issue in the future. Further work is required to establish the dura-
tion of specificity of SPIO accumulation in tissues to indicate the 
continued presence of delivered cells at the target site. It would 
also be important to define the time course of SPIO clearance 
from tissues if serial administration of cells was considered.
In conclusion, this is the first report of successful magnetic 
resonance cell tracking in humans after systemic administra-
tion of cells. Using a GMP-compliant protocol, human mono-
nuclear cells can be labeled with SPIO on a clinical scale 
without affecting their viability or migratory capacity, and 
intravenous administration of SPIO-labeled cells in humans is 
safe. Cells can be imaged at clinical MRI field strengths after 
local or systemic administration. This technology for in vivo 
cell tracking has many potential cardiovascular applications 
that include monitoring of cell-based therapies for cardiovas-
cular disease and dynamic leukocyte trafficking.
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Figure 7. Negative Mantoux response (control). R2* maps before (A) and 2 hours (B), 24 hours (C), and 48 hours (D) after infusion of 
superparamagnetic particles of iron oxide (SPIO)–labeled cells show no change in R2* in skin and subcutaneous tissue at the site of 
the Mantoux test after cell administration, although there is some artifact at the skin interface in all 4 images. There is no evidence of an 
inflammatory response in the skin at the site of the Mantoux test (E). F, R2* increased significantly in the liver and spleen (P<0.001) but 
not in the skin at the site of the Mantoux test or skeletal muscle (P>0.05) after administration of SPIO-labeled cells.
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CLINICAL PERSPECTIVE
In the coming years, regenerative medicine and cell-based therapies may become important options to limit and even regress 
a wide range of diseases. In clinical trials, however, it is challenging to evaluate the efficacy of cell-based treatments because 
there is no currently available method of determining the proportion of administered cells reaching and remaining in the target 
therapeutic site. As a result, there is considerable interest in the development of strategies that would enable noninvasive clinical 
cell tracking to determine the distribution and time course of infused cells. Magnetic resonance imaging is ideal for this purpose 
because it combines high-spatial resolution with excellent soft tissue contrast while avoiding ionizing radiation. We have labeled 
autologous peripheral blood mononuclear cells with a magnetic resonance imaging contrast agent containing superparamagnetic 
particles of iron oxide (SPIO). We have shown the safety and feasibility of SPIO cell labeling and tracking in humans. Fur-
thermore, this is the first study to demonstrate that SPIO-labeled cells can be tracked to a target site of inflammation following 
intravenous administration. SPIO cell tracking could therefore be a useful tool for the assessment and further development of 
cell-based treatment options. In addition, SPIO cell tracking could be applied to dynamic leukocyte trafficking to investigate the 
contribution of inflammatory processes to disease pathology and to evaluate the effects of novel pharmacological interventions.
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Development of a GMP-compliant protocol for labeling human mononuclear 
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Supplementary Figure 1. SPIO labeled cells 
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Supplementary Figure 2. Uptake of SPIO by CD14+ monocytes 
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